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  DNA	  METHYLATION	  IN	  ACQUIRED	  TAMOXIFEN-­‐RESISTANT	  
BREAST	  CANCER:	  CELL	  LINE	  MODEL	  AND	  CLINICAL	  IMPLICATIONS	  	  MAY	  2016	  	  STEPHANIE	  MARIE	  ZIMMERS,	  B.S.,	  THE	  OHIO	  STATE	  UNIVERSITY	  	  	  Ph.D.,	  UNIVERSITY	  OF	  MASSACHUSETTS	  AMHERST	  	  	  Directed	  by:	  Professor	  Kathleen	  F.	  Arcaro	  	  	   One	  out	  of	  every	  eight	  American	  women	  will	  develop	  invasive	  breast	  cancer	  throughout	  their	  lifetime.	  	  Approximately	  70%	  of	  breast	  cancers	  are	  estrogen	  receptor	  alpha	  (ER)-­‐positive	  and	  can	  therefore	  be	  treated	  with	  an	  anti-­‐estrogen	  such	  as	  tamoxifen.	  	  Although	  tamoxifen	  treatment	  has	  been	  successful	  at	  reducing	  breast	  cancer	  death	  rates,	  nearly	  one-­‐third	  of	  women	  treated	  with	  tamoxifen	  for	  5	  years	  will	  have	  disease	  recurrence.	  	  Therefore,	  it	  is	  imperative	  that	  researchers	  investigate	  the	  mechanisms	  involved	  in	  developing	  acquired	  tamoxifen	  resistance	  and	  identify	  biomarkers	  that	  are	  predictive	  of	  acquired	  resistance.	  	  	  DNA	  methylation	  is	  known	  to	  play	  a	  role	  in	  the	  development	  of	  breast	  cancer	  and	  is	  thought	  to	  be	  involved	  in	  drug	  resistance	  as	  well.	  	  Although	  genome-­‐wide	  hypomethylation	  occurs	  frequently	  in	  breast	  cancer,	  gene-­‐specific	  hypermethylation	  and	  a	  corresponding	  decrease	  in	  expression	  are	  known	  to	  occur	  in	  breast	  cancer.	  	  The	  primary	  objective	  of	  this	  study	  is	  to	  evaluate	  how	  changes	  in	  DNA	  methylation	  in	  response	  to	  the	  DNMT1	  inhibitor,	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  affect	  gene	  expression	  and	  cell	  behavior	  in	  the	  ER-­‐negative	  cell	  line	  model	  of	  tamoxifen-­‐resistance.	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   In	  the	  present	  study,	  I	  utilize	  a	  cell	  line	  model	  of	  acquired	  tamoxifen	  resistance,	  TMX2-­‐28.	  	  This	  cell	  line,	  along	  with	  two	  other	  tamoxifen-­‐resistant	  lines,	  were	  generated	  by	  culturing	  MCF-­‐7	  cells	  in	  the	  presence	  of	  Tamoxifen	  (10-­‐6	  M)	  for	  6	  months.	  	  Cloning	  by	  limiting	  dilution	  lead	  to	  the	  discovery	  of	  three	  tamoxifen-­‐resistant	  cell	  lines.	  	  Two	  of	  which	  retained	  expression	  of	  ER,	  TMX2-­‐4	  and	  TMX2-­‐11,	  and	  one	  that	  no	  longer	  expressed	  ER,	  TMX2-­‐28.	  	  Initial	  studies	  of	  genome-­‐wide	  methylation	  with	  the	  Illumina	  Human	  Methylation	  450	  BeadChip	  found	  TMX2-­‐28	  is	  hypermethylated	  compared	  to	  the	  parental	  cell	  line,	  MCF-­‐7.	  	  Specifically,	  promoter	  methylation	  is	  involved	  in	  regulating	  the	  expression	  of	  at	  least	  two	  genes	  in	  TMX2-­‐28.	  	  Promoter	  methylation	  of	  these	  genes	  decreased	  in	  response	  to	  treatment	  with	  the	  DNMT-­‐inhibitor,	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  and	  a	  corresponding	  increase	  in	  mRNA	  expression	  was	  observed.	  	  Unpublished	  data	  from	  our	  lab	  indicate	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  also	  decreases	  TMX2-­‐28	  cell	  proliferation.	  	  However,	  it	  is	  unclear	  how	  changes	  in	  methylation	  and	  gene	  expression	  induced	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  affect	  the	  behavior	  of	  TMX2-­‐28	  cells.	  	   I	  tested	  the	  hypothesis	  that	  changes	  in	  cell	  behavior	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  are	  caused	  by	  changes	  in	  gene	  expression	  induced	  by	  decreased	  promoter	  methylation.	  	  First	  I	  utilized	  the	  Illumina	  Human	  Methylation	  450	  BeadChip	  to	  study	  changes	  in	  DNA	  methylation	  in	  the	  parental	  cell	  line,	  MCF-­‐7,	  as	  well	  as	  the	  three	  tamoxifen-­‐resistant	  cell	  lines.	  	  I	  confirmed	  results	  from	  previous	  studies	  indicating	  that	  TMX2-­‐28	  is	  hypermethylated	  compared	  to	  the	  parental	  cell	  line,	  MCF-­‐7.	  	  I	  also	  discovered	  that	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  results	  in	  cell	  line-­‐specific	  changes	  in	  DNA	  methylation.	  	  The	  ER-­‐negative,	  tamoxifen-­‐resistant	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cell	  line,	  TMX2-­‐28,	  is	  most	  sensitive	  to	  treatment	  with	  the	  DNMT-­‐inhibitor.	  	  To	  determine	  the	  genes	  most	  likely	  to	  have	  altered	  expression	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment,	  I	  first	  identified	  CpG	  sites	  that	  are	  hypermethylated	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7.	  	  Of	  these	  37,501	  CpGs,	  there	  are	  707	  CpGs	  with	  decreased	  methylation	  after	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  This	  corresponds	  to	  27	  genes	  with	  changes	  in	  at	  least	  2	  CpGs	  located	  in	  the	  promoter.	  	  To	  determine	  other	  cell	  behaviors	  that	  may	  be	  affected	  by	  inhibition	  of	  methylation	  in	  TMX2-­‐28,	  I	  conducted	  a	  2-­‐dimensional	  scratch/wound	  assay.	  	  I	  found	  that	  treatment	  of	  TMX2-­‐28	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  inhibits	  2-­‐dimensional	  migration	  and	  induces	  detachment	  of	  cells	  from	  the	  monolayer.	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  also	  decreased	  cell	  viability.	  	  One	  of	  the	  27	  genes	  I	  identified	  as	  differentially	  methylated	  and	  altered	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  TACSTD2,	  seemed	  likely	  to	  play	  a	  role	  in	  regulating	  these	  behaviors	  in	  TMX2-­‐28.	  	  Expression	  of	  the	  protein	  encoded	  by	  this	  gene,	  tumor-­‐associated	  calcium	  signal	  transducer	  2,	  TROP2,	  is	  regulated	  by	  promoter	  methylation	  in	  lung	  cancer	  and	  TROP2	  is	  involved	  in	  development,	  intracellular	  signaling	  and	  epithelial	  cancers.	  	  Expression	  of	  TROP2	  in	  lung	  cancer	  cell	  lines	  inhibits	  proliferation,	  colony	  formation	  and	  blocks	  phosphorylation	  of	  important	  intracellular	  signaling	  molecules	  involved	  in	  growth	  signaling	  and	  transcription.	  	  Promoter	  methylation	  of	  TACSTD2	  is	  low	  in	  MCF-­‐7	  and	  TROP2	  expression	  is	  high	  while	  promoter	  methylation	  is	  high	  in	  TMX2-­‐28	  and	  TROP2	  expression	  is	  low.	  	  This	  is	  consistent	  with	  the	  idea	  that	  promoter	  methylation	  is	  regulating	  expression.	  	  Therefore,	  I	  tested	  the	  hypothesis	  that	  the	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behavior	  of	  TMX2-­‐28	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  was	  due	  to	  increased	  expression	  of	  TROP2.	  To	  test	  this	  hypothesis,	  I	  first	  confirmed	  that	  treatment	  of	  TMX2-­‐28	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreases	  TACSTD2	  promoter	  methylation	  and	  increases	  TROP2	  expression.	  	  Next,	  I	  generated	  stable	  cell	  lines	  with	  increased	  TROP2	  expression	  (TMX2-­‐28-­‐Trop2)	  and	  knocked	  down	  TROP2	  expression	  in	  MCF-­‐7	  (MCF-­‐7-­‐Trop2-­‐Kd).	  	  I	  quantified	  proliferation,	  adhesion	  to	  fibronectin	  and	  migration	  of	  these	  cell	  lines.	  	  Contrary	  to	  my	  predictions,	  expression	  of	  TROP2	  in	  TMX2-­‐28	  did	  not	  affect	  proliferation	  and	  increased	  both	  adhesion	  to	  fibronectin	  and	  migration.	  	  Interestingly,	  knockdown	  of	  TROP2	  expression	  in	  MCF-­‐7	  increased	  proliferation	  but	  did	  not	  alter	  adhesion	  or	  migration.	  	  	  To	  further	  evaluate	  the	  role	  of	  TROP2	  in	  breast	  cancer,	  TACSTD2	  methylation	  and	  TROP2	  expression	  were	  analyzed	  in	  a	  total	  of	  70	  primary	  and	  recurrent	  clinical	  breast	  cancer	  samples.	  	  TACSTD2	  promoter	  methylation	  was	  lower	  in	  the	  clinical	  samples	  than	  the	  cell	  lines.	  	  In	  agreement	  with	  the	  cell	  line	  data,	  methylation	  of	  the	  three	  TACSTD2	  CpG	  sites	  was	  higher	  in	  ER-­‐negative	  recurrent	  tumors	  that	  were	  initially	  ER-­‐positive	  primary	  tumors.	  	  However,	  there	  was	  no	  correlation	  between	  promoter	  methylation	  and	  TROP2	  expression	  in	  the	  clinical	  samples.	  	  In	  contrast	  to	  previous	  reports,	  I	  found	  no	  association	  between	  TROP2	  expression	  and	  tumor	  grade	  or	  Ki67	  status.	  	  Despite	  the	  small	  size,	  the	  clinical	  sample	  data	  indicate	  that	  our	  cell	  line	  model	  may	  be	  relevant	  for	  studying	  ER-­‐negative,	  tamoxifen	  resistant	  breast	  cancer.	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Additionally,	  I	  characterized	  DNA	  methylation	  and	  protein	  expression	  patterns	  of	  several	  luminal	  and	  basal	  cytokeratins.	  	  According	  to	  the	  methylation	  status	  determined	  by	  the	  450	  BeadChip	  and	  protein	  expression	  determined	  by	  IHC	  for	  the	  parental	  cell	  line	  and	  the	  three	  tamoxifen-­‐resistant	  cell	  lines,	  promoter	  methylation	  seems	  to	  play	  a	  role	  in	  regulating	  expression	  of	  p40,	  the	  basal	  cytokeratins	  CK5	  and	  CK14,	  and	  the	  luminal	  cytokeratins	  CK8,	  CK17,	  CK18	  and	  CK20.	  	  I	  found	  that	  MCF-­‐7,	  TMX2-­‐4	  and	  TMX2-­‐11	  express	  luminal	  (low	  molecular	  weight)	  cytokeratins	  while	  TMX2-­‐28	  express	  a	  combination	  of	  luminal	  and	  basal	  cytokeratins.	  	  These	  new	  IHC	  data	  are	  consistent	  with	  previously	  published	  work	  from	  our	  lab	  and	  demonstrate	  that	  TMX2-­‐28	  have	  a	  mixed	  basal-­‐luminal	  phenotype.	  	  DNA	  methylation	  of	  cytokeratin	  genes	  may	  be	  useful	  as	  an	  alternative	  indicator	  of	  tumor	  subtype	  and	  provide	  insight	  into	  mechanisms	  controlling	  expression	  of	  these	  important	  prognostic	  markers.	  The	  results	  presented	  in	  the	  present	  study	  demonstrate	  that	  DNA	  methylation	  may	  play	  an	  important	  role	  in	  ER-­‐negative,	  tamoxifen	  resistant	  breast	  cancer.	  	  TMX2-­‐28	  cells	  rely	  on	  a	  TROP2-­‐independent	  mechanism	  to	  sustain	  proliferative	  signals.	  	  TROP2	  acts	  to	  promote	  adhesion	  and	  migration	  in	  TMX2-­‐28.	  	  Further	  studies	  are	  necessary	  to	  determine	  the	  mechanism	  by	  which	  TROP2	  increases	  adhesion	  and	  migration	  as	  well	  as	  the	  role	  of	  TROP2	  in	  drug	  resistant	  breast	  cancer.	  	  Due	  to	  the	  high	  percentage	  of	  clinical	  samples	  positive	  for	  TROP2	  expression,	  TROP2	  may	  serve	  as	  a	  method	  for	  targeted	  drug	  delivery	  for	  recurrent	  breast	  cancer.	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Breast	  Cancer	  and	  Biology	  of	  the	  Breast	  	   The	  breast	  is	  composed	  of	  glands	  or	  lobules,	  which	  are	  capable	  of	  producing	  milk,	  ducts	  that	  connect	  the	  milk-­‐producing	  glands	  to	  the	  nipple,	  connective	  stromal	  and	  fat	  tissue.	  	  Breast	  cancer	  results	  from	  the	  uncontrolled	  growth	  of	  cells	  in	  the	  breast.	  	  Most	  breast	  cancers	  arise	  from	  cells	  in	  the	  lobules	  or	  ducts	  (Figure	  1.1).	  	  Breast	  cancer	  has	  two	  general	  categories,	  in	  situ	  (non-­‐invasive)	  and	  invasive.	  	  In	  situ	  cancers	  remain	  in	  the	  ducts	  or	  lobules	  while	  invasive	  cancers	  begin	  in	  a	  duct	  or	  lobule	  but	  spread	  into	  the	  surrounding	  normal	  tissue	  (Figure	  1.2).	  	  Breast	  cancers	  can	  be	  further	  categorized	  by	  stage	  to	  indicate	  whether	  the	  cancer	  is	  located	  in	  one	  area	  of	  the	  breast	  or	  has	  spread	  to	  healthy	  tissue	  within	  the	  breast	  or	  other	  areas	  of	  the	  body.	  1	  Expression	  of	  hormone	  receptors	  is	  also	  used	  for	  classification	  and	  evaluation	  of	  therapeutic	  options.	  	   According	  to	  the	  American	  Cancer	  Society,	  breast	  cancer	  is	  the	  most	  common	  type	  of	  cancer	  among	  women	  in	  the	  United	  States,	  excluding	  skin	  cancer.	  2	  Approximately	  one	  out	  of	  every	  eight	  American	  women	  will	  develop	  invasive	  breast	  cancer	  throughout	  their	  lifetime.	  	  Breast	  cancer	  is	  the	  second	  leading	  cause	  of	  cancer-­‐related	  deaths	  among	  women.	  	  Roughly	  290,000	  women	  were	  estimated	  to	  be	  diagnosed	  with	  breast	  cancer	  in	  2015.	  	  It	  was	  estimated	  that	  about	  40,000	  women	  would	  die	  of	  breast	  cancer	  in	  2015.	  2	  The	  majority	  of	  breast	  cancer-­‐related	  deaths	  occur	  due	  to	  metastasis	  to	  other	  sites	  within	  the	  body.	  3	  Only	  5-­‐10%	  of	  breast	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cancers	  result	  from	  inherited	  genetic	  mutations	  in	  genes	  such	  as	  BRCA1	  and	  BRCA2.	  	  Nearly	  85%	  of	  breast	  cancers	  occur	  in	  women	  with	  no	  family	  history	  of	  the	  disease.	  	  These	  cancers	  occur	  as	  a	  result	  of	  accumulated	  genetic	  and/or	  epigenetic	  mutations	  acquired	  over	  the	  course	  of	  one’s	  lifetime.1	  	  
Etiology	  of	  Breast	  Cancer	  	   Breast	  cancer	  is	  a	  heterogeneous	  disease	  in	  which	  decisions	  about	  therapeutic	  options	  are	  often	  based	  on	  gene	  expression	  and	  histological	  profiles.	  	  Breast	  cancers	  can	  be	  classified	  into	  4	  subtypes,	  as	  reviewed	  by	  Eroles	  and	  colleagues.	  4	  The	  most	  common	  breast	  cancer	  subtype	  is	  Luminal	  A	  (73%	  of	  breast	  cancers).	  5	  These	  cancer	  cells	  have	  a	  gene	  expression	  signature	  similar	  to	  normal	  luminal	  epithelial	  cells	  that	  line	  mammary	  ducts	  (Figure	  1.3).	  4,6	  They	  express	  estrogen	  receptor	  alpha	  (ER),	  progesterone	  receptor	  (PR),	  B-­‐cell	  lymphoma	  2	  (Bcl-­‐2)	  and	  cytokeratins	  CK8/18	  and	  are	  epidermal	  growth	  factor	  receptor	  2	  (HER2)	  negative.	  	  Patients	  with	  Luminal	  A	  breast	  cancers	  have	  a	  better	  overall	  prognosis	  than	  those	  with	  other	  breast	  cancer	  subtypes.	  4,5	  Luminal	  B	  breast	  cancers	  which	  represent	  about	  10%	  of	  breast	  cancers	  are	  more	  aggressive	  than	  luminal	  A	  and	  have	  a	  higher	  histological	  grade	  and	  proliferative	  index.	  4,5	  These	  breast	  cancers	  express	  ER	  and	  HER2	  and	  have	  increased	  expression	  of	  proliferative	  genes.	  	  HER2	  positive	  tumors	  have	  high	  or	  overexpression	  of	  HER2	  and	  other	  genes	  in	  the	  HER2	  pathway,	  along	  with	  overexpression	  of	  genes	  involved	  in	  proliferation.	  4	  Approximately	  5%	  of	  breast	  cancers	  are	  HER2	  positive.	  5	  Basal-­‐like	  cancers	  have	  a	  gene	  expression	  signature	  similar	  to	  basal/myoepithelial	  cells,	  which	  line	  the	  mammary	  ducts.	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These	  cancers	  express	  high	  molecular	  weight	  cytokeratins	  CK5	  and	  CK17,	  P-­‐cadherin,	  caveolin	  1	  and	  2,	  nestin,	  CD44	  and	  epidermal	  growth	  factor	  receptor	  (EGFR)	  and	  are	  usually	  ER-­‐	  and	  PR-­‐negative.	  	  Triple	  negative	  breast	  cancers	  lack	  expression	  of	  ER,	  PR	  and	  HER2	  and	  some	  are	  also	  considered	  basal-­‐like.	  	  Basal-­‐like	  cancers	  have	  a	  worse	  prognosis	  than	  luminal	  cancers	  and	  make	  up	  roughly	  12%	  of	  all	  breast	  cancers.4,5	  	  
The	  Hallmarks	  of	  Cancer	  	   Hanahan	  and	  Weinberg	  first	  described	  six	  hallmarks	  of	  cancer	  cells	  in	  2000.	  7	  The	  hallmarks	  are	  characteristics	  of	  cancer	  cells	  that	  allow	  for	  escape	  of	  normal	  cell	  function	  and	  malignant	  growth.	  	  They	  defined	  the	  six	  hallmarks	  as	  sustained	  proliferative	  signaling,	  escape	  of	  growth	  suppression,	  activation	  of	  invasion	  and	  metastasis,	  induction	  of	  angiogenesis,	  resistance	  of	  cell	  death	  and	  replicative	  immortality	  (Figure	  1.4).	  7	  Cancer	  cells	  can	  employ	  a	  variety	  of	  different	  mechanisms	  in	  order	  to	  achieve	  these	  hallmarks,	  including	  dysregulation	  of	  normal	  cell	  signaling	  pathways	  and	  altered	  protein	  function.	  	  Researchers	  in	  the	  cancer	  field	  have	  therefore	  focused	  on	  understanding	  how	  cancer	  cells	  attain	  these	  hallmarks	  and	  developing	  novel	  therapeutic	  strategies	  to	  inhibit	  them.	  	  Hanahan	  and	  Weinberg	  have	  since	  modified	  their	  initial	  list	  of	  the	  hallmarks	  of	  cancer.	  	  In	  2011,	  they	  added	  two	  emerging	  hallmarks;	  altered	  cell	  metabolism	  and	  evading	  immune	  surveillance.	  	  They	  also	  identified	  two	  enabling	  characteristics	  that	  facilitate	  and	  promote	  tumor	  growth:	  genomic	  instability/mutations	  and	  inflammation	  (Figure	  1.4).	  8	  The	  research	  presented	  in	  this	  dissertation	  focuses	  on	  epigenetic	  alterations,	  which	  are	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related	  to	  genomic	  instability,	  one	  of	  the	  enabling	  characteristics	  of	  cancer	  cells,	  and	  aspects	  related	  to	  two	  of	  the	  six	  hallmarks	  of	  cancer:	  sustaining	  growth	  and	  promoting	  invasion/metastasis.	  	  Specifically,	  the	  goal	  of	  this	  project	  is	  to	  investigate	  the	  role	  of	  epigenetic	  alterations	  in	  drug	  resistant	  breast	  cancer	  and	  determine	  the	  effects	  of	  inhibition	  of	  DNA	  methylation	  on	  proliferation,	  adhesion	  and	  migration	  in	  a	  drug	  resistant	  breast	  cancer	  cell	  line.	  	  	  
Epigenetics	  and	  DNA	  Methylation	  	   Epigenetics	  is	  the	  study	  of	  heritable	  changes	  in	  gene	  expression	  that	  are	  not	  a	  result	  of	  changes	  in	  the	  underlying	  DNA	  sequence.	  9-­‐11	  Epigenetic	  control	  of	  gene	  expression	  is	  important	  for	  regulating	  many	  different	  cellular	  processes	  including	  development,	  tissue-­‐specific	  differentiation	  and	  X-­‐chromosome	  inactivation.	  	  When	  epigenetic	  regulation	  is	  altered,	  it	  can	  lead	  to	  diseases	  including	  cancer.	  	  	  Epigenetic	  mechanisms	  include	  DNA	  methylation	  and	  histone	  modifications,	  which	  alter	  chromatin	  structure	  and	  accessibility	  of	  DNA	  to	  regulate	  gene	  expression.	  9,11	  Chromosomes	  are	  made	  of	  condensed	  DNA	  called	  chromatin.	  	  Chromatin	  is	  composed	  of	  nucleosomes,	  which	  contain	  DNA	  wrapped	  around	  an	  octamer	  of	  four	  core	  histone	  proteins	  (H3,	  H4,	  H2A	  and	  H2B).	  12	  In	  normal	  cells,	  condensed	  chromatin	  is	  not	  transcriptionally	  active	  and	  has	  dense	  nucleosomes,	  DNA	  methylation	  and	  deacetylated	  histones,	  while	  transcribed	  regions	  of	  the	  genome	  have	  open	  nucleosome	  positioning,	  unmethylated	  DNA	  and	  acetylated	  histones	  (Figure	  1.5).	  13	  As	  reviewed	  by	  Baylin	  and	  Jones,	  gene	  expression	  is	  regulated	  by	  a	  combination	  of	  DNA	  methylation,	  nucleosome	  positioning	  and	  
	  5	  
histone	  modifications	  which	  are	  controlled	  by	  the	  Polycomb	  group	  (PcG)	  complex.	  14	  DNA	  methylation	  occurs	  in	  DNA	  where	  a	  cytosine	  is	  followed	  by	  a	  guanine	  residue	  (CpG	  dinucleotides).	  	  Methyl	  groups	  from	  S-­‐adenosylmethionine	  (SAM)	  are	  added	  to	  position	  5	  of	  cytosine	  by	  DNA	  methyltransferases	  (DNMTs)	  (Figure	  1.6).15-­‐18	  Epigenetic	  alterations	  such	  as	  global	  hypomethylation,	  regional	  hypermethylation	  and	  chromatin	  remodeling	  are	  known	  to	  occur	  during	  carcinogenesis.	  13	  Specifically,	  aberrant	  DNA	  methylation	  is	  known	  to	  occur	  early	  in	  tumorigenesis13,16	  and	  is	  often	  seen	  in	  breast	  cancer.	  16	  Hypermethylation	  of	  CpG-­‐rich	  regions	  of	  the	  genome	  approximately	  1	  kb	  in	  length	  (CpG	  islands)19	  clustered	  in	  the	  promoter	  region	  of	  genes	  can	  lead	  to	  suppression	  of	  gene	  expression	  and	  often	  silencing	  of	  tumor	  suppressors	  and	  transcription	  factors.	  11,20,21	  Because	  these	  epigenetic	  changes	  associated	  with	  breast	  cancer	  are	  thought	  to	  occur	  early	  during	  disease	  progression,	  they	  could	  potentially	  be	  used	  as	  biomarkers.	  	  Targeting	  DNA	  methylation	  could	  be	  an	  effective	  therapy	  for	  breast	  cancer	  because	  DNA	  methylation	  may	  be	  reversed	  by	  epigenetic	  therapies	  or	  dietary	  changes.11,22	  	  
Tamoxifen	  Resistance	  and	  DNA	  Methylation	  	   Estrogen	  (17-­‐Beta-­‐estradiol	  or	  E2)	  signaling	  regulates	  cell	  proliferation	  and	  survival	  and	  is	  critical	  for	  many	  aspects	  of	  normal	  female	  physiology	  such	  as	  reproduction	  and	  behavior.	  	  E2	  binds	  to	  ER	  and	  regulates	  ligand-­‐activated	  genomic	  as	  well	  as	  non-­‐genomic	  signaling	  pathways	  in	  normal	  and	  cancerous	  breast	  tissue.	  	  Approximately	  70%	  of	  breast	  cancers	  are	  ER-­‐positive	  and	  can	  therefore	  be	  treated	  with	  an	  anti-­‐estrogen	  such	  as	  tamoxifen.	  23	  Tamoxifen	  is	  one	  of	  the	  drugs	  used	  as	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endocrine	  therapy	  and	  it	  acts	  as	  a	  selective	  estrogen	  receptor	  modulator	  (SERM).	  24	  It	  works	  by	  competing	  with	  estrogen	  for	  binding	  to	  the	  ligand-­‐binding	  domain	  of	  the	  ER.	  	  Binding	  of	  tamoxifen	  to	  ER	  induces	  a	  conformational	  change,	  which	  inactivates	  the	  AF-­‐2	  domain	  of	  ER	  resulting	  in	  receptor	  stabilization.	  25	  Although	  tamoxifen	  treatment	  has	  been	  successful	  at	  reducing	  breast	  cancer	  death	  rates,	  approximately	  one-­‐third	  of	  women	  treated	  with	  tamoxifen	  for	  5	  years	  will	  have	  disease	  recurrence.26	  This	  initial	  response	  to	  therapy	  followed	  by	  disease	  progression	  is	  known	  as	  acquired	  resistance.	  23	  Therefore,	  it	  is	  imperative	  that	  researchers	  identify	  biomarkers	  that	  are	  predictive	  of	  acquired	  resistance.	  	  These	  biomarkers	  may	  also	  be	  utilized	  as	  novel	  therapeutic	  targets	  for	  tamoxifen-­‐resistant	  breast	  cancers.	  	   There	  are	  several	  mechanisms	  that	  lead	  to	  acquired	  resistance	  to	  endocrine	  therapies	  and	  disease	  recurrence.	  	  Acquired	  resistance	  can	  result	  from	  loss	  of	  ER	  expression,	  epigenetic	  modifications,	  expression	  of	  altered	  forms	  of	  ER,	  post-­‐translational	  modifications	  of	  ER,	  increased	  activity	  of	  transcription	  factors	  along	  with	  deregulation	  of	  ER	  co-­‐activators,	  increased	  signals	  from	  receptor	  tyrosine	  kinase	  signaling	  pathways,	  improper	  regulation	  of	  the	  cell	  cycle	  and	  apoptosis,	  mutations	  in	  the	  gene	  encoding	  ER,	  ESR1,	  altered	  drug	  metabolism	  and	  selection	  of	  pre-­‐existing	  cancer	  initiating	  cells	  or	  cancer	  stem	  cells.	  23,27,28	  Cancer	  cells	  utilize	  these	  alterations	  to	  give	  themselves	  a	  survival	  advantage	  and	  continue	  to	  grow	  despite	  suppression	  of	  estrogen	  signaling.	  29	  Interestingly,	  DNA	  methylation	  is	  known	  to	  play	  a	  role	  in	  breast	  cancer16	  and	  has	  been	  shown	  to	  be	  involved	  in	  tamoxifen	  resistance	  as	  well.	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   Genome-­‐wide	  hypomethylation	  occurs	  frequently	  in	  breast	  cancer.	  	  However,	  as	  reviewed	  by	  Connolly	  and	  Stearns,	  30	  certain	  breast	  cancer-­‐related	  genes	  are	  known	  to	  be	  hypermethylated	  in	  tumor	  samples.	  	  Our	  lab	  as	  well	  as	  others	  have	  demonstrated	  that	  changes	  in	  DNA	  methylation	  across	  the	  genome	  occur	  in	  ER-­‐positive,	  tamoxifen-­‐resistant	  breast	  cancer	  cell	  lines.	  25,27,31	  However,	  the	  role	  of	  promoter	  methylation	  and	  regulation	  of	  gene	  expression	  is	  poorly	  understood	  in	  ER-­‐negative,	  tamoxifen-­‐resistant	  disease.	  	  	  The	  majority	  of	  cell-­‐line	  models	  of	  tamoxifen	  resistance	  are	  ER-­‐positive.	  	  This	  is	  indicative	  of	  recurrence	  patterns	  in	  patients,	  as	  the	  majority	  of	  recurrences	  from	  ER-­‐positive	  tumors	  retain	  ER	  expression.	  32,33	  However,	  approximately	  10-­‐12%	  of	  local	  or	  metastatic	  recurrences	  from	  primary	  tumors	  lose	  expression	  of	  ER	  (Figure	  1.7).	  32,33	  Patients	  with	  these	  ER-­‐negative,	  recurrent	  tumors	  have	  limited	  treatment	  options.	  	  Tamoxifen	  is	  the	  main	  drug	  used	  to	  treat	  premenopausal	  women	  with	  ER-­‐positive	  disease	  after	  surgery	  and	  radiation/chemotherapy.	  34	  ER-­‐positive	  patients	  with	  disease	  progression	  are	  then	  treated	  with	  another	  ER	  antagonist,	  such	  as	  fulvestrant,	  or	  aromatase	  inhibitors.	  34	  However,	  these	  drugs	  will	  not	  benefit	  patients	  with	  ER-­‐negative	  recurrent	  disease.	  	  If	  the	  recurrent	  disease	  is	  HER2-­‐positive,	  anti-­‐HER2	  therapy	  may	  be	  utilized.	  	  The	  other	  options	  for	  patients	  with	  ER-­‐negative	  recurrent	  disease	  are	  targeted	  therapies	  such	  as	  mTOR	  or	  PI3K	  inhibitors	  or	  other	  experimental	  treatments.	  34	  Hyperactivation	  of	  the	  PI3K/AKT/mTOR	  pathway	  has	  been	  shown	  to	  contribute	  to	  disease	  progression	  of	  ER-­‐positive	  breast	  cancer	  and	  resistance	  to	  endocrine	  therapy.	  35	  Although	  there	  is	  a	  lack	  of	  biomarkers	  that	  predict	  benefit	  from	  treatment	  of	  advanced	  breast	  cancer	  with	  mTOR	  inhibitors,	  there	  is	  evidence	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that	  PI3K/AKT/mTOR	  inhibition	  can	  improve	  the	  benefit	  of	  endocrine	  therapy	  in	  ER-­‐positive	  breast	  cancer.	  	  However,	  due	  to	  the	  ability	  of	  cancer	  cells	  to	  compensate	  for	  alterations	  in	  signaling	  pathways,	  it	  is	  likely	  that	  tumors	  resistant	  to	  mTOR	  targeting	  will	  emerge.	  36	  Further	  studies	  are	  needed	  to	  determine	  whether	  PI3K/AKT/mTOR	  inhibitors	  should	  be	  used	  with	  existing	  endocrine	  therapy	  or	  inhibitors	  of	  upstream	  or	  downstream	  effectors	  and	  whether	  isoform-­‐specific	  or	  pan-­‐PI3K	  inhibition	  is	  better.	  	  There	  is	  also	  a	  need	  to	  develop	  new	  methods	  for	  identifying	  patients	  who	  are	  likely	  to	  respond	  to	  PI3K/AKT/mTOR	  inhibition	  by	  either	  molecular	  signatures	  of	  biomarkers	  or	  large-­‐scale	  genomic	  screening.	  	  Therefore,	  additional	  targets	  are	  needed	  for	  treatment	  of	  advanced,	  endocrine	  resistant	  breast	  cancer.	  	  The	  goal	  of	  this	  project	  is	  to	  evaluate	  the	  role	  of	  DNA	  methylation	  in	  ER-­‐negative,	  tamoxifen-­‐resistant	  disease	  and	  the	  use	  of	  the	  DNMT1-­‐inhibitor,	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  as	  a	  potential	  epigenetic	  therapy	  for	  ER-­‐negative	  recurrent	  disease.	  	  
Tamoxifen-­‐Resistant	  Cell	  Line	  Model	  	   This	  study	  focuses	  primarily	  on	  an	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  line,	  TMX2-­‐28.	  	  This	  cell	  line,	  and	  two	  other	  tamoxifen-­‐resistant	  lines,	  were	  generated	  by	  culturing	  MCF-­‐7	  cells	  in	  the	  presence	  of	  Tamoxifen	  (10-­‐6	  M)	  for	  6	  months.	  37	  Cloning	  by	  limiting	  dilution	  lead	  to	  the	  discovery	  of	  three	  tamoxifen-­‐resistant	  cell	  lines.	  	  Two	  of	  which	  retained	  expression	  of	  ERα,	  TMX2-­‐4	  and	  TMX2-­‐11,	  and	  one	  that	  no	  longer	  expressed	  ERα,	  TMX2-­‐28	  (Figure	  1.8).	  	  All	  three	  tamoxifen-­‐resistant	  cell	  lines	  retain	  an	  epithelial-­‐like	  phenotype,	  similar	  to	  the	  parental	  line,	  MCF-­‐7.	  	  Previous	  work	  in	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our	  lab	  demonstrated	  that	  TMX2-­‐28	  cells	  have	  a	  Ras	  Homolog	  Gene	  Family	  Member,	  A	  (RhoA)-­‐dependent	  invasion	  mechanism	  and	  express	  S-­‐phase	  kinase-­‐associated	  protein	  2	  (SKP2),	  which	  targets	  the	  cyclin-­‐dependent	  kinase	  (CDK)	  inhibitor	  p27	  for	  degradation	  and	  facilitates	  cell	  cycle	  progression	  and	  increased	  proliferation.	  38,39	  Initial	  studies	  of	  genome-­‐wide	  methylation	  with	  the	  HM450K	  BeadChip	  found	  over	  33,000	  hypermethylated	  CpG	  sites	  in	  TMX2-­‐28	  compared	  to	  the	  parental	  cell	  line,	  MCF-­‐7.	  	  Specifically,	  promoter	  methylation	  is	  involved	  in	  regulating	  the	  expression	  of	  at	  least	  two	  genes	  in	  TMX2-­‐28,	  zinc	  finger	  350	  (ZNF350)	  and	  melanoma	  antigen	  family	  D1	  (MAGED1).	  31	  Promoter	  methylation	  of	  ZNF350	  and	  MAGED1	  decreased	  in	  response	  to	  treatment	  with	  the	  DNMT-­‐inhibitor,	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  and	  a	  corresponding	  increase	  in	  mRNA	  expression	  was	  observed	  for	  both	  genes.	  	  Unpublished	  data	  from	  our	  lab	  indicate	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreases	  TMX2-­‐28	  cell	  proliferation.	  	  However,	  it	  is	  unclear	  how	  changes	  in	  methylation	  and	  gene	  expression	  induced	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  affect	  the	  behavior	  of	  TMX2-­‐28	  cells.	  	  
Cell	  Proliferation,	  Adhesion	  and	  Migration	  	   Sustaining	  proliferation,	  altering	  adhesion	  and	  promoting	  migration	  are	  some	  of	  the	  key	  characteristics	  of	  all	  cancer	  cells.	  7,8	  The	  majority	  of	  breast	  cancer	  deaths	  are	  caused	  by	  metastases.	  3	  Therefore,	  understanding	  what	  promotes	  the	  growth	  and	  migration	  of	  breast	  cancer	  cells	  is	  indispensable	  for	  developing	  new	  therapeutics.	  	  In	  tamoxifen-­‐resistant	  disease,	  breast	  cancer	  cells	  have	  circumvented	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estrogen	  signaling	  and	  rely	  on	  alterative	  signaling	  pathways	  to	  sustain	  malignant	  progression.	  	  	  	   Growth	  signaling	  pathways	  such	  as	  the	  phosphatidylinositol	  3-­‐kinase	  (PI3K)/AKT	  and	  insulin-­‐like	  growth	  factor	  1	  receptor	  (IGF1-­‐R)	  are	  activated	  in	  anti-­‐estrogen-­‐resistant	  cell	  lines.	  28,40	  AKT	  phosphorylates	  effector	  proteins	  that	  are	  involved	  in	  cell	  survival,	  proliferation	  and	  metabolic	  signaling.	  41	  IGF	  signaling	  is	  known	  to	  regulate	  angiogenesis,	  proliferation,	  metastasis	  and	  apoptosis	  resistance.	  	  The	  two	  main	  pathways	  involved	  in	  IGF	  signaling	  are	  the	  mitogen-­‐activated	  protein	  kinase	  (MAPK)	  and	  PI3K/AKT	  pathways.	  42	  Overexpression	  of	  IGF1-­‐R	  has	  been	  implicated	  in	  cell	  culture	  models	  of	  antiestrogen	  resistance.	  28	  IGF1	  promotes	  terminal	  end	  bud	  growth	  and	  extension	  of	  the	  ductal	  network	  in	  the	  normal	  breast	  and	  is	  important	  for	  mammary	  gland	  development.	  	  Anti-­‐apoptotic	  signals	  are	  generated	  through	  IGF1-­‐R	  signaling	  via	  the	  PI3K/AKT	  and	  RAS/MAPK	  pathways.	  	  IGF1R	  signaling	  also	  works	  to	  control	  cell	  cycle	  progression	  through	  the	  MAPK/	  extracellular	  signal-­‐related	  kinase	  (ERK)	  pathway.	  	  Although	  some	  tamoxifen-­‐	  and	  aromatase-­‐resistant	  cell	  culture	  and	  mouse	  tumor	  models	  express	  low	  levels	  of	  IGF1-­‐R,	  protein	  phosphorylation	  remains	  high	  resulting	  in	  constitutive	  activation	  of	  signaling	  pathways.	  43	  Understanding	  how	  these	  signaling	  pathways	  work	  both	  on	  their	  own	  and	  collectively	  to	  facilitate	  disease	  progression	  will	  help	  identify	  new	  targets	  for	  the	  personalized	  treatment	  of	  breast	  cancer.	  	   Another	  important	  aspect	  of	  disease	  progression	  is	  metastasis,	  or	  the	  spread	  of	  cancer	  to	  secondary	  sites	  throughout	  the	  body.	  	  Metastasis	  begins	  when	  tumor	  cells	  invade	  the	  local	  surrounding	  tissue.	  	  The	  cancer	  cells	  must	  then	  invade	  blood	  or	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lymphatic	  vessels	  though	  a	  process	  known	  as	  intravasation.	  	  The	  blood	  stream	  or	  lymphatic	  vessels	  then	  transport	  the	  cancer	  cells	  to	  other	  areas	  of	  the	  body.	  	  If	  they	  succeed	  in	  exiting	  the	  vessel	  (extravasation)	  and	  establishing	  a	  new	  tumor	  at	  this	  secondary	  location,	  then	  the	  metastatic	  cascade	  is	  complete	  (Figure	  1.9).	  3,44	  	  	   Metastasis	  begins	  with	  growth	  of	  the	  primary	  tumor	  and	  invasion	  of	  the	  surrounding	  local	  tissue.	  	  This	  is	  accomplished	  by	  altering	  cell-­‐cell	  adhesion	  and	  cell	  adhesion	  to	  the	  extracellular	  matrix	  (ECM).	  	  Cadherins	  are	  known	  to	  regulate	  cell-­‐cell	  adhesion	  and	  are	  important	  for	  breast	  cancer	  metastasis.	  3	  Cell	  adhesion	  to	  the	  ECM	  is	  facilitated	  by	  integrins	  and	  is	  important	  for	  both	  invasion	  and	  extravasation.3,44	  Additionally,	  cancer	  cells	  can	  degrade	  the	  ECM	  with	  metalloproteinases	  (MMPs)	  and	  the	  urokinase	  plasminogen	  activator	  (uPA)	  system.3	  Various	  adhesion	  and	  signaling	  molecules	  are	  involved	  in	  facilitating	  extravasation.	  	  Ras-­‐related	  C3	  botulinum	  toxin	  substrate	  1	  (rho	  family,	  small	  GTP	  binding	  protein)	  (Rac1)	  and	  Rho	  associated	  coiled-­‐coil	  containing	  protein	  kinase	  1	  (ROCK1)	  are	  involved	  in	  regulating	  the	  formation	  of	  stress	  fibers	  and	  regulating	  intracellular	  tension.	  	  ERK,	  SRC	  proto-­‐oncogene,	  non-­‐receptor	  tyrosine	  kinase	  (SRC)	  and	  PI3K	  signaling	  aids	  in	  loosening	  endothelial	  cell	  junctions.	  	  Then	  β1	  integrin	  and	  focal	  adhesion	  kinase	  (FAK)	  signaling	  are	  important	  for	  establishing	  protrusions	  which	  help	  cancer	  cells	  invade	  the	  basement	  membrane	  surrounding	  the	  vasculature	  and	  ultimately	  establish	  a	  new	  tumor	  at	  the	  secondary	  site.	  44	  In	  addition	  to	  these	  mechanisms,	  cancer	  cells	  recruit	  and	  interact	  with	  host	  cells	  to	  facilitate	  metastasis.	  	  The	  release	  of	  cytokines	  and	  proteases	  from	  stromal	  cells	  can	  stimulate	  proliferation	  of	  cancer	  cells	  and	  metastasis.	  	  Mesenchymal	  stem	  cells	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(MSCs)	  can	  be	  recruited	  to	  the	  tumor	  where	  they	  differentiate	  into	  fibroblasts.	  	  Host-­‐derived,	  tumor-­‐associated	  macrophages	  are	  important	  for	  migration	  and	  invasion	  as	  well	  as	  suppression	  of	  the	  immune	  system.	  45	  Therefore,	  it	  is	  also	  important	  to	  consider	  these	  aspects	  of	  the	  tumor	  microenvironment	  when	  developing	  therapies	  for	  preventing	  metastasis	  or	  targeting	  secondary	  tumors.	  	  
Tumor-­‐Associated	  Calcium	  Signal	  Transducer	  2	  (TROP2)	  	   TROP2	  (trophoblast	  antigen	  protein	  2	  or	  tumor-­‐associated	  calcium	  signal	  transducer	  2)	  is	  a	  35.7	  kDa	  transmembrane	  protein	  encoded	  by	  the	  intronless	  gene	  
TACSTD2.	  46,47	  TROP2	  was	  first	  identified	  as	  a	  marker	  of	  trophoblast	  cells	  which	  are	  cells	  that	  invade	  the	  uterine	  wall	  during	  placental	  implantation.	  48	  TROP2	  is	  closely	  related	  to	  Trop1	  or	  epithelial	  cell	  adhesion	  molecule	  (Epcam).	  	  The	  two	  proteins	  have	  49%	  sequence	  identity	  and	  67%	  similarity,	  the	  greatest	  homology	  occurs	  in	  the	  transmembrane	  region	  and	  the	  thyroglobulin	  repeat	  domain.	  49	  TROP2	  has	  a	  short	  cytoplasmic	  tail	  that	  is	  involved	  in	  intracellular	  signaling.	  	  The	  cytoplasmic	  tail	  of	  TROP2	  can	  be	  phosphorylated	  by	  protein	  kinase	  c	  (PKC)	  50	  and	  also	  contains	  a	  phosphatidylinositol	  4,5	  bisphosphate	  (PIP2)	  binding	  site.	  51	  The	  cytoplasmic	  tail	  is	  similar	  to	  a	  HIKE	  domain52	  and	  may	  be	  involved	  in	  binding	  pleckstrin	  homology	  domains	  such	  as	  those	  found	  in	  G-­‐proteins,	  kinases,	  ankyrin	  and	  kinesin.	  53	  The	  HIKE	  domain	  similarity	  also	  indicates	  the	  potential	  role	  for	  TROP2	  in	  calcium	  signaling	  as	  the	  calcium	  signaling	  molecule,	  Calmodulin,	  can	  bind	  HIKE	  domains	  in	  G-­‐proteins.53,54	  Mutations	  in	  TACSTD2	  are	  known	  to	  cause	  the	  autosomal	  recessive	  disorder	  Gelatinous	  drop-­‐like	  corneal	  dystrophy	  (GDLD)	  in	  humans,	  a	  disease	  causing	  corneal	  amyloidosis	  and	  ultimately	  blindness.	  55	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As	  reviewed	  by	  McDougall	  54	  and	  others,	  TROP2	  is	  known	  to	  regulate	  various	  aspects	  of	  lung	  and	  kidney	  development,	  and	  is	  also	  involved	  in	  intracellular	  signaling	  and	  expressed	  in	  many	  epithelial	  cancers.	  	  By	  binding	  to	  neuregulin	  1	  (NRG1),	  TROP2	  can	  sequester	  NRG	  in	  the	  cytoplasm,	  therefore	  blocking	  release	  of	  NRG1	  ectodomain	  and	  preventing	  ErbB3	  signaling.	  56	  TROP2	  can	  regulate	  focal	  adhesion	  dynamics	  by	  recruiting	  RACK1	  to	  the	  membrane	  and	  binding	  β1	  integrin,	  which	  increases	  FAK	  phosphorylation	  leading	  to	  increased	  cell	  motility	  and	  decreased	  adhesion.	  57	  When	  cleaved	  by	  regulated	  intramembrane	  proteolysis,	  the	  resulting	  intracellular	  TROP2	  fragment	  can	  interact	  with	  β-­‐catenin	  to	  promote	  transcription	  of	  Cyclin	  D1	  and	  c-­‐myc.	  58	  TROP2	  has	  been	  shown	  to	  affect	  MAPK	  signaling	  by	  regulating	  ERK	  phosphorylation.	  59-­‐62	  Activation	  of	  TROP2	  can	  increase	  intracellular	  calcium	  concentrations.	  63	  This	  presumably	  occurs	  via	  the	  predicted	  PIP2	  binding	  site	  in	  the	  cytoplasmic	  tail	  of	  TROP2.	  	  Hydrolysis	  of	  PIP2	  yields	  diacylglycerol	  (DAG)	  and	  inositol	  1,4,5-­‐triphosphate	  (IP3).	  	  DAG	  can	  then	  activate	  the	  PKC	  and	  MAPK	  pathways,	  while	  IP3	  binds	  to	  its	  receptor	  on	  the	  endoplasmic	  reticulum,	  which	  causes	  calcium	  to	  be	  released	  from	  intracellular	  stores.	  54	  TROP2	  may	  be	  involved	  in	  promoting	  tumor	  growth	  and	  metastasis,	  54	  however	  TROP2	  seems	  to	  have	  the	  opposite	  effect	  in	  lung	  cancer	  as	  expression	  of	  TROP2	  inhibits	  tumor	  growth.61	  	   Interestingly,	  Lin	  and	  colleagues	  61	  found	  that	  TACSTD2	  expression	  is	  regulated	  by	  promoter	  methylation	  in	  lung	  cancer	  cell	  lines	  and	  lung	  adenocarcinoma	  tissues.	  	  Low	  TROP2	  mRNA	  expression	  was	  observed	  along	  with	  hypermethylation	  of	  the	  TACSTD2	  promoter.	  	  Normal	  tissues	  had	  high	  TROP2	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expression,	  while	  tumor	  tissues	  had	  promoter	  methylation	  and	  low	  TROP2	  expression.	  	  Furthermore,	  treatment	  of	  CL1-­‐0	  and	  A549	  cell	  lines	  with	  the	  DNMT	  inhibitor,	  5-­‐aza-­‐2’-­‐deoxycytidine,	  decreased	  methylation	  and	  restored	  TROP2	  mRNA	  and	  protein	  expression.	  	  Forced	  TACSTD2	  expression	  in	  lung	  cancer	  cell	  lines	  inhibits	  proliferation	  and	  colony	  formation	  and	  blocks	  phosphorylation	  of	  AKT	  and	  ERK.	  	  Knockdown	  of	  TACSTD2	  increases	  proliferation,	  colony	  formation	  and	  phosphorylation	  of	  AKT	  and	  ERK.	  	  Additionally,	  TACSTD2	  knockdown	  increases	  tumor	  volume	  in	  a	  mouse	  xenograft	  model.	  The	  authors	  also	  found	  that	  TROP2	  interacts	  directly	  with	  IGF-­‐1.	  	  The	  region	  between	  the	  EGF-­‐like	  and	  thyroglobulin	  type-­‐1	  domain	  of	  TROP2	  mediated	  this	  interaction.	  	  Overexpression	  of	  Trop2	  inhibits	  IGF-­‐1R	  signaling	  by	  blocking	  phosphorylation	  of	  AKT	  and	  decreasing	  β-­‐catenin	  expression.	  	  They	  conclude	  that	  silencing	  of	  TACSTD2	  expression	  in	  lung	  cancer	  results	  in	  increased	  IGF-­‐1R	  signaling,	  activation	  of	  AKT	  and	  ERK	  and	  increased	  expression	  of	  β-­‐catenin	  and	  Slug,	  which	  contribute	  to	  tumor	  invasion,	  metastasis	  and	  angiogenesis.61	  	   Although	  TROP2	  seems	  to	  suppress	  tumor	  growth	  in	  lung	  cancer,	  it	  has	  been	  found	  to	  promote	  the	  growth	  of	  other	  types	  of	  cancer.	  	  TROP2	  mRNA	  has	  been	  found	  in	  normal	  tissues	  including	  breast,	  cervix,	  endometrium,	  oesophagus,	  fallopian	  tubes,	  kidney,	  pancreas,	  placenta,	  prostate,	  respiratory	  tract,	  salivary	  glands,	  seminal	  vesicles,	  stomach,	  tonsils,	  thymus	  and	  vagina.	  64	  Increased	  TROP2	  expression	  in	  tumor	  tissue	  compared	  to	  normal	  tissue	  has	  been	  found	  in	  lung,	  breast,	  stomach,	  pancreas,	  liver,	  kidney,	  colorectal	  and	  ovarian	  cancers.	  64	  In	  breast	  cancer,	  membrane	  localization	  of	  TROP2	  is	  correlated	  with	  a	  poor	  prognosis	  while	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intracellular	  TROP2	  is	  associated	  with	  increased	  survival.	  65	  However,	  it	  is	  not	  known	  whether	  TROP2	  expression	  is	  regulated	  by	  promoter	  methylation	  in	  breast	  cancer	  and	  the	  role	  of	  TROP2	  in	  tamoxifen	  resistance	  is	  not	  clear.	  Therefore,	  another	  objective	  of	  this	  project	  is	  to	  evaluate	  the	  role	  of	  TROP2	  in	  tamoxifen	  resistance.	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(A)	   	   	   	   (B)	   	   	   	   (C)	  	  
	  
Figure	  1.1:	  Normal	  Breast	  Anatomy.	  	  Profile	  of	  normal	  breast	  (A).	  	  Structure	  of	  terminal	  duct	  lobular	  unit	  where	  milk	  is	  produced	  (B).	  	  Cross	  section	  of	  breast	  duct	  showing	  myoepithelia/basal	  cells	  and	  luminal	  epithelial	  cells	  (C).	  	  Image	  from	  http://www.pathophys.org/breast-­‐cancer/.6	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(A)	   	   	   	   	  (B)	   	   	   	   	  	  	  	  (C)	  
	  









Figure1.3:	  Basal	  Verses	  Luminal	  Breast	  Cancers.	  	  Cross	  sectional	  view	  of	  mammary	  duct	  showing	  location	  of	  luminal	  epithelial	  and	  myoepithelial	  cells	  (A).	  Summary	  of	  molecular	  subtypes	  of	  breast	  cancer	  and	  the	  cells	  from	  which	  they	  originate.	  	  Incidences	  of	  molecular	  subtypes,	  hormone	  receptor	  expression	  (estrogen	  receptor	  (ER)	  and	  progesterone	  receptor	  (PR)	  and	  human	  epidermal	  growth	  factor	  receptor	  (HER2)	  status	  based	  on	  general	  U.S.	  populations	  in	  2010	  from	  the	  NCI	  SEER	  Database	  and	  adapted	  from5	  (B).	  Modified	  from	  http://www.pathophys.org/breast-­‐cancer/.6	  	  







Figure	  1.4:	  The	  Hallmarks	  of	  Cancer.	  	  The	  six	  original	  Hallmarks	  of	  Cancer	  as	  defined	  by	  Hanahan	  Weinberg	  in	  2000	  (A).	  	  Two	  additional	  hallmarks	  and	  two	  enabling	  characteristics	  of	  cancer	  cells	  as	  defined	  by	  Hanahan	  and	  Weinberg	  in	  2011	  (B).	  	  Images	  from	  Hanahan	  and	  Weinberg.	  Cell.	  2011.8	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Figure	  1.5:	  Chromatin	  Structure	  and	  Epigenetics	  in	  Normal	  Cells.	  In	  normal	  cells,	  untranscribed	  regions	  of	  the	  genome	  have	  condensed	  chromatin	  (heterochromatin)	  with	  tightly	  packed	  nucleosomes,	  methylated	  CpG	  sites	  and	  deacetylated	  histones.	  	  Transcribed	  regions	  of	  the	  genome	  (euchromatin)	  are	  characterized	  by	  open	  nucleosome	  positioning	  with	  unmethylated	  CpG	  sites	  and	  acetylated	  histones.	  	  Image	  from	  Azad	  et	  al.	  2013.13	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Figure	  1.6:	  DNA	  Methyltransferase	  (DNMT)	  Converts	  Cytosine	  to	  5-­‐
Methylcytosine.	  DNMT	  catalyzes	  the	  conversion	  of	  cytosine	  to	  5-­‐methylcytosine	  by	  transferring	  a	  methyl	  group	  (CH3)	  from	  S-­‐adenosylmethionine	  (SAM)	  to	  the	  5-­‐carbon	  position	  of	  cytosine.	  Figure	  from	  of	  Gibney	  and	  Nolan	  2010.18	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Figure	  1.7:	  Treatment	  of	  Recurrent	  Breast	  Cancer.	  Flow	  chart	  depicting	  treatment	  of	  recurrent	  breast	  cancer	  with	  approximate	  percentages	  of	  cases	  indicated	  in	  parentheses.	  (ER+:	  ER-­‐positive,	  ER-­‐:	  ER-­‐negative,	  SERM:	  selective	  estrogen	  receptor	  modulator).	  	  Information	  summarized	  from	  24,28,29,32,33.	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(A)	   	   	   	   	   	   	   (B)	  
	  
Figure	  1.8:	  Development	  of	  Tamoxifen-­‐Resistant	  Cell	  Lines.	  Schematic	  of	  Tamoxifen	  selection	  (A)	  (adapted	  from37).	  	  Estrogen	  receptor	  (ER),	  progesterone	  receptor	  (PR)	  and	  human	  epidermal	  growth	  factor	  receptor-­‐2	  (HER-­‐2)	  status	  for	  the	  parental	  line,	  MCF-­‐7,	  and	  the	  three	  tamoxifen-­‐resistant	  lines,	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28	  (B)	  (positive:	  +,	  negative:	  -­‐).	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DNA	  METHYLATION	  ANLYSIS	  	  
Introduction	  Aberrant	  DNA	  methylation	  is	  known	  to	  occur	  early	  during	  tumorigenesis	  and	  is	  often	  seen	  in	  breast	  cancer.	  	  Methyl	  groups	  are	  added	  to	  the	  cytosines	  of	  CpG	  dinucleotides	  by	  DNA	  methyltransferases	  (DNMTs).	  16	  CpG-­‐rich	  regions	  of	  the	  genome	  that	  are	  approximately	  1kb	  in	  length	  are	  known	  as	  CpG	  islands.	  19	  Although	  global	  hypomethylation	  is	  characteristic	  of	  cancer	  cells	  and	  genomic	  instability,	  methylation	  of	  CpG	  islands	  is	  frequently	  observed	  in	  cancer.	  	  Hypermethylation	  of	  CpG	  islands	  clustered	  in	  the	  promoter	  region	  of	  genes	  leads	  to	  suppression	  of	  gene	  expression	  and	  often	  silencing	  of	  tumor	  suppressors	  and	  transcription	  factors.	  21	  Because	  these	  epigenetic	  changes	  associated	  with	  breast	  cancer	  are	  thought	  to	  occur	  early	  during	  disease	  progression,	  they	  could	  potentially	  be	  used	  as	  biomarkers.	  	  Targeting	  DNA	  methylation	  could	  be	  an	  effective	  therapy	  for	  breast	  cancer	  because	  DNA	  methylation	  may	  be	  reversed	  by	  epigenetic	  therapies	  or	  dietary	  changes.	  	  However,	  it	  will	  be	  necessary	  to	  identify	  the	  patients	  who	  are	  likely	  to	  benefit	  from	  epigenetic	  therapy	  in	  order	  to	  minimize	  off-­‐target	  effects.	  Treatment	  with	  the	  DNMT1	  inhibitor,	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  decreases	  methylation	  and	  is	  known	  to	  restore	  expression	  of	  genes	  that	  are	  hypermethylated	  in	  cancer.	  66-­‐69	  Upon	  incorporation	  into	  DNA,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  binds	  covalently	  with	  DNMT1	  (forming	  an	  irreversible	  intermediate),	  which	  leads	  to	  enzyme	  degradation,	  loss	  of	  methylation	  with	  subsequent	  cell	  divisions	  and	  re-­‐
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expression	  of	  genes	  silenced	  by	  promoter	  methylation	  (Figure	  2.1).	  70,71	  Treatment	  with	  5-­‐aza-­‐2’-­‐deoxycytidine	  is	  an	  effective	  epigenetic	  therapy	  for	  myelodysplastic	  syndrome	  (MDS).	  72	  Currently,	  it	  is	  being	  evaluated	  as	  a	  possible	  treatment	  for	  solid	  tumors.	  	  However,	  it	  is	  not	  known	  whether	  5-­‐aza-­‐2’-­‐deoxycytidine	  treatment	  would	  be	  an	  effective	  therapy	  for	  ER-­‐negative,	  recurrent	  breast	  cancer.	  	  Therefore,	  I	  will	  examine	  the	  effect	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  on	  methylation	  in	  the	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  line,	  TMX2-­‐28,	  and	  determine	  the	  role	  of	  promoter	  methylation	  in	  regulation	  of	  gene	  expression	  and	  cell	  behavior.	  Endocrine	  resistance	  causes	  changes	  in	  gene	  expression	  in	  various	  signaling	  pathways	  including	  estrogen	  receptor	  (ER),	  growth	  factor,	  cytoplasmic,	  cell	  cycle,	  apoptosis	  and	  cell	  survival	  signaling.	  23	  Aberrant	  DNA	  methylation	  is	  known	  to	  be	  an	  early	  event	  during	  tumorigenesis	  and	  occurs	  frequently	  in	  breast	  cancer.	  13,16	  Several	  studies	  involving	  endocrine	  resistance	  and	  DNA	  methylation	  use	  ER-­‐positive,	  tamoxifen-­‐resistant	  cell	  line	  models.	  	  Changes	  in	  DNA	  methylation	  across	  the	  genome	  have	  been	  observed	  in	  ER-­‐positive,	  tamoxifen-­‐resistant	  breast	  cancer	  cell	  lines.	  25,27,31	  Gene-­‐specific	  differences	  in	  DNA	  methylation	  have	  been	  shown	  to	  correlate	  with	  changes	  in	  mRNA	  expression	  in	  other	  ER-­‐positive,	  tamoxifen-­‐resistant	  lines.	  73	  However,	  there	  is	  little	  information	  on	  the	  role	  of	  methylation	  in	  the	  development	  of	  ER-­‐negative,	  acquired	  tamoxifen	  resistance.	  	  These	  patients	  have	  limited	  treatment	  options	  available	  upon	  disease	  recurrence	  and	  could	  possibly	  benefit	  from	  epigenetic	  therapy.	  According	  to	  Lin	  et	  al.	  2013,	  there	  are	  three	  methods	  for	  the	  development	  of	  tamoxifen	  resistance.	  	  The	  first	  is	  that	  ER-­‐positive	  cells	  acquire	  epigenetic	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alterations,	  which	  result	  in	  changes	  in	  mRNA	  expression	  of	  genes	  important	  for	  estrogen-­‐dependent	  growth.	  	  Second,	  tamoxifen	  treatment	  results	  in	  the	  selection	  of	  pre-­‐existing	  cancer	  initiating	  cells/cancer	  stem	  cells.	  	  The	  third	  mechanism	  is	  a	  combination	  of	  the	  two	  mechanisms.	  	  Modified	  DNA	  methylation-­‐specific	  digital	  karyotyping	  (MMSDK)	  and	  digital	  gene	  expression	  (DGE)	  combined	  with	  next-­‐generation	  parallel	  sequencing	  was	  used	  to	  compare	  DNA	  methylation	  and	  gene	  expression	  profiles	  of	  parental	  and	  MCF-­‐7-­‐derived,	  ER-­‐positive	  tamoxifen-­‐resistant	  cell	  lines.	  	  Two	  different	  resistant	  cell	  models	  were	  used.	  	  Both	  were	  treated	  with	  4-­‐hydroxy	  tamoxifen	  but	  in	  different	  methods.	  	  The	  TAMR	  cell	  lines	  were	  grown	  in	  the	  presence	  of	  1μM	  tamoxifen	  and	  the	  LCC1/LCC2	  cells	  were	  cultured	  in	  media	  with	  increasing	  doses	  of	  tamoxifen.	  	  Differences	  in	  global	  methylation	  (all	  CpG	  sites	  interrogated)	  and	  global	  gene	  expression	  were	  observed	  between	  the	  parental	  cell	  line	  and	  the	  TAMR	  cell	  lines.	  	  Overall,	  the	  TAMR	  cell	  lines	  had	  higher	  methylation	  than	  MCF-­‐7.	  	  In	  general,	  the	  authors	  conclude	  that	  DNA	  methylation	  in	  the	  promoter	  region	  is	  associated	  with	  decreased	  gene	  expression.	  	  Some	  of	  the	  genes	  identified	  in	  their	  analyses	  with	  high	  expression	  in	  the	  TAMR	  cell	  lines	  were	  associated	  with	  pluripotency	  and	  differentiation,	  such	  as	  SOX2.	  	  Therefore,	  the	  authors	  conclude	  that	  stem	  cell-­‐like	  cells	  and	  cancer-­‐initiating	  cells	  may	  play	  a	  role	  in	  ER-­‐positive,	  acquired	  tamoxifen	  resistance.27	  In	  an	  earlier	  study,	  Fan	  and	  colleagues	  examined	  DNA	  methylation	  and	  gene	  expression	  in	  tamoxifen-­‐	  and	  fulvestrant-­‐resistant	  clones	  of	  MCF-­‐7	  cells.	  	  Tamoxifen-­‐	  and	  fulvestrant-­‐resistant	  cell	  lines	  were	  derived	  from	  a	  clone	  of	  MCF-­‐7	  cells,	  stably	  transfected	  with	  an	  ERα-­‐responsive	  luciferase	  reporter	  and	  exposed	  to	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4-­‐hydroxytamoxifen	  or	  Fulvestrant	  for	  12	  months.	  	  MCF-­‐7-­‐T	  (tamoxifen-­‐resistant)	  cells	  expressed	  ERα	  protein	  at	  a	  higher	  level	  than	  MCF-­‐7	  cells.	  	  MCF-­‐7-­‐F	  (fulvestrant-­‐resistant)	  cells	  had	  a	  90%	  decrease	  in	  ERα	  protein	  compared	  to	  MCF-­‐7	  cells.	  	  The	  authors	  examined	  gene	  expression	  using	  the	  Affymetrix	  Human	  Genome	  U133	  Plus	  2.0	  Array	  and	  DNA	  methylation	  using	  a	  custom	  60-­‐mer	  oligonucleotide	  microarray	  covering	  approximately	  44,000	  CpG-­‐rich	  fragments	  and	  12,000	  promoters.	  	  They	  found	  that	  activation	  of	  genes	  that	  promote	  cell	  growth	  was	  correlated	  with	  promoter	  hypomethylation	  in	  the	  antiestrogen-­‐resistant	  line	  more	  frequently	  than	  inactivation	  of	  genes	  due	  to	  hypermethylation.	  	  Gene	  expression	  in	  the	  tamoxifen-­‐resistant	  line	  and	  the	  parental	  cell	  line	  was	  more	  similar	  than	  gene	  expression	  in	  the	  fulvestrant-­‐resistant	  and	  parental	  cell	  line.	  	  Genes	  in	  the	  EGFR/ErbB2	  pathway	  were	  involved	  in	  regulating	  cell	  growth	  in	  both	  the	  MCF-­‐7-­‐T	  and	  MCF-­‐7-­‐F	  cell	  lines.	  	  Altered	  signaling	  pathways	  in	  MCF-­‐7-­‐T	  included	  PKA,	  caveolins,	  annexins,	  S100	  calcium	  binding	  proteins,	  MAPK	  phosphatases	  and	  inhibitors	  of	  differentiation.	  	  Activation	  of	  β-­‐catenin	  was	  important	  in	  the	  fulvestrant-­‐resistant	  cell	  line.	  	  In	  contrast	  to	  results	  from	  our	  lab	  and	  results	  from	  other	  labs,	  activation	  of	  genes	  due	  to	  promoter	  hypomethylation	  was	  more	  common	  in	  these	  antiestrogen-­‐resistant	  cell	  lines	  than	  inactivation	  due	  to	  promoter	  hypermethylation.25	  Interestingly,	  Stone	  et	  al.	  2012	  found	  that	  tamoxifen	  treatment	  caused	  promoter	  methylation	  and	  silencing	  of	  estrogen-­‐responsive	  genes	  in	  another	  ER-­‐positive	  cell	  line	  models	  of	  tamoxifen	  resistance.	  	  MCF-­‐7	  cells	  were	  treated	  with	  4-­‐hydroxytamoxifen	  (1	  x	  10-­‐7	  M)	  for	  10	  months	  and	  then	  withdrawn	  from	  tamoxifen	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(grown	  in	  tamoxifen-­‐free	  media	  for	  up	  to	  6	  months).	  	  The	  TAM-­‐R	  cells	  still	  expressed	  ER	  protein,	  but	  had	  reduced	  protein	  expression	  levels.	  	  Withdraw	  from	  tamoxifen	  restored	  expression	  of	  ER,	  but	  the	  cells	  were	  still	  resistant	  to	  tamoxifen.	  	  Increased	  promoter	  methylation	  was	  observed	  for	  pS2	  and	  PR	  in	  the	  resistant	  and	  withdrawn	  cells.	  	  Combined	  treatment	  of	  5-­‐Azacytidine	  with	  17-­‐Beta-­‐estradiol	  (E2)	  decreases	  methylation	  and	  restores	  gene	  expression	  of	  pS2	  and	  PR.	  	  The	  authors	  found	  that	  combined	  5-­‐Azacytidine	  (analog	  that	  is	  incorporated	  into	  DNA	  and	  RNA)	  treatment	  with	  E2	  inhibits	  proliferation	  in	  the	  withdrawn	  cells.	  	  The	  authors	  conclude	  that	  tamoxifen	  exposure	  causes	  silencing	  of	  estrogen-­‐responsive	  genes	  via	  increased	  promoter	  methylation.	  	  These	  genes	  normally	  function	  to	  inhibit	  proliferation	  and	  reactivation	  of	  these	  genes	  with	  5-­‐Azacytidine	  could	  be	  a	  potential	  therapeutic	  for	  tamoxifen-­‐resistant	  breast	  cancer.73	  Prior	  studies	  in	  our	  lab	  have	  shown	  that	  ER-­‐negative,	  TMX2-­‐28	  cells	  have	  increased	  DNA	  methylation	  compared	  to	  the	  parental	  line,	  MCF-­‐7.	  	  The	  Illumina	  Human	  Methylation	  450	  BeadChip	  was	  used	  to	  examine	  differences	  in	  DNA	  methylation	  between	  two	  tamoxifen-­‐resistant	  cell	  lines,	  TMX2-­‐11	  (ER-­‐positive)	  and	  TMX2-­‐28	  (ER-­‐negative),	  and	  the	  parental	  cell	  line,	  MCF-­‐7.	  	  The	  ER-­‐negative,	  TMX2-­‐28	  cell	  line	  had	  more	  hypermethylated	  CpG	  sites	  compared	  to	  the	  parental	  cell	  line	  than	  TMX2-­‐11.	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreased	  promoter	  methylation	  of	  two	  genes,	  MAGED1	  and	  ZNF350,	  which	  were	  hypermethylated	  in	  both	  TMX2-­‐11	  and	  TMX2-­‐28.	  	  Promoter	  methylation	  seems	  to	  regulate	  expression	  of	  MAGED1	  and	  ZNF350	  in	  TMX2-­‐28,	  as	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  increased	  mRNA	  expression	  in	  this	  cell	  line.	  31	  However,	  little	  is	  known	  about	  the	  relationship	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between	  DNA	  methylation,	  regulation	  of	  gene	  expression	  and	  disease	  progression	  in	  this	  model	  of	  acquired	  Tamoxifen-­‐resistance.	  	  Therefore,	  I	  will	  examine	  the	  effect	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  on	  methylation	  in	  the	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  line,	  TMX2-­‐28,	  using	  the	  Human	  Methylation	  450	  BeadChip.	  	  I	  will	  also	  investigate	  the	  role	  of	  promoter	  methylation	  in	  regulation	  of	  gene	  expression	  and	  cell	  behavior	  by	  determining	  the	  effect	  of	  treating	  cells	  with	  the	  methylation	  inhibitor,	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  on	  cell	  proliferation,	  adhesion	  and	  migration.	  	  
Materials	  and	  Methods	  Cell	  culture:	  	  MCF-­‐7	  cells	  were	  purchased	  from	  the	  American	  Type	  Culture	  Collection	  (ATCC).	  	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28	  cells	  were	  provided	  by	  John	  Gierthy	  (Wadsworth	  Center	  Albany,	  NY).	  	  Cells	  were	  grown	  in	  Dulbecco’s	  modified	  eagle	  medium	  (without	  phenol	  red).	  	  Medium	  was	  supplemented	  with	  5%	  cosmic	  calf	  serum	  (Hyclone	  Cat.	  No.	  SH30087.03),	  2.0	  mM	  of	  L-­‐glutamine,	  0.1	  mM	  of	  nonessential	  amino	  acids	  and	  250	  ng/mL	  of	  insulin.	  	  Cells	  were	  maintained	  at	  37°C,	  5%	  CO2	  in	  a	  humidified	  incubator	  and	  passaged	  at	  subconfluence	  or	  media	  exchanged	  every	  2	  days.	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment:	  	  Cells	  were	  seeded	  into	  6-­‐well	  plates	  and	  allowed	  to	  adhere	  overnight	  at	  37°C,	  5%	  CO2.	  	  Cells	  were	  treated	  with	  either	  0.1%	  DMSO	  (vehicle	  control)	  or	  2.5	  μM	  5-­‐Aza-­‐2’-­‐deoxycytidine	  (Aza	  or	  5-­‐Aza-­‐CdR)	  (Sigma-­‐Aldrich	  Cat.	  No.	  A3656)	  in	  0.1%	  DMSO	  for	  96	  hours,	  with	  media	  exchanged	  every	  other	  day.	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DNA	  and	  RNA	  Isolation:	  	  DNA	  was	  isolated	  with	  the	  QIAamp	  DNA	  Mini	  Kit	  (Qiagen	  Cat.	  No.	  51304)	  as	  per	  manufacturer	  instructions	  and	  protocols	  described	  previously.	  74,75	  RNA	  was	  isolated	  using	  TriReagent	  (Molecular	  Research	  Center,	  Inc.	  Cat.	  No.	  TR118).	  	  Purified	  DNA	  and	  RNA	  were	  quantified	  using	  a	  NanoDrop	  8000	  (Thermo	  Scientific).	  Illumina	  Human	  Methylation	  450	  BeadChip:	  	  DNA	  samples	  from	  control	  and	  Aza-­‐treated	  MCF-­‐7,	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28	  cells	  were	  sent	  to	  the	  University	  of	  Southern	  California	  for	  HM450	  BeadChip	  (Illumina	  Cat.	  No.	  WG-­‐314-­‐1003)	  analysis.	  	  Briefly,	  DNA	  was	  quantified	  using	  an	  Alu	  PCR	  reaction	  and	  bisulfite-­‐treated.	  	  Bisulfite-­‐treated	  DNA	  was	  then	  quantified	  by	  additional	  PCR	  reactions	  prior	  to	  running	  on	  the	  array.	  	  Then	  the	  DNA	  was	  enzymatically	  fragmented	  at	  37	  °C	  for	  1	  hour	  and	  precipitated	  in	  100%	  2-­‐propanol	  at	  4	  °C	  for	  30	  min.	  followed	  by	  centrifugation	  at	  3000	  ×	  g	  at	  4	  °C	  for	  20	  min.	  	  After	  resuspension	  in	  hybridization	  buffer	  of	  dried	  pellets,	  samples	  were	  incubated	  at	  48	  °C	  for	  1	  hour	  followed	  by	  95	  °C	  for	  20	  min.	  after	  which	  the	  samples	  were	  loaded	  onto	  the	  HM450	  BeadChip	  and	  incubated	  at	  48	  °C	  for	  16-­‐24	  hours.	  	  After	  hybridization	  of	  DNA	  to	  the	  primers	  on	  the	  BeadChip,	  wash	  buffers	  were	  used	  to	  remove	  non-­‐specific	  and	  unhybridized	  DNA.	  	  A	  single-­‐base	  extension	  of	  the	  hybridized	  primers	  was	  then	  conducted	  using	  labeled	  nucleotides	  and	  the	  BeadChip	  was	  stained	  with	  Cy-­‐3	  and	  Cy-­‐5	  fluorescent	  dyes.	  	  The	  BeadChip	  was	  then	  read	  using	  the	  Illumina	  iScan	  Reader.	  	  Illumina	  GenomeStudio	  was	  then	  used	  to	  analyze	  the	  image	  data	  to	  determine	  the	  efficiency	  of	  the	  reaction.	  	  The	  ratio	  of	  the	  fluorescent	  signals	  of	  methylated	  to	  unmethylated	  sites	  (beta	  values)	  was	  used	  to	  calculate	  the	  methylation	  of	  interrogated	  CpG	  loci.	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The	  HM450	  BeadChip	  includes	  485,764	  cytosine	  sites	  across	  the	  human	  genome	  and	  is	  enriched	  for	  gene	  promoters	  (482,421	  of	  the	  sites	  are	  CpG	  sites	  and	  3,343	  are	  CNG	  sites).	  76	  The	  functional	  distribution,	  as	  defined	  by	  Illumina,	  of	  the	  sites	  is	  as	  follows:	  200,339	  sites	  are	  located	  in	  the	  promoter	  (within	  200-­‐1500	  bp	  upstream	  of	  the	  transcription	  start	  site,	  5’-­‐UTR	  or	  exon	  1),	  15,383	  are	  in	  the	  3’-­‐UTR,	  150,212	  are	  in	  the	  gene	  body	  and	  119,830	  sites	  are	  intergenic.	  	  When	  considering	  the	  CpG	  content	  or	  neighborhood	  distribution	  of	  sites,	  150,254	  are	  located	  in	  a	  CpG	  island,	  112,072	  and	  47,161	  are	  located	  in	  CpG	  shores	  and	  shelves,	  respectively	  and	  the	  remaining	  176,277	  are	  isolated	  CpG’s	  in	  the	  “open	  sea.”	  	  The	  majority	  of	  sites	  on	  the	  HM450	  BeadChip,	  361,766,	  are	  located	  in	  genes	  that	  encode	  RNA	  transcripts.	  	  While	  4,168	  sites	  are	  non-­‐coding	  and	  119,830	  are	  intergenic	  (Figure	  2.2).	  mRNA	  Expression	  Array:	  	  RNA	  was	  isolated	  from	  two	  biological	  replicates	  of	  MCF-­‐7	  and	  TMX2-­‐28	  cells	  (cultured	  under	  normal	  conditions	  without	  Aza)	  as	  described	  above.	  	  The	  total	  quantity	  of	  RNA	  sent	  to	  the	  Troester	  Lab	  at	  the	  University	  of	  North	  Carolina	  Chapel	  Hill	  ranged	  from	  3.7	  –	  6.8	  μg.	  	  Samples	  were	  run	  on	  the	  Agilent	  4x44k	  V2	  Microarray	  with	  2-­‐color,	  low	  input	  quick	  amp	  labeling	  kit	  (Agilent).	  	  Collaborators	  at	  the	  University	  of	  North	  Carolina	  Chapel	  Hill	  conducted	  preliminary	  data	  analysis.	  Data	  Analysis:	  	  The	  methylation	  data	  obtained	  from	  the	  HM450	  BeadChip	  was	  analyzed	  using	  Genome	  Studio	  Methylation	  Module	  (v.1.9.0).	  	  Detection	  p-­‐values	  of	  <	  0.01	  were	  used	  to	  select	  statistically	  significant	  CpG	  site	  data.	  	  Figures	  were	  made	  in	  either	  Microsoft	  Excel	  or	  PowerPoint	  for	  Mac	  2011.	  	  Statistical	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analysis	  was	  conducted	  using	  the	  SatPlus	  application	  (v.	  5.8.2.0).	  	  RT-­‐PCR	  data	  was	  analyzed	  using	  an	  un-­‐paired	  Student	  t	  test	  (StatPlus	  for	  Mac	  v.	  5.8.2.0).	  Two-­‐Step	  Reverse	  Transcriptase	  PCR	  (RT-­‐PCR):	  	  Changes	  in	  gene	  expression	  after	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  were	  confirmed	  by	  two-­‐step	  RT-­‐PCR.	  	  RNA	  was	  reverse	  transcribed	  using	  the	  High-­‐Capacity	  cDNA	  Reverse	  Transcription	  Kit	  (Applied	  Biosytems)	  supplemented	  with	  the	  RNase	  Inhibitor,	  RNasin	  (Promega).	  	  cDNA	  was	  then	  quantified	  using	  a	  NanoDrop	  8000	  (Thermo	  Scientific)	  and	  diluted	  to	  50	  ng/μL.	  	  Primers	  for	  RT-­‐PCR	  were	  designed	  to	  span	  an	  exon-­‐exon	  junction	  using	  Primer-­‐BLAST	  (NIH)	  (Table	  2.1).	  	  RT-­‐PCR	  was	  conducted	  using	  the	  FastStart	  Universal	  SYBR	  Green	  Master	  (with	  Rox	  Reference	  Dye)	  (Roche)	  on	  the	  Stratagene	  MxPro	  (Mx3005P,	  Agilent).	  	  Relative	  mRNA	  expression	  will	  be	  quantified	  using	  the	  Standard	  Curve	  Method	  normalized	  to	  beta-­‐actin	  or	  by	  comparison	  of	  cycle	  thresholds.	  	  
Results	  
5-­‐Aza-­‐2’-­‐deoxycytidine	  Alters	  Global	  DNA	  Methylation	  Previous	  studies	  in	  cell	  line	  models	  have	  indicated	  that	  DNA	  methylation	  may	  be	  involved	  in	  tamoxifen	  resistance.	  25,27,73	  However,	  the	  majority	  of	  these	  studies	  involve	  ER-­‐positive,	  tamoxifen-­‐resistant	  cell	  lines	  and	  little	  is	  known	  about	  the	  role	  of	  DNA	  methylation	  in	  ER-­‐negative,	  acquired	  tamoxifen	  resistance.	  	  Using	  the	  HM450	  BeadChip,	  our	  lab	  found	  global	  differences	  (among	  the	  CpG	  sites	  included	  on	  the	  HM450	  BeadChip)	  in	  DNA	  methylation	  between	  tamoxifen-­‐resistant	  cell	  lines	  compared	  to	  the	  parental	  cell	  line,	  MCF-­‐7.	  31	  DNA	  methylation	  in	  the	  ER-­‐negative,	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tamoxifen-­‐resistant	  cell	  line,	  TMX2-­‐28,	  differed	  the	  most	  from	  the	  parental	  cell	  line,	  MCF-­‐7.	  	  Overall,	  TMX2-­‐28	  is	  hypermethylated	  compared	  to	  the	  parental	  cell	  line.	  	  However,	  it	  is	  not	  known	  how	  the	  DNMT1	  inhibitor,	  5-­‐Aza-­‐2’	  -­‐deoxycytidine,	  affects	  global	  methylation	  in	  MCF-­‐7	  or	  the	  tamoxifen-­‐resistant	  cell	  lines.	  To	  examine	  the	  effect	  of	  5-­‐Aza-­‐2’-­‐deoxycytine	  treatment	  on	  DNA	  methylation	  in	  the	  parental	  cell	  line,	  MCF-­‐7,	  and	  the	  three	  tamoxifen-­‐resistant	  cell	  lines	  were	  treated	  with	  2.5	  μM	  5-­‐Aza-­‐2’-­‐deoxycytidine	  or	  vehicle	  control	  for	  96	  hours.	  	  DNA	  was	  isolated	  and	  sent	  to	  the	  University	  of	  Southern	  California	  for	  HM450	  analysis.	  	  The	  data	  were	  analyzed	  using	  Illumina	  Genome	  Studio	  software.	  	  First,	  global	  DNA	  methylation	  (among	  the	  CpG	  sites	  included	  on	  the	  HM450	  BeadChip)	  in	  each	  tamoxifen-­‐resistant	  cell	  line	  (vehicle	  control-­‐treated	  sample)	  was	  compared	  to	  the	  parental	  cell	  line,	  MCF-­‐7	  vehicle	  control.	  	  In	  agreement	  with	  previously	  published	  data,	  31	  the	  ER-­‐negative	  cell	  line,	  TMX2-­‐28,	  displayed	  the	  greatest	  difference	  in	  DNA	  methylation	  from	  MCF-­‐7	  and	  had	  a	  large	  number	  of	  hypomethylated	  CpG	  sites	  (Figure	  2.3).	  	  This	  confirmed	  previous	  findings	  from	  a	  single	  experiment	  in	  our	  lab.	  	  Comparing	  TMX2-­‐28-­‐Control	  to	  MCF-­‐7-­‐Control	  and	  filtering	  beta	  values	  to	  include	  those	  greater	  than	  or	  equal	  to	  0.1	  and	  a	  fold-­‐change	  greater	  than	  or	  equal	  to	  1.8,	  there	  are	  37,501	  (8%)	  CpG	  sites	  hypermethylated	  in	  TMX2-­‐28,	  14,956	  (3%)	  CpG	  sites	  are	  hypomethylated	  and	  432,294	  (89%)	  are	  the	  same	  between	  the	  two	  cell	  lines	  (Table	  2.2).	  To	  determine	  the	  changes	  in	  methylation	  induced	  by	  5-­‐Aza-­‐2’-­‐deoxycytine	  treatment	  for	  each	  cell	  line,	  beta	  values	  for	  96-­‐hour	  5-­‐Aza-­‐2’-­‐deoxycytine	  treated	  cells	  were	  compared	  to	  those	  for	  vehicle	  control	  treated	  samples	  for	  each	  cell	  line.	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Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  affects	  global	  methylation	  in	  all	  four	  cell	  lines	  (Figure	  2.4).	  	  	  The	  ER-­‐negative	  cell	  line,	  TMX2-­‐28,	  has	  the	  greatest	  change	  in	  DNA	  methylation	  in	  response	  to	  the	  DNMT1	  inhibitor.	  	  A	  large	  number	  of	  CpG	  sites	  are	  hypomethylated	  in	  TMX2-­‐28	  while	  there	  is	  little	  change	  in	  methylation	  in	  MCF-­‐7	  treated	  with	  Aza.	  	  Using	  the	  same	  criteria	  described	  above	  to	  compare	  TMX2-­‐28-­‐Aza	  to	  TMX2-­‐28-­‐Control,	  59	  (0.01%)	  CpG	  sites	  are	  hypermethylated,	  6,637	  (1%)	  CpG	  sites	  are	  hypomethylated	  and	  478,145	  (99%)	  are	  unchanged	  (Table	  2.3).	  	  	  
Top	  5	  Genes	  With	  Decreased	  Methylation	  in	  TMX2-­‐28	  After	  5-­‐Aza-­‐2’-­‐
deoxycytidine	  Treatment	  	   To	  determine	  the	  top	  CpG	  sites	  in	  TMX2-­‐28	  that	  were	  demethylated	  upon	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment,	  beta	  values	  in	  TMX2-­‐28-­‐Control	  and	  TMX2-­‐28-­‐Aza	  ≥	  0.1	  with	  detection	  p-­‐value	  ≤	  0.01	  were	  filtered	  by	  negative	  fold	  change	  ≥	  1.8	  (average	  beta	  value	  of	  TMX2-­‐28-­‐Control	  over	  average	  beta	  value	  of	  TMX2-­‐28-­‐Aza).	  	  There	  are	  6,637	  CpG	  sites	  with	  decreased	  methylation	  in	  TMX2-­‐28	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  (Table	  2.3).	  	  The	  genes	  containing	  CpG	  sites	  with	  the	  greatest	  fold	  change	  are	  NADH	  dehydrogenase	  (ubiquinone)	  iron-­‐sulfur	  protein	  6,	  mitochondrial	  (NDUFS6),	  chromosome	  21	  open	  reading	  frame	  91	  (C21orf91),	  mitogen-­‐activated	  protein	  kinase	  8	  interacting	  protein	  3	  (MAPK8IP3),	  chromosome	  1	  open	  reading	  frame	  115	  (C1orf115)	  and	  chromosome	  1	  open	  reading	  frame	  31	  (C1orf31)	  (Table	  2.4).	  	  However,	  most	  of	  these	  single	  CpG	  sites	  were	  either	  located	  in	  the	  gene	  body	  where	  the	  relationship	  between	  methylation	  and	  gene	  expression	  is	  less	  direct	  or	  in	  open	  reading	  frames	  not	  a	  gene	  coding	  region.	  	  Therefore,	  further	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analysis	  was	  necessary	  to	  determine	  genes	  with	  more	  than	  one	  CpG	  site	  in	  the	  promoter	  region,	  which	  were	  demethylated	  upon	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  in	  TMX2-­‐28.	  	  Demethylation	  of	  CpG	  sites	  in	  the	  promoter	  region	  is	  likely	  to	  have	  an	  effect	  on	  gene	  translation.	  	  
Top	  7	  Genes	  With	  More	  Than	  One	  CpG	  Site	  in	  the	  Promoter	  Region	  With	  
Decreased	  Methylation	  in	  TMX2-­‐28	  After	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment	  	   To	  better	  identify	  decreases	  in	  methylation	  induced	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  that	  are	  likely	  to	  affect	  gene	  expression,	  the	  same	  filtering	  criteria	  described	  in	  the	  previous	  section	  but	  only	  genes	  with	  more	  than	  one	  differentially	  methylated	  CpG	  site	  in	  the	  promoter	  region	  were	  included.	  	  The	  top	  seven	  genes	  that	  contain	  more	  than	  one	  CpG	  with	  decreased	  methylation	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  are	  chromosome	  1	  open	  reading	  frame	  31	  (C1orf31),	  mitogen-­‐activated	  protein	  kinase	  15	  (MAPK15),	  HtrA	  serine	  peptidase	  1	  (HTRA1),	  zinc	  finger	  protein	  (ZNF677),	  NK6	  homeobox	  2(NKX6-­‐2),	  delta-­‐like	  1	  homolog	  (DLK1)	  and	  trophoblast	  antigen	  protein	  2	  or	  tumor-­‐associated	  calcium	  signal	  transducer	  2	  (TACSTD2)	  (Table	  2.5).	  	  To	  identify	  a	  set	  of	  genes	  with	  decreased	  promoter	  methylation	  and	  changes	  in	  gene	  expression,	  this	  list	  was	  compared	  with	  data	  from	  the	  mRNA	  expression	  array	  comparing	  MCF-­‐7	  to	  TMX2-­‐28.	  	  
Genes	  Likely	  Re-­‐expressed	  in	  TMX2-­‐28	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment	  	   Because	  I	  want	  to	  identify	  genes	  that	  are	  regulated	  by	  promoter	  methylation	  that	  are	  likely	  re-­‐expressed	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  data	  from	  the	  mRNA	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expression	  array	  comparing	  MCF-­‐7	  to	  TMX2-­‐28	  was	  also	  examined.	  	  If	  promoter	  methylation	  is	  regulating	  expression	  of	  a	  gene	  in	  TMX2-­‐28,	  I	  predict	  that	  gene	  expression	  would	  be	  decreased	  in	  TMX2-­‐28	  compared	  to	  the	  parental	  cell	  line,	  MCF-­‐7,	  because	  global	  methylation	  is	  higher	  in	  TMX2-­‐28	  (Figure	  2.3	  and	  Table	  2.2).	  	  According	  to	  the	  analysis	  of	  the	  mRNA	  expression	  array,	  there	  are	  2,414	  genes	  with	  decreased	  mRNA	  expression	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7	  (Table	  2.6).	  	  Using	  the	  criteria	  above	  for	  CpG	  sites	  with	  decreased	  methylation	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  in	  TMX2-­‐28,	  I	  identified	  genes	  that	  have	  lower	  expression	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7	  and	  that	  have	  decreased	  methylation	  in	  TMX2-­‐28	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  There	  are	  6,637	  CpG	  sites	  that	  are	  hypomethylated	  in	  TMX2-­‐28	  after	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  However,	  some	  of	  these	  decreases	  in	  methylation	  occur	  in	  areas	  outside	  the	  promoter	  region.	  	  The	  genes	  with	  decreased	  expression	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7	  and	  decreased	  methylation	  in	  TMX2-­‐28	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  are	  listed	  in	  Table	  2.8.	  	  Because	  this	  analysis	  identified	  genes	  with	  demethylation	  in	  areas	  other	  than	  the	  promoter,	  I	  decided	  to	  revise	  our	  analysis	  to	  better	  identify	  genes	  whose	  expression	  could	  be	  regulated	  by	  methylation	  in	  the	  promoter	  region	  and	  are	  affected	  by	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  I	  predict	  genes	  which	  have	  low	  expression	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7	  and	  have	  CpG	  sites	  in	  the	  promoter	  region	  that	  are	  demethylated	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  may	  be	  more	  likely	  to	  be	  re-­‐expressed	  in	  TMX2-­‐28	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	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  Genes	  With	  Differential	  Methylation	  in	  the	  Promoter	  Region	  and	  
Demethylated	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  	   To	  better	  identify	  genes	  possibly	  regulated	  by	  promoter	  methylation,	  I	  examined	  CpG	  sites	  that	  were	  differentially	  methylated	  in	  the	  promoter	  region	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7	  and	  demethylated	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  I	  filtered	  the	  HM450	  data,	  using	  the	  same	  criteria	  described	  above,	  to	  include	  CpG	  sites	  with	  an	  average	  β-­‐value	  greater	  than	  or	  equal	  to	  0.1,	  a	  fold-­‐change	  greater	  than	  or	  equal	  to	  1.8	  and	  a	  detection	  p-­‐value	  less	  than	  0.01	  (Table	  2.2).	  	  Using	  these	  criteria	  to	  compare	  TMX2-­‐28-­‐Control	  to	  the	  parental	  cell	  line,	  MCF-­‐7-­‐Control,	  37,501	  (8%)	  CpG	  sites	  are	  hypermethylated,	  14,956	  (3%)	  CpG	  sites	  are	  hypomethylated	  and	  432,294	  (89%)	  are	  unchanged.	  	  Using	  the	  same	  criteria	  to	  compare	  TMX2-­‐28-­‐Aza	  to	  TMX2-­‐28-­‐Control,	  59	  (0.01%)	  CpG	  sites	  are	  hypermethylated,	  6,637	  (1%)	  CpG	  sites	  are	  hypomethylated	  and	  478,145	  (99%)	  are	  unchanged	  (Table	  2.3).	  	  Of	  the	  37,501	  CpG	  sites	  with	  increased	  methylation	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7,	  there	  are	  707	  CpG	  sites	  which	  are	  hypermethylated	  in	  TMX2-­‐28	  compared	  to	  the	  parental	  line,	  MCF-­‐7,	  and	  also	  have	  decreased	  methylation	  in	  TMX2-­‐28	  after	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  (Table	  2.7).	  	  I	  predict	  that	  these	  differentially	  methylated	  CpG	  sites,	  which	  have	  decreased	  methylation	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment,	  are	  likely	  to	  regulate	  expression	  of	  genes	  that	  may	  be	  re-­‐expressed	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine.	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Distribution	  of	  CpG	  Sites	  that	  are	  Hypermethylated	  in	  TMX2-­‐28	  and	  Have	  
Decreased	  Methylation	  After	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment	  
	   To	  identify	  genes	  for	  which	  expression	  was	  likely	  regulated	  by	  promoter	  methylation,	  I	  examined	  the	  distribution	  of	  the	  707	  CpG	  sites	  identified	  as	  hypermethylated	  in	  TMX2-­‐28	  with	  decreased	  methylation	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  (A	  summary	  of	  the	  selection	  process	  and	  HM450K	  filtering	  is	  presented	  in	  Figure	  2.6).	  	  Of	  these	  CpG	  sites,	  251	  (35%)	  are	  located	  in	  the	  promoter	  (TSS200	  or	  TSS1500	  region),	  129	  (18%)	  are	  in	  the	  5’UTR/1st	  Exon,	  223	  (32%)	  are	  in	  the	  body,	  13	  (2%)	  are	  in	  the	  3’UTR	  and	  91	  (13%)	  are	  intergenic	  (Figure	  2.7	  (A)).	  	  The	  neighborhood	  distribution	  for	  these	  CpG	  sites	  is	  as	  follows:	  268	  (38%)	  are	  located	  within	  a	  CpG	  island,	  230	  (32%)	  are	  in	  north	  or	  south	  shores,	  27	  (4%)	  are	  in	  north	  or	  south	  shelves	  and	  182	  (26%)	  are	  found	  in	  the	  open	  sea	  (Figure	  2.7	  (B)).	  	  Out	  of	  the	  251	  GpG	  sites	  in	  the	  promoter	  region	  that	  are	  hypermethylated	  in	  TMX2-­‐28	  and	  have	  decreased	  methylation	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment,	  there	  are	  27	  genes	  for	  which	  there	  are	  2	  or	  more	  CpG	  sites	  with	  significant	  changes	  in	  methylation	  (Table	  2.8).	  	  I	  predict	  that	  these	  target	  genes	  are	  likely	  re-­‐expressed	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  
Methylation	  Pattern	  of	  TACSTD2	  in	  Control-­‐	  and	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐
Treated	  Cell	  Lines	  	   TACSTD2	  is	  one	  of	  the	  genes	  identified	  as	  being	  differentially	  methylated	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7	  and	  has	  decreased	  methylation	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  TACSTD2	  encodes	  the	  protein	  tumor-­‐associated	  calcium	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signal	  transducer	  2	  (TROP2).	  46,47	  TROP2	  plays	  an	  important	  role	  in	  development,	  intracellular	  signaling	  and	  epithelial	  cancers.	  54	  Expression	  of	  TROP2	  is	  regulated	  by	  promoter	  methylation	  in	  lung	  cancer.	  	  Forced	  expression	  of	  TROP2	  in	  lung	  cancer	  cell	  lines	  inhibits	  proliferation	  and	  colony	  formation	  and	  blocks	  phosphorylation	  of	  AKT	  and	  ERK.	  61	  Three	  CpG	  cites	  in	  the	  promoter	  of	  TACSTD2	  were	  identified	  as	  hypermethylated	  in	  TMX2-­‐28	  with	  decreased	  methylation	  after	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  (Table	  2.8).	  	  The	  mean	  average	  beta	  values	  for	  these	  3	  CpGs	  (MAPINFO	  numbers:	  59043370,	  59043280	  and	  59043255)	  in	  MCF-­‐7-­‐Control,	  TMX2-­‐28-­‐Control	  and	  TMX2-­‐28-­‐5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  cell	  lines	  are	  0.04,	  0.71	  and	  0.32,	  respectively	  (Figure	  2.8,	  A).	  	  Mean	  methylation	  of	  these	  3	  CpGs	  in	  TMX2-­‐28	  decreased	  by	  approximately	  0.40	  after	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  Interestingly,	  methylation	  of	  TACSTD2	  in	  TMX2-­‐28	  was	  most	  sensitive	  to	  treatment	  with	  the	  DNMT-­‐1	  inhibitor	  (Figure	  2.8,	  B).	  	  Therefore,	  it	  would	  be	  interesting	  to	  investigate	  the	  role	  of	  TROP2	  in	  our	  cell	  line	  model	  of	  ER-­‐negative,	  tamoxifen-­‐resistant	  breast	  cancer.	  	  
Further	  Characterization	  of	  Target	  Genes	  Identified	  by	  Changes	  in	  Promoter	  
Methylation	  	   I	  then	  consulted	  the	  mRNA	  expression	  array	  to	  determine	  if	  any	  of	  the	  27	  target	  genes	  were	  differentially	  expressed	  between	  TMX2-­‐28	  and	  MCF-­‐7.	  	  If	  translation	  is	  regulated	  by	  promoter	  methylation,	  I	  predict	  that	  these	  genes	  would	  have	  decreased	  expression	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7.	  	  Eight	  of	  the	  genes	  were	  identified	  on	  the	  array;	  5	  have	  decreased	  expression	  in	  TMX2-­‐28	  as	  I	  predicted	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(CGNL1,	  CKB,	  NFIA,	  SPRED2	  and	  TACSTD2)	  however,	  3	  have	  increased	  expression	  in	  TMX2-­‐28	  (SERPINB5,	  SGCE	  and	  ZNF331)	  (Table	  2.8).	  	  This	  is	  not	  unusual	  as	  promoter	  methylation	  is	  not	  the	  only	  regulatory	  factor	  that	  determines	  mRNA	  expression.	  	  Translation	  also	  depends	  on	  chromatin	  structure	  and	  position	  of	  nucleosomes	  as	  well	  as	  the	  availability	  of	  transcription	  factors,	  coactivators	  and	  corepressors.	  	   Based	  on	  our	  predictions	  for	  genes	  regulated	  by	  promoter	  methylation,	  I	  predict	  that	  the	  targets	  I	  identified	  will	  have	  lower	  methylation	  and	  higher	  mRNA	  expression	  in	  MCF-­‐7	  than	  TMX2-­‐28	  and	  that	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  will	  increase	  mRNA	  expression	  in	  TMX2-­‐28	  due	  to	  decreased	  methylation.	  	  I	  therefore	  wanted	  to	  evaluate	  the	  expression	  level	  of	  these	  genes	  in	  MCF-­‐7.	  	  I	  consulted	  the	  Human	  Protein	  Atlas,	  Cell	  Line	  Atlas	  online	  database	  to	  determine	  approximate	  mRNA	  expression	  levels	  in	  MCF-­‐7.	  	  I	  then	  narrowed	  our	  list	  of	  target	  genes	  to	  those	  with	  predicted	  moderate	  or	  high	  expression	  levels	  in	  MCF-­‐7.	  	  Additionally,	  I	  also	  consulted	  published	  literature	  regarding	  protein	  function	  and	  possible	  role	  in	  cancer	  or	  breast	  cancer.	  	  Gene-­‐specific	  RT-­‐PCR	  primers	  were	  designed	  to	  span	  an	  exon-­‐exon	  junction	  using	  Primer-­‐BLAST	  (NIH)	  for	  10	  genes	  that	  had	  predicted	  moderate	  expression	  in	  MCF-­‐7,	  interesting	  predicted	  function	  in	  breast	  cancer	  or	  unknown	  role	  in	  breast	  cancer.	  	  Eight	  of	  the	  10	  primers	  amplified	  a	  single	  product	  as	  determined	  by	  melting	  curve	  analysis	  and	  the	  MCF-­‐7	  and	  TMX2-­‐28	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  and	  control	  samples	  were	  analyzed	  for	  mRNA	  expression	  based	  on	  cycle	  thresholds.	  	  Average	  cycle	  thresholds	  and	  beta-­‐values	  are	  listed	  in	  Table	  2.9.	  	  By	  comparison	  of	  cycle	  thresholds	  (non-­‐normalized	  RT-­‐PCR	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data),	  two	  genes	  had	  increased	  expression	  in	  TMX2-­‐28-­‐5	  Aza-­‐2’-­‐deoxycytidine-­‐treated	  (PCR	  product	  amplified	  at	  an	  earlier	  cycle),	  TACSTD2	  and	  SERPINB5.	  	  Because	  so	  few	  of	  the	  mRNA	  expression	  patterns	  matched	  our	  predictions,	  I	  examined	  the	  expression	  of	  ERα	  and	  two	  previously	  examined	  genes,	  MAGED1	  and	  ZNF350	  and	  compared	  cycle	  thresholds	  with	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  samples	  (Table	  2.10).	  	  Expression	  patterns	  for	  ERα	  agreed	  with	  previously	  published	  data	  for	  MCF-­‐7	  and	  TMX2-­‐28.	  38	  Importantly,	  expression	  patterns	  for	  MAGED1	  in	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  MCF-­‐7	  and	  TMX2-­‐28	  cells	  were	  verified,	  as	  previously	  reported.	  31	  	  	   mRNA	  expression	  of	  four	  target	  genes	  was	  examined	  by	  RT-­‐PCR	  using	  the	  standard	  curve	  method	  and	  normalized	  to	  beta-­‐actin	  (Figure	  2.9).	  	  As	  predicted	  if	  regulated	  by	  promoter	  methylation,	  mRNA	  expression	  of	  two	  genes,	  TACSTD2	  and	  CGNL1,	  was	  increased	  in	  TMX2-­‐28	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  whereas	  expression	  was	  unchanged	  in	  MCF-­‐7.	  	  However,	  mRNA	  expression	  of	  ZNF331	  increased	  in	  TMX2-­‐28-­‐5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  which	  does	  not	  agree	  with	  our	  prediction. 
	  
Discussion	  	   In	  American	  women,	  breast	  cancer	  is	  the	  most	  common	  cancer	  diagnosis	  and	  it	  is	  the	  second-­‐leading	  cause	  of	  cancer-­‐related	  deaths.	  2	  About	  70%	  of	  breast	  cancers	  are	  ER-­‐positive.	  26,77	  These	  patients	  can	  be	  treated	  with	  hormonal	  therapy,	  such	  as	  Tamoxifen.	  	  However,	  about	  one-­‐third	  of	  ER-­‐positive	  patients	  treated	  with	  Tamoxifen	  for	  five	  years	  have	  recurrence.	  26	  This	  acquired	  resistance	  is	  a	  huge	  obstacle	  in	  the	  clinic	  because	  of	  limited	  treatment	  options.	  	  There	  are	  several	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studies,	  including	  one	  from	  our	  lab,	  indicating	  that	  DNA	  methylation	  may	  be	  involved	  in	  the	  development	  of	  Tamoxifen	  resistance.	  25,27,31,73	  Therefore,	  epigenetic	  therapies	  that	  alter	  DNA	  methylation	  may	  prove	  to	  be	  promising	  therapy	  for	  tamoxifen-­‐resistant	  disease.	  	  However,	  it	  is	  unclear	  how	  DNMT	  inhibitors	  such	  as	  5-­‐Aza-­‐2’-­‐deoxycytidine	  affect	  cell	  behavior,	  specifically	  in	  ER-­‐negative,	  acquired	  Tamoxifen	  resistance.	  	   The	  objective	  of	  the	  present	  study	  was	  to	  investigate	  how	  5-­‐Aza-­‐2’-­‐deoxycytidine	  affects	  global	  methylation	  in	  our	  cell	  line	  model	  of	  acquired	  Tamoxifen	  resistance	  and	  identify	  genes	  regulated	  by	  promoter	  methylation	  that	  are	  re-­‐expressed	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  	  To	  accomplish	  this,	  I	  first	  confirmed	  previous	  results	  from	  a	  single	  experiment,	  31	  examining	  global	  methylation	  differences	  between	  the	  tamoxifen-­‐resistant	  cell	  lines	  and	  the	  parental	  cell	  line,	  MCF-­‐7.	  	  In	  agreement	  with	  this	  initial	  study,	  TMX2-­‐28	  is	  hypermethylated	  compared	  to	  MCF-­‐7.	  	  Also,	  the	  same	  trend	  of	  decreasing	  methylation	  was	  observed	  for	  CpG	  sites	  in	  the	  promoter	  regions	  of	  MAGED1	  and	  ZNF350,	  two	  genes	  previously	  identified	  as	  being	  differentially	  methylated.	  31	  Expanding	  on	  these	  results,	  I	  also	  examined	  the	  effect	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  on	  global	  methylation	  in	  the	  parental	  cell	  line	  and	  the	  tamoxifen-­‐resistant	  cell	  lines.	  	  I	  found	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  alters	  global	  methylation	  in	  a	  cell-­‐line	  specific	  manner.	  	  The	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  line,	  TMX2-­‐28,	  is	  most	  sensitive	  to	  inhibition	  of	  methylation	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  I	  then	  sought	  to	  identify	  genes	  with	  changes	  in	  promoter	  methylation	  that	  might	  be	  re-­‐expressed	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  I	  did	  this	  by	  identifying	  genes	  with	  CpG	  sites	  in	  the	  promoter	  that	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are	  differentially	  methylated	  between	  TMX2-­‐28	  and	  MCF-­‐7	  and	  also	  have	  decreased	  methylation	  in	  TMX2-­‐28	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  	  	   I	  predicted	  that	  if	  gene	  expression	  is	  regulated	  by	  promoter	  methylation,	  genes	  with	  hypermethylated	  CpG	  sites	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7	  will	  have	  lower	  mRNA	  expression	  in	  TMX2-­‐28	  and	  that	  treatment	  with	  the	  DNMT1	  inhibitor,	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  will	  decrease	  methylation	  and	  result	  in	  increased	  mRNA	  expression	  in	  TMX2-­‐28.	  	  Indeed,	  there	  were	  five	  genes	  in	  our	  target	  list	  of	  27	  genes	  (Table	  2.8)	  for	  which	  mRNA	  expression	  determined	  by	  microarray	  is	  lower	  in	  TMX2-­‐28	  than	  MCF-­‐7	  (CGNL1,	  CKB,	  NFIA,	  SPRED2	  and	  TACSTD2).	  	  I	  predict	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  will	  likely	  increase	  expression	  of	  these	  genes	  in	  TMX2-­‐28.	  	  However,	  three	  of	  the	  27	  target	  genes	  have	  increased	  expression	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7	  (SERPINB5,	  SGCE	  and	  ZNF331).	  	  It	  is	  likely	  that	  other	  epigenetic	  modifications	  or	  availability	  of	  transcription	  factors	  and/or	  coactivators	  are	  acting	  to	  regulate	  expression	  of	  these	  genes.	  	  I	  then	  determined	  which	  genes	  are	  predicted	  to	  have	  moderate	  to	  high	  expression	  in	  MCF-­‐7	  using	  the	  Human	  Protein	  Atlas.	  	  Ultimately	  RT-­‐PCR	  primers	  were	  designed	  for	  10	  of	  the	  target	  genes	  based	  on	  predicted	  expression	  in	  MCF-­‐7	  and	  information	  regarding	  protein	  function	  in	  the	  literature.	  	  Comparing	  average	  cycle	  thresholds	  for	  control	  and	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  cells,	  mRNA	  expression	  of	  two	  genes	  (TACSTD2	  and	  SERPINB5)	  increased	  in	  TMX2-­‐28	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  This	  increase	  in	  mRNA	  expression	  agrees	  with	  our	  prediction	  if	  gene	  expression	  is	  regulated	  by	  promoter	  methylation	  in	  TMX2-­‐28.	  	  However,	  the	  mRNA	  expression	  array	  found	  that	  expression	  of	  SERPINB5	  is	  higher	  in	  TMX2-­‐28	  than	  the	  parental	  cell	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line,	  MCF-­‐7,	  which	  does	  not	  agree	  with	  our	  prediction	  because	  I	  know	  that	  methylation	  is	  higher	  in	  TMX2-­‐28.	  	  Therefore,	  expression	  of	  SERPINB5	  does	  not	  seem	  to	  be	  regulated	  by	  promoter	  methylation.	  	  Because	  our	  predictions	  for	  differences	  in	  TACSTD2	  expression,	  which	  seems	  to	  be	  regulated	  by	  promoter	  methylation,	  agree	  with	  the	  mRNA	  expression	  array	  and	  RT-­‐PCR	  data,	  I	  decided	  to	  explore	  the	  role	  of	  TACSTD2	  in	  our	  Tamoxifen	  resistance	  model.	  	   The	  TACSTD2	  gene	  encodes	  the	  protein	  TROP2.	  46,47	  TROP2	  is	  related	  to	  Trop1/	  epithelial	  cell	  adhesion	  molecule	  (Epcam)	  49	  however,	  TROP2	  has	  different	  roles	  in	  cell	  signaling.	  	  As	  reviewed	  by	  McDougall	  et	  al.	  2014,	  54	  TROP2	  is	  expressed	  in	  a	  variety	  of	  epithelial	  cancers	  and	  can	  affect	  many	  different	  aspects	  relating	  to	  cancer	  cell	  proliferation,	  migration	  and	  intracellular	  signaling.	  	  TROP2	  is	  involved	  in	  regulating	  intracellular	  calcium	  levels,	  63	  which	  may	  contribute	  to	  increased	  proliferation	  due	  to	  activation	  of	  PKC	  signaling.54Another	  mechanism	  by	  which	  TROP2	  can	  promote	  proliferation	  is	  through	  binding	  β-­‐catenin	  and	  promoting	  transcription	  of	  Cyclin	  D1	  and	  c-­‐myc.	  58	  TROP2	  is	  involved	  in	  regulating	  focal	  adhesion	  dynamics,	  a	  central	  aspect	  involved	  in	  cell	  migration.	  57	  TROP2	  can	  also	  regulate	  activation	  of	  ERK	  signaling,	  an	  important	  pathway	  for	  sustaining	  cell	  proliferation.	  59-­‐62	  Interestingly,	  TACSTD2	  expression	  is	  regulated	  by	  promoter	  methylation	  in	  lung	  adenocarcinoma.	  61	  Here	  the	  authors	  demonstrate	  the	  TROP2	  interacts	  with	  IGF1	  to	  inhibit	  IGF1-­‐R	  signaling.	  	  This	  prevents	  activation	  of	  AKT	  and	  ERK	  and	  inhibits	  proliferation	  and	  colony	  formation.	  61	  Previously	  unpublished	  data	  from	  our	  lab	  indicates	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  which	  decreased	  promoter	  methylation	  of	  TACSTD2	  and	  increases	  mRNA	  expression	  of	  TROP2,	  inhibits	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proliferation	  in	  TMX2-­‐28	  (Kristin	  Williams,	  unpublished).	  	  Therefore,	  I	  want	  to	  test	  the	  hypothesis	  that	  increased	  expression	  of	  TROP2,	  resulting	  from	  decreased	  promoter	  methylation,	  inhibits	  proliferation	  in	  TMX2-­‐28.	  	   Additionally,	  TROP2	  may	  have	  an	  important	  role	  in	  breast	  cancer	  as	  intracellular	  localization	  was	  found	  to	  be	  an	  important	  prognostic	  factor.65	  Ambrogi	  and	  colleagues	  found	  that	  TROP2	  localized	  to	  the	  membrane	  was	  indicative	  of	  poor	  prognosis	  while	  intracellular	  TROP2	  was	  associated	  with	  increased	  patient	  survival.65	  However,	  the	  role	  of	  TROP2	  in	  tamoxifen	  resistance	  is	  unknown.	  	  Therefore,	  I	  will	  utilize	  our	  cell	  line	  model	  of	  tamoxifen	  resistance	  to	  investigate	  the	  role	  of	  TROP2	  in	  drug	  resistant	  breast	  cancer	  as	  well	  as	  the	  potential	  role	  of	  methylation	  in	  regulation	  of	  TACSTD2	  expression.	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Table	  2.1	  Primers	  Used	  to	  Detect	  Relative	  mRNA	  Expression	  of	  Genes	  
Gene	   Accession	  Number	  
Forward	  Sequence	  (5’-­‐
3’)	   Reverse	  Sequence	  (5’–	  3’)	  Beta-­‐actin	   NM_001101.3	   GGACTTCGAGCAAGAGATGG	   AGCACTGGTTGGCGTACAG	  CGNL1	   NM_032866.4	   GGCTGAGGAGGAAATCGACA	   CTCGGCAGCTTCTTCAGTCTTA	  ERα	   NM_000125	   ATGATCAACTGGGCGAAGAG	   GATCTCCACCATGCCCTCTA	  GFI1	   NM_001127216.1	   GACCGTTTGTCCCCCGAAT	   CATTGACTTCTCCGAGGCTGG	  MAGED1	   NM_001005332	   CCTTCTTCGTCAAGCCCCCAG	   AGGCAGCATTTGGACCCTTT	  MYEOV2	   NM_138336.1	   TCAGGACTGCCCAGGACAAG	   CCCGTTCAGTTCACATCTCTCT	  PDGFB	   NM_033016.2	   TTTATCATGGGCCTCGGGGA	   CGGGTCATGTTCAGGTCCAA	  PLOD2	   NM_000935.2	   GGGTCTCTGCGTTCTCGC	   ATAATTTATCTGTGGGGATGCTCG	  SERPINB5	   NM_002639.4	   CAGAGTCAACAAGACAGACACCA	   TGGACTCATCCTCCACATCCT	  SGCE	   NM_001099400.1	   TCAACGCTTCCTGTGTTCCA	   CGAAAATCTCCTGTAGTCTGCTG	  SND1	   NM_014390.2	   GCAGGGGAGAGTTCTGCATT	   GGACCTCTCTGTTGCCGTAG	  
TACSTD
2	  (3’UTR)	   NM_002353.2	   AATGTATCCCCTTTCGGTCC	   TCCCGGGTTGTCATACAGAT	  
TACSTD




Table	  2.2	  Changes	  in	  Global	  Methylation	  Between	  Tamoxifen-­‐Resistant	  Cell	  Lines	  and	  MCF-­‐7	  









	   Hypermethylated	   Fold	  change	  ≥1.8	  in	  TMX2-­‐28-­‐Control	  (TMX2-­‐28-­‐Control/MCF-­‐7-­‐Control),	  β-­‐value	  ≥0.1	  in	  TMX2-­‐28-­‐Control,	  Detection	  p-­‐value	  ≤	  0.01	  for	  TMX2-­‐28-­‐Control	  and	  MCF-­‐7-­‐Control	   37,501	  (8%)	  








	   Hypermethylated	   	   3,563	  (0.7%)	  Hypomethylated	   	   13,810	  (3%)	  









	   Hypermethylated	   	   5,887	  (1%)	  Hypomethylated	   	   4,802	  (0.99%)	  
No	  Change	   	   474,257	  (98%)	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Table	  2.3	  Changes	  in	  Global	  Methylation	  Between	  TMX2-­‐28-­‐5-­‐Aza-­‐2’-­‐
deoxycytidine-­‐Treated	  and	  TMX2-­‐28-­‐Control	  
Change	  in	  
Methylation	   Filter	  
No.	  of	  
CpG	  Sites	  
Hypermethylated	   Fold	  change	  ≥1.8	  in	  TMX2-­‐28-­‐Aza	  (TMX2-­‐28-­‐Aza/TMX2-­‐28-­‐Control),	  β-­‐value	  ≥0.1	  in	  TMX2-­‐28-­‐Aza,	  Detection	  p-­‐value	  ≤	  0.01	  for	  TMX2-­‐28-­‐Aza	  	  and	  TMX2-­‐28-­‐Control	  
59	  (0.01%)	  
Hypomethylated	   Fold	  change	  ≥1.8	  in	  TMX2-­‐28-­‐Control	  (TMX2-­‐28-­‐Control/TMX2-­‐28-­‐Aza),	  β-­‐value	  ≥0.1	  in	  TMX2-­‐28-­‐Control,	  Detection	  p-­‐value	  ≤	  0.01	  for	  TMX2-­‐28-­‐Aza	  	  and	  TMX2-­‐28-­‐Control	  
6,637	  (1%)	  
No	  Change	   Detection	  p-­‐value	  ≤	  0.01	  for	  TMX2-­‐28-­‐Control	  and	  MCF-­‐7	  control	  (484,841)	  minus	  	  No.	  of	  hypermethylated	  and	  hypomethylated	  	  CpG	  sites	   478,145	  (99%)	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Table	  2.4	  Top	  5	  Genes	  in	  TMX2-­‐28	  Containing	  CpG	  Sites	  With	  the	  Largest	  











Island	  1809712	   NDUFS6	   NM_004553	   6.09	   Body	   n/a	  19191892	   C21orf91	   NM_017447,	  NM_001100421,	  NM_001100420	   5.68	   TSS200	   Island	  1787806	   MAPK8IP3	   NM_001040439,	  NM_015133	   5.44	   Body,	  Body	   N	  Shelf	  220863263	   C1orf115	   NM_024709	   5.00	   TSS1500	   N	  Shore	  234509074	   C1orf31	   NM_001012985	   4.87	   TSS1500	   Island	  
	  
	  
	   	  
	  52	  
	  
Table	  2.5	  Top	  7	  Genes	  in	  TMX2-­‐28	  Containing	  CpG	  Sites	  With	  the	  Largest	  












Island	  234509074	   C1orf31	   NM_001012985	   4.87	   TSS1500	   Island	  234509059	   C1orf31	   NM_001012985	   51.8	   TSS1500	   Island	  144798331	   MAPK15	   NM_139021	   4.11	   TSS200	   N	  Shore	  144798354	   MAPK15	   NM_139021	   2.70	   TSS200	   N	  Shore	  124220854	   HTRA1	   NM_002775	   3.54	   TSS200	   Island	  124220856	   HTRA1	   NM_002775	   2.08	   TSS200	   Island	  124220504	   HTRA1	   NM_002775	   1.91	   TSS1500	   Island	  53758233	   ZNF677	   NM_182609	   3.00	   TSS200	   S	  Shore	  53758521	   ZNF677	   NM_182609	   1.82	   TSS1500	   S	  Shore	  134600848	   NKX6-­‐2	   NM_177400	   2.90	   TSS1500	   Island	  134599807	   NKX6-­‐2	   NM_177400	   2.29	   TSS1500	   Island	  134599934	   NKX6-­‐2	   NM_177400	   2.21	   TSS1500	   Island	  134600858	   NKX6-­‐2	   NM_177400	   1.94	   TSS1500	   Island	  101192973	   DLK1	   NM_003836	   2.89	   TSS1500	   Island	  101193017	   DLK1	   NM_003836	   2.06	   TSS1500	   Island	  59043255	   TACSTD2	   NM_002353	   2.69	   TSS200	   Island	  59043280	   TACSTD2	   NM_002353	   2.05	   TSS200	   Island	  59043370	   TACSTD2	   NM_002353	   1.92	   TSS1500	   S	  Shore	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Table	  2.6	  Differences	  in	  mRNA	  Expression	  
Between	  TMX2-­‐28	  and	  MCF-­‐7*	  
Change	  in	  mRNA	  
Expression	  in	  
TMX2-­‐28	  
No.	  of	  Genes	  
Decreased	   2,414	  (72%)	  
Increased	   958	  (28%)	  *	  Total	  no.	  of	  genes	  with	  significant	  changes	  in	  mRNA	  expression	  between	  TMX2-­‐28	  and	  MCF-­‐7	  is	  3,372	  (12%	  of	  total)	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Table	  2.7	  Hypermethylated	  CpG	  Sites	  in	  TMX2-­‐28	  CpG	  That	  Have	  Decreased	  
Methylation	  After	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment	  
Change	  in	  
Methylation	   Filter	  
No.	  of	  
CpG	  Sites	  
Hypermethylated	   Fold	  change	  ≥1.8	  in	  TMX2-­‐28-­‐Control	  (TMX2-­‐28-­‐Control/MCF-­‐7-­‐Control),	  β-­‐value	  ≥0.1	  in	  TMX2-­‐28-­‐Control,	  Detection	  p-­‐value	  ≤	  0.01	  for	  TMX2-­‐28-­‐Control	  	  and	  MCF-­‐7-­‐Control	   37,501	  
Hypomethylated	   Filter	  criteria	  from	  above	  and	  Fold	  change	  ≥1.8	  in	  TMX2-­‐28-­‐Control	  (TMX2-­‐28-­‐Control/TMX2-­‐28-­‐Aza),	  β-­‐value	  ≥0.1	  in	  TMX2-­‐28-­‐Control,	  Detection	  p-­‐value	  ≤	  0.01	  for	  TMX2-­‐28-­‐Aza	   707	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Table	  2.8	  Genes	  With	  More	  Than	  One	  CpG	  Site	  in	  the	  
Promoter	  Differentially	  Methylated	  in	  TMX2-­‐28	  and	  
Decreased	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  
UCSC	  Refgene	  




7	  ASZ1	   2	   n/a	  C17orf102;	  TMEM132E	   2	   n/a	  CGNL1	   2	   Decreased	  CKB	   2	   Decreased	  CRMP1	   2	   n/a	  ENTPD7	   2	   n/a	  GFI1	   3	   n/a	  HTRA1	   2	   n/a	  IGF2BP1	   2	   n/a	  KIAA1826	   2	   n/a	  MAP9	   2	   n/a	  MAPK15	   2	   n/a	  MYEOV2	   2	   n/a	  NFIA	   2	   Decreased	  PDGFB	   2	   n/a	  PIK3R1	   2	   n/a	  PLOD2	   2	   n/a	  PON2	   2	   n/a	  RAET1L	   3	   n/a	  SERPINB5	   2	   Increased	  SGCE	   2	   Increased	  SND1;LRRC4	   3	   n/a	  SPRED2	   2	   Decreased	  
TACSTD2	   3	   Decreased	  TMEM216	   2	   n/a	  ZFR2	   2	   n/a	  ZNF331	   3	   Increased	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Table	  2.9	  Average	  Promoter	  Methylation	  (Beta	  value)	  from	  Illumina	  Human	  Methylation	  450	  BeadChip	  and	  
mRNA	  Expression	  (Cycle	  Number)	  for	  MCF-­‐7	  and	  TMX2-­‐28	  Cells	  from	  the	  72-­‐hr.	  Aza	  Exposure	  Experiment.	  	   TACSTD2	   SND1	   PDGFB	   ZNF331	   CGNL1	  	   MCF-­‐7	   TMX2-­‐28	   MCF-­‐7	   TMX2-­‐28	   MCF-­‐7	   TMX2-­‐28	   MCF-­‐7	   TMX2-­‐28	   MCF-­‐7	   TMX2-­‐28	  
Control	  
Methylation	  Beta	  value	   0.042	   0.71	   0.18	   0.78	   0.057	   0.64	   0.15	   0.63	   0.11	   0.48	  
Aza	  
Methylation	  Beta	  value	   0.039	   0.32	   0.14	   0.38	   0.039	   0.31	   0.14	   0.30	   0.084	   0.21	  
Control	  
Expression	  Cycle	  No.	   24.33	   34.24	   27.26	   26.48	   40.44	   39.01	   30.74	   27.74	   34.01	   36.55	  
Aza	  
Expression	  	  Cycle	  No.	   24.35	   28.99	  é	   28.29	   29.09	  ê	   41.68	   41.31	  ê	   31.37	   30.99	  ê	   33.50	  	   36.75	  Arrows	  represent	  the	  direction	  of	  the	  change	  in	  expression	  in	  TMX2-­‐28-­‐Aza	  compared	  to	  TMX2-­‐28-­‐Control	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Table	  2.9	  con’t	  	   SGCE	   GFI1	   SERPINB5	   PLOD2	   MYEOV2	  	   MCF-­‐7	   TMX2-­‐28	   MCF-­‐7	   TMX2-­‐28	   MCF-­‐7	   TMX2-­‐28	   MCF-­‐7	   TMX2-­‐28	   MCF-­‐7	   TMX2-­‐28	  
Control	  
Methylation	  Beta	  value	   0.17	   0.69	   0.098	   0.38	   0.063	   0.43	   0.23	   0.73	   0.28	   0.66	  
Aza	  
Methylation	  Beta	  value	   0.15	   0.34	   0.079	   0.18	   0.062	   0.22	   0.19	   0.38	   0.22	   0.35	  
Control	  
Expression	  Cycle	  No.	   40.49	   34.95	   35.11	   33.89	   37.44	   32.91	   n/a	   n/a	   n/a	   n/a	  
Aza	  




Table	  2.10	  Average	  Cycle	  Thresholds	  for	  Control	  and	  5-­‐Aza-­‐2’-­‐
deoxycytidine	  for	  Previously	  Validated	  Genes	  
Cell	  line	  –	  Treatment	   ERα	   MAGED1	   ZNF350	  
MCF-­‐7-­‐Control	   27.51	   34.29	   31.28	  
MCF-­‐7-­‐Aza	   28.41	   33.37	   31.17	  
TMX2-­‐28-­‐Control	   37.65	   39.57	   31.35	  
TMX2-­‐28-­‐Aza	   38.11	   33.85	   31.35	  
	  
	  










Figure	  2.1:	  Structure	  and	  Intracellular	  Metabolism	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  (A)	  Structure	  of	  cytidine,	  5-­‐Methyl-­‐cytidine,	  5-­‐Azacytidine	  and	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  R	  =	  ribose.	  dR	  =	  deoxyribose.	  	  Image	  from	  P.	  Fenaux	  2005.	  78	  (B)	  Intracellular	  metabolism	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  or	  Decitabine	  (top)	  and	  5-­‐Azacytidine	  (bottom).	  	  R	  =	  ribose,	  dR	  =	  deoxyribose,	  P	  =	  phosphate.	  Image	  from	  
Ghoshal	  and	  Bai,	  2007.	  70
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(A)	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  (B)	   	   	   	   	   	  	  	  	  	  (C)	  
	  
Figure	  2.2:	  Distribution	  of	  Sites	  on	  the	  HM450	  BeadChip.	  Summary	  of	  the	  functional	  genomic	  distribution	  (FGD)	  listed	  as	  promoter	  (within	  200-­‐1500	  bp	  upstream	  of	  the	  transcription	  start	  site,	  5’-­‐UTR,	  or	  exon	  1),	  3’-­‐UTR,	  gene	  body	  or	  intergenic	  (A).	  	  Distribution	  of	  sites	  in	  terms	  of	  CpG	  content	  and	  neighborhood,	  as	  defined	  by	  Illumina	  (B).	  	  Distribution	  of	  sites	  with	  respect	  to	  RNA	  transcripts	  (C).	  	  Images	  from	  Sandoval	  et	  al.	  2011.76
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(A)	   	   	   	   	   	   	   	   	   	   (B)	  
	   	   	   	   	   	   	  
	  
(C)	  
	   	   	   	   (Figure	  2.3)	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Figure	  2.3:	  Global	  Methylation	  Patterns	  Differ	  Among	  Tamoxifen-­‐Resistant	  Cell	  Lines.	  	  Scatter	  plots	  indicating	  genome-­‐wide	  methylation	  differences	  between	  tamoxifen-­‐resistant	  cell	  lines,	  (A)	  TMX2-­‐4,	  (B)	  TMX2-­‐11	  and	  (C)	  TMX2-­‐28	  compared	  with	  the	  parental	  line,	  MCF-­‐7.	  	  Each	  black	  dot	  on	  the	  plot	  represents	  a	  CpG	  site	  analyzed	  on	  the	  Human	  Methylation	  450	  BeadChip.	  	  Center	  red	  line	  represents	  equal	  average	  beta	  values	  in	  the	  two	  samples	  and	  outer	  red	  lines	  indicate	  a	  1.8-­‐fold	  change	  in	  average	  beta	  values.	  Value	  of	  r2	  from	  Genome	  Studio	  represents	  goodness-­‐of-­‐fit	  of	  linear	  regression.	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(A)	   	   	   	   	   	   	   	   	   	   (B)	  
	   	   	   	   	   	   	  
(C)	   	   	   	   	   	   	   	   	   	   (D)	  
	   	   	   	   	   	   	  (Figure	  2.4)	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Figure	  2.4:	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment	  Causes	  Cell	  Line-­‐Specific	  Changes	  in	  Global	  Methylation.	  Scatter	  plots	  indicating	  genome-­‐wide	  differences	  in	  methylation	  for	  72-­‐hour	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  (A)	  MCF-­‐7,	  (B)	  TMX2-­‐4,	  (C)	  TMX2-­‐11	  and	  (D)	  TMX2-­‐28	  compared	  to	  control	  for	  each	  cell	  line.	  	  Each	  black	  dot	  on	  the	  plot	  represents	  a	  CpG	  site	  analyzed	  on	  the	  Human	  Methylation	  450	  BeadChip.	  	  Center	  red	  line	  represents	  equal	  average	  beta	  values	  in	  the	  two	  samples	  and	  outer	  red	  lines	  indicate	  a	  1.8-­‐fold	  change	  in	  average	  beta	  values.	  	  Value	  of	  r2	  from	  Genome	  Studio	  represents	  goodness-­‐of-­‐fit	  of	  linear	  regression.	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Figure	  2.6:	  Summary	  of	  Selection	  Process	  for	  Target	  Genes.	  	  Flow	  chart	  describing	  the	  selection	  process	  and	  filtering	  utilized	  to	  identify	  genes	  with	  CpG	  sites	  located	  in	  the	  promoter	  that	  were	  hypermethylated	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7	  and	  had	  decreased	  methylation	  when	  TMX2-­‐28	  cells	  were	  treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  Number	  of	  CpG	  sites	  indicated	  in	  parentheses.	  	  (See	  also	  Table	  2.7)	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(A)	   	   	   	   	   	   	   	   	   	   (B)	  
	   	   	   	   	   	  	  
Figure	  2.7:	  Functional	  Genomic	  Location	  and	  Neighborhood	  Distribution	  of	  Differentially	  Methylated	  CpG	  Sites	  
in	  TMX2-­‐28	  with	  Decreased	  Methylation	  After	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment.	  	  Pie	  charts	  indicated	  the	  (A)	  functional	  genomic	  distribution	  and	  (B)	  neighborhood	  locations	  for	  the	  707	  CpG	  sites	  identified	  as	  having	  increased	  methylation	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7	  and	  also	  decreased	  methylation	  in	  TMX2-­‐28	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.
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(A)	  
	   	  




Figure	  2.8:	  Methylation	  Patterns	  for	  TACSTD2	  in	  DMSO-­‐Control	  and	  5-­‐Aza-­‐2’-­‐
deoxycytidine-­‐Treated	  Cell	  Lines.	  Heatmaps	  indicating	  methylation	  of	  CpG	  sites	  in	  







	  (Figure	  2.9)	  	  






Figure	  2.9:	  	  Relative	  mRNA	  Expression	  of	  Target	  Genes	  in	  DMSO-­‐Control	  and	  5-­‐
Aza-­‐2’-­‐deoxycytidine-­‐Treated	  Cells.	  	  Relative	  mRNA	  expression	  of	  (A)	  CGNL1,	  (B)	  SND1,	  (C)	  TACSTD2	  and	  (D)	  ZNF331	  determined	  by	  RT-­‐PCR	  normalized	  to	  Beta-­‐actin	  (n	  =	  3).	  





5-­‐AZA-­‐2’-­‐DEOXYCYTIDINE	  INHIBITS	  PROLIFERATION,	  MIGRATION	  AND	  
ADHESION	  IN	  TMX2-­‐28	  
	  
Introduction	  	   Hanahan	  and	  Weinberg	  characterized	  the	  ability	  of	  cancer	  cells	  to	  maintain	  continuous	  proliferation	  and	  initiate	  invasion	  and	  metastasis	  as	  two	  of	  the	  six	  Hallmarks	  of	  Cancer.	  7,8	  These	  hallmarks	  are	  critical	  features	  of	  cancer	  cells	  required	  for	  facilitating	  tumor	  growth	  and	  metastasis.	  	  Specifically,	  tumor	  cells	  rely	  on	  growth	  factor	  signals	  and	  mitogenic	  signals	  (both	  paracrine	  and	  autocrine	  signaling)	  to	  promote	  uncontrolled	  cell	  growth.	  	  Cancer	  cells	  can	  achieve	  this	  deregulated	  signaling	  by	  several	  mechanisms:	  production	  of	  growth	  factor	  ligands	  to	  facilitate	  autocrine	  signaling,	  manipulation	  of	  normal	  cells	  to	  produce	  growth	  factors	  required	  by	  the	  cancer	  cells,	  overexpression	  of	  growth	  factor	  receptors	  at	  the	  cancer	  cell	  membrane,	  alterations	  in	  protein	  structure	  that	  result	  in	  ligand-­‐independent	  signal	  activation	  or	  constitutive	  activation	  of	  members	  of	  the	  signaling	  pathways	  downstream	  of	  receptors.	  	  Somatic	  mutations	  can	  also	  facilitate	  proliferative	  signaling	  by	  activating	  pathways	  downstream	  of	  receptors,	  such	  as	  the	  MAPK	  and	  Akt/PKB	  signaling	  pathways.	  	  Cancer	  cells	  may	  also	  disrupt	  negative	  feedback	  mechanisms	  that	  suppress	  proliferation.	  8	  One	  or	  more	  of	  these	  means	  are	  often	  employed	  by	  cancer	  cells	  to	  sustain	  uncontrolled	  cell	  proliferation	  and	  promote	  tumorigenesis.	  	  Signaling	  pathways	  can	  be	  constitutively	  activated	  by	  mutations	  and	  or	  epigenetic	  changes.	  	  Cell	  cycle	  proteins	  known	  to	  have	  altered	  expression	  in	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cancer	  may	  include	  Rb,	  cyclin	  dependent	  kinases	  (CDKs),	  and	  CDK	  inhibitors.	  	  The	  Wnt,	  IGF	  and	  PI3K/Akt	  signaling	  pathways	  are	  a	  few	  examples	  of	  pathways	  that	  are	  often	  constitutively	  active	  in	  cancer	  cells.79	  Breast	  cancer	  cells	  can	  utilize	  a	  variety	  of	  mechanisms	  to	  facilitate	  uncontrolled	  cell	  proliferation.	  	  In	  some	  cell	  lines,	  overexpression	  of	  the	  ubiquitin	  ligase,	  Cullin7,	  can	  promote	  both	  proliferation	  and	  invasion	  by	  downregulating	  p53.80	  The	  tumor	  stroma	  and	  surrounding	  microenvironment	  can	  also	  contribute	  to	  sustained	  proliferative	  signaling.	  	  Cancer-­‐associated	  fibroblasts	  in	  the	  mammary	  gland	  can	  produce	  growth	  factors	  such	  as,	  hepatocyte	  growth	  factor	  (HGF),	  epidermal	  growth	  factor	  (EGF),	  basic	  fibroblast	  growth	  factor	  (bFGF)	  and	  insulin-­‐like	  growth	  factor	  (IGF),	  which	  can	  promote	  cancer	  cell	  proliferation	  by	  activating	  paracrine	  signaling	  networks.	  81	  The	  PI3K-­‐AKT-­‐mTOR	  pathway	  is	  a	  key	  signaling	  pathway	  that	  mediates	  extracellular	  and	  intracellular	  growth	  and	  survival	  signaling.	  	  It	  has	  been	  shown	  to	  play	  an	  important	  role	  in	  endocrine	  resistance	  and	  drugs	  that	  target	  components	  of	  this	  pathway	  have	  been	  successful	  in	  the	  clinical	  setting.	  	  The	  cell	  cycle	  can	  also	  be	  subject	  to	  aberrant	  regulation	  during	  breast	  cancer	  progression.	  	  Inhibitors	  of	  CDK4/6,	  which	  regulate	  the	  G1-­‐S	  phase	  transition,	  are	  also	  being	  evaluated	  for	  use	  in	  the	  clinic.	  82	  Changes	  in	  these	  pathways,	  which	  lead	  to	  sustained	  proliferation,	  can	  arise	  due	  to	  genetic	  and/or	  epigenetic	  alterations.	  	   Additionally	  during	  disease	  progression,	  cancer	  cells	  acquire	  the	  ability	  to	  invade	  local	  surrounding	  tissue,	  intravasate	  into	  neighboring	  blood	  and	  lymphatic	  vessels,	  survive	  in	  the	  blood	  system,	  extravasate	  into	  tissue	  at	  a	  distant	  site	  and	  colonize	  this	  secondary	  site	  by	  establishing	  micrometastases	  which	  eventually	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develop	  into	  macroscopic	  tumors.	  	  This	  process	  is	  known	  as	  the	  invasion-­‐metastasis	  cascade,	  which	  can	  be	  regulated	  by	  properties	  of	  the	  cancer	  cells	  themselves	  and	  also	  by	  recruitment	  of	  immune	  and	  stromal	  cells	  by	  the	  cancer	  cells	  to	  alter	  the	  extracellular	  matrix,	  making	  it	  easier	  for	  cancer	  cells	  to	  disseminate	  and	  colonize	  a	  distant	  site.8	  	   Different	  types	  of	  tumors	  have	  distinct	  patterns	  of	  metastases.	  	  Breast	  cancer	  has	  a	  high	  propensity	  to	  metastasize	  to	  bone,	  while	  colorectal	  cancer	  spreads	  mainly	  to	  the	  liver,	  prostate	  cancer	  tends	  to	  metastasize	  to	  bone	  and	  kidney	  cancer	  prefers	  the	  lung.	  	  Breast	  cancer	  also	  has	  a	  high	  rate	  of	  lung	  and	  liver	  metastases.	  83	  Different	  breast	  cancer	  subtypes	  also	  exhibit	  preferential	  metastasis	  to	  various	  sites.	  	  Luminal	  and	  HER2-­‐positive	  cancers	  tend	  to	  spread	  to	  the	  brain,	  liver	  and	  lung	  while	  basal-­‐like	  tumors	  prefer	  brain,	  lung	  and	  distant	  lymph	  nodes.	  84	  ER-­‐positive/PR-­‐positive	  tumors	  metastasize	  mainly	  to	  bone,	  HER2-­‐positive	  to	  the	  liver	  and	  triple-­‐negative	  cancers	  to	  the	  lung	  and	  brain.	  85	  As	  reviewed	  by	  Scully	  et	  al.	  2012,	  3	  the	  majority	  of	  breast	  cancer-­‐related	  deaths	  occur	  due	  to	  metastasis	  to	  other	  sites	  within	  the	  body.	  	  Therefore,	  understanding	  how	  cancer	  cells	  escape	  from	  the	  primary	  tumor,	  survive	  in	  circulation	  and	  establish	  tumors	  at	  secondary	  sites	  is	  essential	  for	  identifying	  new	  therapeutic	  targets.	  	   Scully	  and	  colleagues	  describe	  some	  of	  the	  key	  steps	  in	  breast	  cancer	  metastasis,	  which	  begins	  with	  tumor	  cells	  altering	  cell-­‐cell	  adhesion	  and	  cell	  adhesion	  to	  the	  extracellular	  matric	  (ECM).	  	  Cell-­‐cell	  adhesion	  is	  regulated	  by	  cadherins	  and	  adherence	  to	  the	  ECM	  is	  facilitated	  by	  integrins.	  	  Tumor	  cells	  utilize	  MMPs	  and	  the	  urokinase	  plasminogen	  activator	  system	  to	  degrade	  components	  of	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the	  ECM	  and	  allow	  tumors	  cells	  to	  invade	  local	  tissue.	  	  Tumor	  cells	  can	  then	  migrate	  individually	  or	  collectively.	  	  Single	  cell	  migration	  is	  either	  protease-­‐dependent	  (mesenchymal)	  or	  –independent	  (amoeboid-­‐like).	  	  Mesenchymal	  single-­‐cell	  migration	  is	  regulated	  by	  mechanisms	  governing	  the	  epithelial-­‐to-­‐mesenchymal	  transition	  (EMT),	  such	  as	  gain	  of	  expression	  of	  mesenchymal	  markers	  like	  vimentin,	  Snail,	  and	  Slug	  and	  also	  activation	  of	  TGFβ,	  WNT	  and	  PI3K/AKT	  signaling	  pathways.	  	  The	  tumor	  microenvironment	  and	  recruitment	  of	  macrophages	  is	  also	  important	  for	  proliferative	  signaling,	  invasion,	  angiogenesis	  and	  immune	  evasion.	  3	  Drugs	  that	  target	  the	  signaling	  molecules	  that	  regulate	  these	  processes	  are	  imperative	  for	  preventing	  deaths	  due	  to	  breast	  cancer	  metastasis.	  	  	  	   The	  DNMT1	  inhibitor,	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  has	  potential	  as	  an	  epigenetic	  therapeutic	  for	  breast	  cancer.	  	  Inhibition	  of	  DNMT1	  leads	  to	  decreased	  methylation	  and	  potentially	  re-­‐expression	  of	  genes	  that	  have	  been	  silenced	  by	  promoter	  methylation	  during	  disease	  progression.	  	  Used	  alone	  or	  in	  combination	  with	  other	  cancer	  therapeutics,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  may	  prove	  to	  be	  beneficial	  for	  treating	  tamoxifen-­‐resistant	  breast	  cancer.	  	   Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  is	  known	  to	  inhibit	  cell	  growth	  and	  migration	  and	  induce	  re-­‐expression	  of	  genes	  silenced	  by	  DNA	  methylation	  in	  certain	  cell	  lines.	  	  In	  the	  bladder	  cancer	  cell	  line,	  T24,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  results	  in	  re-­‐expression	  of	  maspin,	  which	  is	  silenced	  by	  DNA	  promoter	  methylation.	  	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  of	  T24	  cells	  also	  inhibits	  proliferation,	  migration	  and	  invasion	  and	  results	  in	  increased	  apoptosis.	  86	  Treatment	  of	  the	  human	  multiple	  myeloma	  cell	  line,	  RPMI-­‐8226,	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  results	  in	  re-­‐expression	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of	  the	  tumor	  suppressor,	  DLC-­‐1,	  and	  dose-­‐dependent	  inhibition	  of	  growth	  and	  induction	  of	  apoptosis.	  87	  5-­‐Aza-­‐2’-­‐deoxycytidine	  is	  also	  known	  to	  inhibit	  growth	  of	  HeLa	  cells	  and	  re-­‐express	  the	  apoptosis	  regulatory	  protein,	  APAF-­‐1.88	  	   Inhibition	  of	  DNMT1	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  is	  known	  to	  decrease	  methylation	  of	  genes	  and	  correspondingly	  increase	  gene	  expression	  in	  breast	  cancer	  cell	  lines	  as	  well.	  	  In	  the	  human	  breast	  cancer	  cell	  line,	  MRK-­‐nu-­‐1,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  decreases	  methylation	  of	  retinoic	  acid	  receptor	  beta	  2	  (RARβ2),	  resulting	  in	  increased	  gene	  expression.	  	  In	  addition,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  induces	  cell-­‐cycle	  arrest	  and	  inhibits	  proliferation.	  89	  A	  similar	  effect	  on	  cell-­‐cycle	  arrest	  and	  proliferation	  was	  observed	  in	  MCF-­‐7	  cells	  treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  along	  with	  increased	  expression	  of	  APAF-­‐1.	  90	  Decreased	  promoter	  methylation	  and	  increased	  expression	  of	  IGFBP-­‐3	  has	  been	  observed	  in	  MCF-­‐7	  and	  T47D	  breast	  cancer	  cell	  lines.	  	  Additionally,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  inhibited	  growth	  and	  colony	  formation	  as	  well	  as	  increased	  cell	  death	  in	  these	  cell	  lines.	  91	  While	  these	  tissue	  culture	  experiments	  have	  identified	  genes	  with	  changes	  in	  methylation	  induced	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  the	  effect	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  on	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  lines	  is	  not	  known.	  	  Investing	  this	  concept	  will	  provide	  insight	  as	  to	  whether	  5-­‐Aza-­‐2’-­‐deoxycytidine	  could	  be	  utilized	  as	  a	  valuable	  therapy	  for	  ER-­‐negative,	  recurrent	  breast	  cancer	  after	  Tamoxifen	  treatment.	  	  	   In	  addition	  to	  the	  growth	  inhibitory	  effects	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  on	  breast	  cancer	  cell	  lines,	  89-­‐91	  5-­‐Aza-­‐2’-­‐deoxycytidine	  has	  also	  been	  shown	  to	  affect	  migration	  and	  invasion	  in	  other	  tissue	  culture	  experiments.	  	  The	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bladder	  cancer	  cell	  line,	  T24,	  has	  reduced	  migration	  and	  invasion	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  86	  Decreased	  promoter	  methylation	  and	  increased	  protein	  expression	  of	  maspin	  in	  extravillous	  trophoblast	  cells	  induced	  by	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  also	  results	  in	  inhibition	  of	  migration	  and	  invasion.	  92	  5-­‐Aza-­‐2’-­‐deoxycytidine	  has	  also	  been	  shown	  to	  decrease	  promoter	  methylation	  of	  miR495	  in	  gastric	  cancer	  cell	  lines,	  resulting	  in	  increase	  expression	  of	  miR495.	  	  This	  microRNA	  then	  represses	  PRL-­‐3	  expression	  and	  inhibits	  migration	  and	  invasion.	  93	  Therefore,	  we	  wanted	  to	  test	  the	  hypothesis	  that	  changes	  in	  DNA	  methylation	  and	  gene	  expression	  induced	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  may	  affect	  proliferation	  and	  migration	  in	  the	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  line,	  TMX2-­‐28,	  and	  could	  have	  potential	  as	  a	  therapeutic	  for	  Tamoxifen	  resistance	  in	  the	  clinic.	  	   In	  order	  to	  determine	  the	  effect	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  on	  these	  biological	  processes,	  MCF-­‐7	  and	  TMX2-­‐28	  cells	  were	  treated	  with	  2.5	  μM	  5-­‐Aza-­‐2’-­‐deoxycytidine	  for	  48	  to	  120	  hours.	  	  Cell	  proliferation	  was	  determined	  using	  the	  colorimetric	  assay	  with	  the	  Cell	  Titer	  96®	  Aqueous	  One	  Solution	  (Promega),	  adhesion	  to	  fibronectin	  was	  determined	  using	  pre-­‐coated	  fibronectin	  plates	  and	  staining	  adherent	  cells	  with	  crystal	  violet,	  migration	  assay.	  	  Evaluating	  the	  effect	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  on	  these	  biological	  processes	  provided	  a	  quantitative	  method	  for	  assessing	  whether	  this	  therapy	  might	  be	  effective	  for	  treatment	  of	  ER-­‐negative,	  Tamoxifen-­‐reistant	  disease.	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Materials	  and	  Methods	  Cell	  culture:	  	  MCF-­‐7	  cells	  were	  purchased	  from	  the	  American	  Type	  Culture	  Collection	  (ATCC).	  	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28	  cells	  were	  provided	  by	  John	  Gierthy	  (Wadsworth	  Center	  Albany,	  NY).	  	  Cells	  were	  grown	  in	  Dulbecco’s	  modified	  eagle	  medium	  (without	  phenol	  red).	  	  Medium	  was	  supplemented	  with	  5%	  cosmic	  calf	  serum	  (Hyclone	  Cat.	  No.	  SH30087.03),	  2.0	  mM	  of	  L-­‐glutamine,	  0.1	  mM	  of	  nonessential	  amino	  acids	  and	  250	  ng/mL	  of	  insulin.	  	  Cells	  were	  maintained	  at	  37°C,	  5%	  CO2	  in	  a	  humidified	  incubator	  and	  passaged	  at	  subconfluence	  or	  media	  exchanged	  every	  2	  days.	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment:	  	  Cells	  were	  seeded	  into	  plates	  or	  flasks	  and	  allowed	  to	  adhere	  overnight	  at	  37°C,	  5%	  CO2.	  	  Cells	  were	  treated	  with	  either	  0.1%	  DMSO	  (vehicle	  control)	  or	  2.5	  μM	  5-­‐Aza-­‐2’-­‐deoxycytidine	  (Aza	  or	  5-­‐Aza-­‐CdR)	  (Sigma-­‐Aldrich	  Cat.	  No.	  A3656)	  in	  0.1%	  DMSO	  for	  96	  hours,	  with	  media	  exchanged	  every	  other	  day.	  Proliferation	  Assay:	  	  Cells	  were	  seeded	  in	  a	  96-­‐well	  plate	  at	  5,000	  cells/well	  and	  treated	  with	  2.5	  μM	  Aza	  or	  DMSO	  (at	  50%	  re-­‐feed	  with	  100	  μL	  of	  growth	  media	  with	  Aza	  or	  DMSO)	  for	  48	  hrs.	  or	  2,500	  cells/well	  and	  treated	  with	  2.5	  μM	  Aza	  or	  DMSO	  for	  120	  hrs.	  	  At	  the	  time	  of	  the	  assay,	  20	  μL	  of	  Cell	  Titer	  96®	  Aqueous	  One	  Solution	  (Promega,	  Madison,	  WI)	  was	  added	  to	  each	  well	  containing	  100	  μL	  of	  growth	  media.	  	  The	  plate	  was	  then	  incubated	  at	  37°C,	  5%	  CO2	  for	  1	  hr.	  30	  min.	  	  Absorbance	  at	  490	  nm	  was	  read	  on	  a	  VersaMax	  Tunable	  Microplate	  reader	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(Molecular	  Devices,	  Sunnyvale,	  CA).	  	  Cell	  proliferation	  was	  quantified	  as	  a	  percentage	  of	  the	  control	  for	  each	  cell	  line.	  Migration/Wound-­‐healing	  Assay:	  	  TMX2-­‐28	  and	  MCF-­‐7	  cell	  cultures	  were	  treated	  in	  triplicate	  with	  2.5	  µM	  5-­‐Aza-­‐2’-­‐deoxycytidine	  (Aza)	  or	  vehicle	  control	  (DMSO)	  for	  48	  hours	  and	  allowed	  to	  reach	  90%	  confluency.	  	  Then	  the	  monolayer	  was	  scratched	  with	  a	  pipette	  tip	  and	  washed	  with	  PBS	  to	  remove	  detached	  cells.	  	  The	  wound	  boundary	  was	  then	  imaged	  every	  24	  hours	  to	  monitor	  cell	  migration	  for	  48	  hours	  in	  the	  presence	  of	  Aza.	  Cell	  Viability	  Assay:	  	  The	  viability	  of	  adherent	  and	  non-­‐adherent	  cells	  was	  determined	  by	  counting	  cells	  stained	  with	  the	  membrane	  exclusion	  dye,	  trypan	  blue.	  	  Adherent	  cells	  were	  washed	  once	  with	  PBS	  and	  incubated	  in	  trypsin	  for	  10	  minutes.	  	  A	  single-­‐cell	  suspension	  was	  formed	  by	  the	  addition	  of	  media	  and	  a	  10	  μL	  aliquot	  will	  be	  diluted	  1:1	  with	  trypan	  blue.	  	  Live	  and	  dead	  cells	  will	  be	  counted	  using	  a	  hemocytometer.	  	  Non-­‐adherent	  cells	  will	  be	  pelleted,	  resuspended	  in	  PBS,	  stained	  and	  counted	  as	  described	  above.	  Adhesion	  Assay	  (pre-­‐coated	  plates):	  	  Cells	  were	  seeded	  in	  a	  96-­‐well	  plate	  pre-­‐coated	  with	  human	  fibronectin	  (Corning,	  Bedford,	  MA)	  at	  20,000	  cells/well	  and	  incubated	  at	  37°C,	  5%	  CO2	  for	  30	  min.	  	  Shaking	  the	  plate	  on	  a	  plate	  shaker	  for	  10-­‐15	  sec	  displaced	  non-­‐adherent	  cells.	  	  The	  cell	  suspension	  was	  then	  removed	  and	  the	  wells	  were	  washed	  three	  times	  with	  100	  μL	  of	  wash	  buffer	  (0.1%	  BSA	  in	  serum-­‐free	  media).	  	  The	  cells	  were	  fixed	  by	  incubating	  with	  100	  μL	  of	  4%	  paraformaldehyde	  in	  PBS	  for	  10-­‐15	  min.	  	  The	  wells	  were	  then	  washed	  with	  wash	  buffer	  and	  removed	  by	  dumping	  out	  and	  tapping	  the	  plate	  on	  the	  bench.	  	  The	  cells	  were	  stained	  with	  5	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mg/mL	  crystal	  violet	  in	  2%	  ethanol	  for	  10	  min.	  	  The	  staining	  solution	  was	  removed	  and	  the	  plates	  were	  washed	  three	  times	  by	  submerging	  in	  water	  and	  discarding	  the	  wash.	  	  Excess	  water	  was	  removed	  by	  tapping	  the	  plate	  on	  the	  bench	  and	  the	  plate	  was	  dried	  for	  at	  least	  24	  hours.	  	  After	  the	  plate	  dried,	  100	  μL	  of	  1%	  SDS	  was	  added	  to	  each	  well	  and	  incubated	  at	  room	  temperature	  for	  30	  min.	  	  Absorbance	  at	  550	  nm	  was	  read	  on	  a	  VersaMax	  Tunable	  Microplate	  reader	  (Molecular	  Devices,	  Sunnyvale,	  CA).	  	  Cell	  adhesion	  to	  fibronectin	  was	  quantified	  as	  a	  percentage	  of	  the	  control	  for	  each	  cell	  line.	  Adhesion	  Assay	  (without	  pre-­‐coated	  plates):	  	  A	  96-­‐well	  plate	  was	  coated	  with	  50	  μL	  of	  fibronectin	  (20	  μg/mL,	  BD	  BioSciences,	  Cat.	  No.	  354008)	  and	  incubated	  at	  
37 °C for 1 hour or at 4°C	  overnight.	  	  The	  plate	  was	  then	  washed	  two	  times	  with	  150	  μL	  of	  washing	  buffer	  (0.1%	  BSA	  in	  serum-­‐free	  media)	  and	  incubated	  with	  150	  μL	  of	  blocking	  buffer	  (0.5%	  BSA	  in	  serum-­‐free	  media)	  at	  37 °C,	  5%	  CO2 for 1 hour.  The 
plate was then washed with washing buffer two times and chilled on ice.  Cells were 
counted and diluted to 200,000 cells/mL.  Cells were seeded into the coated plate at 
20,000 cells/well and incubated	  at	  37°C,	  5%	  CO2	  for	  30	  min.	  	  The	  plate	  was	  then	  washed	  and	  stained	  with	  crystal	  violet	  as	  described	  above.	  	  Pyrosequencing:	  The	  EZ	  DNA	  Methylation-­‐Lightning	  kit	  (Zymo,	  Cat.	  No.	  D5030)	  was	  used	  to	  bisulfite	  treat	  DNA.	  	  PCR	  primers	  were	  designed	  using	  the	  Pyromark	  Assay	  Design	  Software	  (Qiagen).	  	  Bisulfite	  treated	  DNA	  was	  then	  amplified	  using	  the	  EPIK	  Amplification	  kit	  (Bioline,	  Cat.	  No.	  BIO-­‐66025).	  	  Gene-­‐specific	  primers	  targeting	  the	  three	  CpG	  sites	  in	  the	  promoter	  region	  of	  TACSTD2	  (NM_002353)	  GRCh37	  HG19	  Map	  position	  (MAPINFO)	  Ch1	  coordinates:	  58815843,	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58815868	  and	  58815958	  analyzed	  by	  the	  BeadChip	  were	  designed.	  	  Primers	  for	  pyrosequencing:	  FWD	  Biot-­‐5’-­‐GGTTGGGGTTGGGAAAGAA-­‐3’,	  REV	  5’-­‐ACCCCACCTCCTACTACAAACCTA-­‐3’,	  SEQ	  5’-­‐GGAAAGAAAGAAAAGGGA-­‐3’.	  	  The	  Pyromark	  vacuum	  prep	  tool	  (Biotage)	  was	  used	  to	  isolate	  single	  stranded	  products	  for	  pyrosequencing.	  	  The	  Pyromark	  Q24	  system	  (Biotage)	  was	  used	  to	  perform	  pyrosequencing	  reactions	  according	  to	  manufacturer’s	  protocol	  (Qiagen).	  	  Percent	  methylation	  at	  the	  interrogated	  CpG	  sites	  was	  determined	  using	  the	  Pyromark	  Q24	  Software.	  Data	  Analysis:	  Proliferation,	  methylation,	  adhesion	  assay	  and	  migration	  assay	  data	  was	  analyzed	  using	  a	  using	  an	  un-­‐paired	  Student	  t	  test	  (StatPlus	  for	  Mac	  v.	  5.8.2.0).	  	  
Results	  
5-­‐Aza-­‐2’-­‐deoxycytidine	  Inhibits	  Proliferation	  in	  TMX2-­‐28	  	   Sustaining	  proliferative	  signals	  is	  one	  of	  the	  critical	  essential	  characteristics	  acquired	  by	  cancer	  cells.	  7	  One	  of	  the	  mechanisms	  employed	  by	  cancer	  cells	  to	  achieve	  this	  hallmark	  trait	  is	  by	  improper	  regulation	  of	  growth	  signaling	  pathways,	  such	  as	  MAPK	  pathway.	  7	  	  Previous	  work	  in	  our	  lab	  indicated	  that	  96-­‐hour	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  inhibits	  proliferation	  of	  TMX2-­‐28,	  but	  not	  the	  parental	  line,	  MCF-­‐7	  (Kristin	  Williams,	  unpublished	  data).	  	  Using	  a	  MTS	  assay,	  a	  colormetric	  assay	  that	  indicates	  metabolic	  activity,	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  for	  96	  hours	  decreased	  proliferation	  of	  TMX2-­‐28	  by	  approximately	  30%	  (Figure	  3.1).	  	  
	  82	  
Importantly,	  results	  from	  this	  initial	  study	  were	  confirmed	  by	  repeating	  the	  proliferation	  assay	  with	  MCF-­‐7	  and	  TMX2-­‐28	  cells	  treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  for	  120	  hours	  (Figure	  3.2).	  	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  for	  120	  hours	  decreased	  proliferation	  in	  TMX2-­‐28	  by	  39%.	  	  
5-­‐Aza-­‐2’-­‐deoxycytidine	  Inhibits	  Cell	  Migration	  (Scratch/Wound)	  in	  TMX2-­‐28	  To	  determine	  whether	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  affected	  migration,	  I	  conducted	  a	  wound-­‐healing	  assay	  with	  a	  48-­‐hour	  5-­‐Aza-­‐2’-­‐deoxycytidine	  pre-­‐treatment	  for	  triplicates	  of	  MCF-­‐7	  and	  TMX2-­‐28	  5-­‐Aza-­‐2’-­‐deoxycytidine	  -­‐treated	  and	  control.	  	  I	  found	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  increased	  migration	  in	  MCF-­‐7,	  confirming	  what	  is	  known	  in	  the	  literature.	  94	  However,	  treatment	  of	  TMX2-­‐28	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  inhibited	  migration	  (Figure	  3.3).	  	  Over	  the	  course	  of	  this	  experiment	  while	  monitoring	  migration,	  I	  observed	  an	  increase	  in	  the	  number	  of	  floating,	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  TMX2-­‐28	  cells	  (cells	  that	  had	  detached	  from	  the	  bottom	  of	  the	  well).	  	  In	  order	  to	  determine	  whether	  the	  scratch	  (i.e.	  wound	  to	  the	  monolayer)	  or	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  was	  causing	  loss	  of	  adherence,	  I	  repeated	  the	  wound-­‐healing	  assay	  with	  48-­‐hour	  5-­‐Aza-­‐2’-­‐deoxycytidine	  pre-­‐treatment	  both	  with	  and	  without	  the	  scratch.	  	  Regardless	  of	  the	  scratch,	  the	  number	  of	  floating	  TMX2-­‐28	  cells	  increased	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  (Figure	  3.4).	  	  Therefore,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  inhibits	  migration	  and	  adherence	  in	  TMX2-­‐28.	  To	  determine	  whether	  the	  detached	  TMX2-­‐28	  cells	  were	  viable,	  cells	  were	  pre-­‐treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  for	  48	  hours,	  then	  media	  containing	  either	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the	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  or	  control	  (3	  wells	  each)	  TMX2-­‐28	  floating	  cells	  was	  transferred	  to	  a	  new	  well	  of	  a	  6-­‐well	  plate	  every	  6	  to	  24	  hours.	  	  After	  8	  days,	  the	  media	  containing	  the	  floating	  population	  was	  collected,	  cells	  were	  stained	  with	  the	  membrane	  exclusion	  dye,	  Trypan	  blue,	  and	  counted.	  	  The	  adherent	  cells	  (re-­‐adherent	  population)	  were	  incubated	  with	  Trypsin,	  stained	  with	  Trypan	  blue	  and	  counted.	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreased	  the	  viability	  of	  both	  the	  floating	  and	  re-­‐adherent	  populations	  (Figure	  3.5).	  	  Therefore,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  inhibits	  migration,	  adherence	  and	  viability	  of	  TMX2-­‐28.	  	  Based	  on	  these	  preliminary	  results,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  may	  be	  an	  effective	  therapy	  for	  women	  with	  recurrent,	  ER-­‐negative	  breast	  cancer	  after	  Tamoxifen	  treatment.	  	  We	  predict	  that	  treatment	  with	  Aza	  alters	  promoter	  methylation	  and	  therefore	  expression	  of	  genes	  identified	  in	  Chapter	  2	  that	  may	  be	  involved	  in	  regulating	  these	  processes.	  	  
Optimization	  of	  Seeding	  Densities	  for	  Quantitative	  Adhesion	  Assay	  After	  determining	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  inhibits	  proliferation	  in	  TMX2-­‐28	  but	  not	  MCF-­‐7,	  I	  wanted	  to	  determine	  what	  other	  biological	  properties	  might	  be	  affected	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  seems	  to	  also	  promote	  detachment	  of	  TMX2-­‐28	  cells	  from	  the	  monolayer.	  	  However,	  the	  methods	  described	  previously	  to	  monitor	  cell	  detachment	  were	  not	  very	  accurate.	  	  Therefore,	  I	  switched	  to	  a	  more	  sensitive	  and	  quantitative	  method	  to	  monitor	  cell	  adhesion	  to	  fibronectin.	  	  Breifly,	  cells	  are	  given	  a	  certain	  amount	  of	  time	  to	  adhere	  to	  a	  fibronectin-­‐coated	  plate,	  non-­‐adherent	  cells	  are	  then	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washed	  away	  and	  the	  cells	  that	  remain	  are	  fixed	  and	  stained	  with	  crystal	  violet	  which	  is	  then	  solubilized	  in	  SDS	  and	  an	  absorbance	  measurement	  is	  recorded.	  	  First,	  I	  wanted	  to	  determine	  the	  optimum	  seeding	  density	  for	  the	  fibronectin	  adhesion	  assay.	  	  In	  order	  to	  determine	  the	  approximate	  number	  of	  cells	  that	  could	  be	  detected	  with	  the	  adhesion	  assay,	  I	  seeded	  1:10	  serial	  dilutions	  of	  cells	  onto	  a	  plate	  coated	  with	  fibronectin	  the	  day	  before	  (See	  Appendix	  B).	  	  I	  determined	  that	  the	  background	  staining	  needed	  to	  be	  reduced	  in	  order	  to	  have	  a	  more	  sensitive	  assay.	  	  After	  modifying	  the	  protocol	  by	  filtering	  the	  crystal	  violet	  staining	  solution	  and	  washing	  the	  plate	  by	  submerging	  it	  in	  water,	  the	  background	  staining	  was	  reduced	  considerably.	  	  I	  determined	  the	  optimum	  seeding	  density	  for	  the	  assay	  to	  be	  between	  30,000	  and	  14,000	  cells/well.	  	  
Variability	  With	  Initial	  Experiments	  and	  Switch	  to	  Pre-­‐coated	  Fibronectin	  
Plates	  	   In	  order	  to	  determine	  whether	  cell	  adhesion	  to	  fibronectin	  was	  altered	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  cells	  were	  grown	  in	  flasks	  and	  treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  Treatments	  were	  staggered	  such	  that	  each	  would	  finish	  on	  the	  same	  day	  (Figure	  3.6).	  	  Cells	  were	  then	  harvested,	  counted	  and	  diluted.	  	  Three	  experiments	  with	  the	  following	  treatments	  were	  conducted:	  24-­‐hour	  and	  48-­‐hour	  5-­‐Aza-­‐2’-­‐deoxycytidine	  -­‐treatment	  adhesion	  assays	  with	  MCF-­‐7	  and	  TMX2-­‐28.	  	  Based	  on	  previous	  observations,	  I	  predict	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  will	  result	  in	  decreased	  adhesion	  of	  TMX2-­‐28	  cells	  to	  fibronectin.	  	  However,	  the	  results	  from	  these	  first	  three	  experiments	  were	  variable	  (See	  Appendix	  B).	  	  Two	  of	  the	  three	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showed	  an	  increase	  in	  absorbance	  indicating	  an	  increase	  in	  adhesion	  in	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  TMX2-­‐28	  cells.	  	  There	  was	  also	  some	  variability	  in	  adhesion	  for	  MCF-­‐7	  cells.	  	  There	  are	  several	  possible	  explanations	  for	  this.	  	  First,	  there	  could	  be	  inconsistency	  with	  coating	  the	  plates	  by	  hand	  with	  fibronectin.	  	  Second,	  the	  cell	  counts	  obtained	  using	  a	  hemocytometer	  could	  be	  incorrect;	  therefore	  the	  dilutions	  and	  seeding	  densities	  would	  not	  be	  accurate.	  	  	  It	  is	  also	  possible	  that	  prior	  to	  seeding	  in	  the	  96-­‐well	  plate,	  there	  are	  two	  populations	  of	  cells	  in	  the	  flask	  (adherent	  and	  suspension)	  and	  each	  is	  behaving	  differently.	  	  Lastly,	  the	  inconsistency	  could	  simply	  be	  due	  to	  variability	  in	  response	  to	  short-­‐term	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	   I	  then	  switched	  to	  using	  commercially	  available	  pre-­‐coated	  fibronectin	  plates	  to	  minimize	  variability	  from	  coating	  and	  used	  an	  automated	  cell	  counter	  to	  minimize	  variability	  by	  counting	  with	  the	  hemocytometer.	  	  I	  also	  tested	  two	  longer	  treatments	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  48-­‐	  and	  72-­‐hours.	  	  Two	  experiments	  were	  conducted	  in	  parallel,	  one	  for	  which	  the	  adherent	  cells	  in	  the	  flask	  were	  trypsinized	  and	  used	  for	  the	  assay	  and	  the	  other	  for	  which	  the	  adherent	  cells	  in	  the	  flask	  were	  combined	  with	  any	  cells	  that	  may	  have	  already	  detached	  and	  were	  in	  suspension	  in	  the	  flask.	  	  Comparing	  the	  results	  between	  these	  two	  populations	  will	  indicate	  whether	  the	  detached	  cells	  are	  affecting	  the	  behavior	  of	  the	  cells	  that	  were	  adherent.	  	  
5-­‐Aza-­‐2’-­‐deoxycytidine	  Inhibits	  Adhesion	  in	  TMX2-­‐28	  	   Because	  previous	  experiments	  showed	  that	  TMX2-­‐28	  cells	  treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  detach	  from	  the	  monolayer,	  I	  wanted	  to	  see	  if	  there	  was	  a	  difference	  in	  adhesion	  between	  the	  adherent	  cells	  and	  the	  adherent	  cells	  combined	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with	  those	  cells	  that	  were	  in	  suspension.	  	  For	  the	  first	  experiment,	  two	  replicate	  flasks	  were	  seeded	  for	  each	  treatment	  (see	  Appendix	  D).	  	  On	  the	  day	  of	  the	  adhesion	  assay,	  the	  adherent	  cells	  were	  trypsinzed,	  counted	  and	  seeded	  for	  the	  assay.	  	  For	  the	  second	  set,	  cells	  that	  were	  floating	  in	  the	  spent	  media	  were	  combined	  with	  adherent	  cells,	  counted	  and	  seeded	  for	  the	  assay.	  	  Cells	  were	  seeded	  on	  the	  pre-­‐coated	  fibronectin	  plate	  at	  15,400	  cells/well	  (due	  to	  a	  limited	  number	  of	  cells	  in	  one	  of	  the	  samples).	  	  Remaining	  cell	  pellets	  from	  each	  treatment	  flask	  were	  divided	  into	  two	  and	  stored	  at	  -­‐80°C	  for	  DNA	  and	  RNA	  isolation	  at	  a	  later	  date.	  	  Results	  from	  the	  adherent	  population	  only	  indicate	  that	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  inhibits	  adhesion	  of	  TMX2-­‐28	  cells	  to	  fibronectin,	  but	  does	  not	  affect	  adhesion	  of	  MCF-­‐7	  cells	  (Figure	  3.7).	  	   Importantly,	  results	  from	  this	  experiment	  were	  verified	  by	  a	  second	  experiment.	  	  Repeating	  the	  48-­‐hour	  and	  72-­‐hour	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  and	  seeding	  the	  trypsinized	  cells	  at	  30,000	  cells/well	  using	  the	  pre-­‐coated	  plate	  confirmed	  the	  results	  from	  the	  first	  experiment	  with	  the	  pre-­‐coated	  fibronectin	  plate.	  	  (Remaining	  cell	  pellets	  from	  each	  treatment	  flask	  for	  this	  experiment	  were	  also	  divided	  into	  two	  and	  stored	  at	  -­‐80°C	  for	  DNA	  and	  RNA	  isolation).	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  did	  not	  alter	  MCF-­‐7	  adhesion	  to	  fibronectin.	  	  However,	  there	  was	  a	  step-­‐wise	  decrease	  in	  TMX2-­‐28	  adhesion	  to	  fibronectin	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  resulted	  in	  a	  21%	  decrease	  in	  TMX2-­‐28	  adhesion	  to	  fibronectin	  compared	  to	  the	  control	  (Figure	  3.8).	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Validation	  of	  Changes	  in	  Methylation	  Identified	  on	  450	  BeadChip	  	   In	  order	  to	  validate	  the	  changes	  in	  TACSTD2	  promoter	  methylation	  identified	  on	  the	  450	  BeadChip,	  DNA	  from	  the	  cells	  used	  for	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine	  adhesion	  assay	  experiments	  (Figure	  3.6)	  was	  isolated	  and	  promoter	  methylation	  was	  analyzed	  by	  pyrosequencing.	  	  The	  pyrosequencing	  assay	  was	  designed	  to	  include	  two	  of	  the	  three	  CpGs	  identified	  as	  differentially	  methylated	  on	  the	  450	  BeadChip	  (see	  Table	  2.8).	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  for	  48	  or	  72	  hours	  decreased	  promoter	  methylation	  by	  an	  average	  of	  45	  %	  (p	  <	  0.0001)	  and	  36	  %	  (p	  <	  0.0001),	  respectively	  compared	  to	  control	  DMSO	  treated	  TMX2-­‐28	  cells.	  	  There	  was	  no	  change	  in	  promoter	  methylation	  for	  MCF-­‐7	  cells	  after	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  This	  assay	  was	  repeated	  twice	  with	  similar	  results.	  	  This	  confirms	  the	  results	  from	  the	  450	  BeadChip.	  	  
Discussion	  	   Cancer	  can	  be	  considered	  a	  disease	  of	  both	  genetic	  and	  epigenetic	  abnormalities.	  14	  Histone	  modification	  and	  DNA	  methylation	  are	  epigenetic	  alterations	  known	  to	  be	  involved	  in	  cancer	  progression.	  30	  Aberrant	  DNA	  methylation	  and	  silencing	  of	  gene	  promoters	  with	  CpG	  islands	  occurs	  often	  in	  cancer.	  20	  Increased	  promoter	  methylation	  is	  recognized	  as	  an	  early	  and	  fundamental	  event	  in	  carcinogenesis	  and	  specifically	  in	  breast	  cancer.	  13,16	  Changes	  in	  DNA	  methylation	  are	  reversible	  and,	  based	  on	  these	  initial	  experiments,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  seems	  to	  affect	  proliferation,	  migration	  and	  adhesion	  in	  the	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tamoxifen-­‐resistant	  cell	  line	  only,	  indicating	  that	  it	  may	  be	  an	  effective	  therapeutic	  for	  patients	  with	  acquired	  ER-­‐negative	  tamoxifen-­‐resistant	  tumors.	  	   The	  primary	  objective	  of	  this	  study	  is	  to	  evaluate	  how	  changes	  in	  DNA	  methylation	  in	  response	  to	  the	  DNMT1	  inhibitor,	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  affect	  gene	  expression	  and	  cell	  behavior	  related	  to	  the	  Hallmarks	  of	  Cancer	  in	  the	  ER-­‐negative	  model	  of	  tamoxifen-­‐resistance.	  	  The	  results	  from	  this	  study	  will	  help	  determine	  whether	  5-­‐Aza-­‐2’-­‐deoxycytidine	  would	  be	  an	  effective	  therapeutic	  for	  tamoxifen-­‐resistant	  breast	  cancer.	  	  To	  accomplish	  this,	  I	  first	  validated	  previous	  unpublished	  data	  from	  our	  lab	  demonstrating	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  inhibits	  proliferation	  in	  TMX2-­‐28,	  but	  not	  the	  parental	  cell	  line,	  MCF-­‐7.	  	  Next	  I	  determined	  that	  migration	  of	  TMX2-­‐28	  cells	  in	  a	  scratch/wound	  assay	  is	  inhibited	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  However,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  increased	  migration	  in	  the	  parental	  cell	  line,	  MCF-­‐7.	  	  Based	  on	  the	  observation	  during	  the	  scratch/wound	  experiment	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  seemed	  to	  increase	  the	  number	  of	  floating	  cells	  for	  TMX2-­‐28,	  simply	  counting	  cells	  from	  the	  adherent	  and	  suspension	  populations	  and	  staining	  with	  Trypan	  blue	  indicated	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  induced	  detachment	  and	  decreased	  viability	  of	  TMX2-­‐28	  cells.	  	  I	  then	  used	  the	  pre-­‐coated	  fibronectin	  plates	  as	  a	  more	  precise	  and	  quantitative	  measure	  of	  cell	  adhesion	  to	  the	  ECM.	  	  I	  found	  that	  TMX2-­‐28	  cells	  treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  for	  48	  or	  72	  hours	  had	  decreased	  adhesion	  to	  fibronectin,	  while	  MCF-­‐7	  adhesion	  to	  fibronectin	  was	  not	  affected	  by	  the	  treatment.	  	  These	  results	  indicate	  that	  changes	  in	  DNA	  methylation	  resulting	  from	  exposure	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  cause	  changes	  in	  gene	  expression	  that	  decrease	  proliferation	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and	  inhibit	  both	  migration	  and	  adhesion	  in	  TMX2-­‐28.	  	  Treatment	  of	  MCF-­‐7	  cells	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  seemed	  to	  promote	  migration.	  	  However,	  proliferation	  and	  adhesion	  of	  MCF-­‐7	  cells	  is	  not	  affected	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  These	  results	  are	  promising	  and	  indicate	  that	  women	  with	  ER-­‐negative,	  tamoxifen-­‐resistant	  disease	  who	  have	  methylation	  signatures	  similar	  to	  TMX2-­‐28,	  may	  benefit	  from	  5-­‐Aza-­‐2’-­‐deoxycytidine	  therapy.	  	  However,	  based	  on	  the	  result	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  promotes	  migration	  of	  MCF-­‐7	  cells,	  breast	  cancers	  similar	  to	  these	  cells	  should	  not	  be	  treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  	  	   During	  the	  1960’s	  and	  early	  1970’s,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  (decitabine)	  and	  5-­‐azacytidine	  were	  first	  synthesized	  and	  tested	  as	  cytotoxic	  chemotherapeutics.	  95,96	  However,	  their	  demethylating	  activity	  was	  unknown	  until	  10-­‐15	  years	  later.	  97	  5-­‐azacytidine	  was	  approved	  in	  2004	  by	  the	  FDA	  as	  a	  therapy	  for	  myelodysplasia	  (MDS),	  a	  leukemia	  predisposition	  disorder,	  followed	  shortly	  thereafter	  by	  the	  approval	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  in	  2006.	  	  Both	  of	  these	  drugs	  are	  also	  an	  effective	  therapy	  for	  acute	  myeloid	  leukemia	  (AML).	  13	  As	  reviewed	  by	  Visconte	  et	  al.	  
2014,	  98	  MDS	  is	  a	  clonal	  stem	  cell	  malignancy	  characterized	  by	  cytopenia,	  inefficient	  hematopoiesis,	  dysplasia	  in	  one	  or	  more	  myeloid	  cell	  lineages	  and	  increased	  risk	  of	  development	  of	  AML.	  	  Aberrant	  methylation	  of	  tumor	  suppressor	  genes	  is	  known	  to	  occur	  in	  MDS	  along	  with	  altered	  patterns	  of	  DNA	  methylation	  and	  histone	  modifications.	  	  Genetic	  defects	  such	  as	  mutations,	  chromosomal	  aberrations	  and	  copy-­‐number	  alterations	  are	  frequently	  observed	  in	  MDS.	  	  Some	  of	  these	  genetic	  defects	  affect	  genes	  that	  are	  involved	  in	  regulating	  DNA	  methylation	  or	  histone	  modifications.	  	  For	  example,	  mutations	  in	  DNMT3A	  are	  known	  to	  occur	  in	  a	  small	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percentage	  of	  MDS	  patients.	  	  Loss	  of	  function	  mutations	  in	  TET2,	  a	  dioxygenase	  that	  catalyzes	  the	  conversion	  of	  5-­‐methylcytosine	  to	  5-­‐hydroxymethycytosine,	  occur	  in	  20-­‐25%	  of	  MDS	  patients.	  	  This	  leads	  to	  a	  decrease	  in	  5-­‐hydroxymethylcytosine	  levels	  and	  a	  corresponding	  increase	  in	  5-­‐methylcytosine,	  which	  contributes	  to	  DNA	  hypermethylation	  and	  gene	  silencing.	  	  Mutations	  in	  IDH1/2	  are	  also	  known	  to	  occur	  in	  MDS,	  which	  may	  result	  in	  altered	  mitochondria	  function	  and	  lead	  to	  hypermethylation.	  	  Mutations	  in	  the	  polycomb	  group	  member,	  ASXL1,	  have	  also	  been	  found	  in	  MDS	  patients.	  	  These	  mutations	  lead	  to	  alterations	  in	  chromatin	  remodeling	  and	  homeotic	  gene	  repression.	  	  Finally,	  deletions	  of	  chromosome	  7/7q,	  which	  contains	  the	  EZH2	  gene,	  are	  known	  to	  occur	  in	  MDS.	  	  EZH2	  is	  a	  histone	  methyltransferase	  factor	  and	  part	  of	  the	  catalytic	  component	  of	  polycomb	  repressive	  complex	  2	  (PRC2),	  which	  is	  responsible	  for	  modifying	  histones	  with	  the	  repressive	  mark,	  H3K27me3.	  98	  With	  these	  epigenetic	  factors	  that	  contribute	  to	  the	  development	  of	  MDS	  and	  ultimately	  progression	  to	  AML,	  it	  is	  clear	  why	  inhibition	  of	  DNMT’s	  by	  5-­‐azacytidine	  or	  5-­‐Aza-­‐2’-­‐deoxycytidine	  leading	  to	  decreased	  methylation	  would	  be	  beneficial	  for	  MDS	  patients.	  	   It	  is	  not	  clear	  why	  the	  tamoxifen-­‐resistant	  TMX2-­‐28	  cells,	  exhibit	  more	  changes	  in	  methylation	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  (Figure	  2.3).	  	  One	  mechanism	  of	  inhibition	  of	  methylation	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  results	  from	  the	  incorporation	  of	  the	  cytosine	  analog	  into	  DNA	  and	  formation	  of	  a	  covalent	  bond	  between	  the	  analog	  and	  DNMT1.	  	  This	  leads	  to	  enzyme	  degradation,	  loss	  of	  methylation	  with	  subsequent	  cell	  divisions	  and	  re-­‐expression	  of	  genes	  silenced	  by	  promoter	  methylation.	  70,71	  However,	  this	  may	  not	  be	  the	  only	  mechanism	  by	  which	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5-­‐Aza-­‐2’-­‐deoxycytidine	  and	  5-­‐Aza-­‐cytidine	  leads	  to	  decreased	  methylation.	  	  DNA	  methyltransferase	  activity	  is	  known	  to	  decrease	  faster	  than	  incorporation	  of	  5-­‐Aza-­‐cytidine	  into	  DNA.	  99	  Additionally,	  gene	  expression	  profile	  analysis	  of	  colon	  cancer	  cells	  treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  show	  that	  changes	  in	  gene	  expression	  occur	  independently	  of	  cell	  cycle	  and	  are	  not	  due	  entirely	  to	  incorporation	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  into	  DNA.	  100	  Ghoshal	  and	  colleagues101	  demonstrated	  that	  DNMT1	  undergoes	  rapid	  and	  selective	  degradation	  via	  the	  proteasomal	  pathway	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  They	  also	  found	  this	  process	  to	  occur	  in	  the	  nucleus,	  independent	  of	  DNA	  replication,	  and	  to	  require	  the	  conserved	  KEN	  box	  domain	  of	  DNMT1.	  101	  It	  is	  likely	  that	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐induced	  changes	  in	  DNA	  methylation,	  gene	  expression	  and	  behavior	  of	  TMX2-­‐28	  result	  from	  a	  combination	  of	  the	  processes	  described	  above.	  	  Therefore,	  cell-­‐line	  specific	  changes	  in	  methylation	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  may	  result	  from	  variations	  in	  expression	  levels	  of	  DNMT1	  or	  components	  of	  the	  proteasomal	  pathway.	  	  It	  may	  be	  useful	  to	  determine	  expression	  levels	  of	  these	  proteins	  or	  the	  presence	  of	  genetic	  mutations	  that	  may	  dictate	  a	  patient’s	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  therapy.	  	   The	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐induced	  inhibition	  of	  proliferation,	  migration	  and	  adhesion	  in	  TMX2-­‐28	  could	  be	  partially	  due	  to	  the	  dependence	  on	  or	  constitutive	  activation	  of	  regulatory	  signaling	  pathways	  in	  this	  cell	  line	  resulting	  from	  loss	  of	  ER	  expression	  or	  tamoxifen	  exposure.	  	  Decreased	  methylation	  and	  re-­‐expression	  of	  genes	  in	  growth	  inhibitory	  or	  negative	  feedback	  mechanisms	  may	  be	  induced	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  Constitutive	  activation	  of	  alternative	  signaling	  pathways	  is	  one	  of	  the	  Hallmarks	  of	  cancer	  cells	  that	  leads	  to	  sustained	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proliferation.	  7,8	  Cell	  culture	  models	  of	  tamoxifen	  resistance	  have	  indicated	  that	  breast	  cancer	  cells	  can	  utilize	  other	  pathways	  to	  overcome	  the	  inhibition	  of	  estrogen	  signaling,	  such	  as	  the	  GPER	  and	  IGF1R	  pathways.	  24,28	  Previous	  studies	  in	  our	  lab	  demonstrated	  that	  TMX2-­‐28	  cells	  overexpress	  the	  S-­‐phase	  kinase-­‐associated	  protein	  2	  (SKP2).	  	  SKP2	  regulates	  the	  cell	  cycle	  by	  targeting	  the	  CDK	  inhibitor,	  p27,	  for	  degradation	  and	  promotes	  cell	  cycle	  progression	  in	  TMX2-­‐28.	  39	  TMX2-­‐28	  cells	  also	  have	  high	  expression	  of	  the	  Ras	  Homolog	  Gene	  Family	  Member,	  A	  (RhoA),	  which	  may	  contribute	  to	  their	  invasive	  behavior.	  38	  However,	  these	  genes	  were	  not	  identified	  as	  having	  significant	  changes	  in	  methylation	  induced	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  But	  it	  is	  likely,	  that	  the	  expression	  of	  many	  genes	  is	  altered	  by	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  and	  a	  global	  measurement	  of	  changes	  in	  mRNA	  expression	  after	  treatment	  would	  be	  beneficial.	  	   The	  specific	  role	  of	  TROP2	  in	  regulating	  the	  response	  of	  TMX2-­‐28	  cells	  to	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  could	  be	  investigated	  further	  by	  knockdown	  and	  overexpression	  studies.	  	  Therefore,	  I	  will	  create	  a	  stable	  TMX2-­‐28	  cell	  line	  with	  increased	  expression	  of	  TACSTD2,	  which	  will	  mimic	  the	  effect	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  I	  will	  also	  generate	  an	  MCF-­‐7	  cell	  line	  with	  decreased	  
TACSTD2	  expression.	  	  I	  predict	  these	  cells	  will	  behave	  similar	  to	  TMX2-­‐28	  cells,	  which	  have	  low	  expression	  of	  TROP2	  under	  normal	  growth	  conditions.	  	  These	  cell	  lines	  will	  help	  to	  further	  investigate	  the	  role	  of	  TROP2	  in	  regulating	  proliferation,	  adhesion	  and	  migration	  in	  tamoxifen	  resistance.	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Figure	  3.1:	  Treatment	  With	  5-­‐Aza-­‐2’-­‐deoxycytidine	  for	  96	  Hours	  Decreases	  
Proliferation	  in	  TMX2-­‐28.	  	  Cell	  proliferation	  in	  96-­‐hr.	  Aza	  treated	  cells,	  represented	  as	  percentage	  of	  control,	  determined	  by	  MTS	  assay	  for	  the	  parental	  cell	  line	  and	  each	  of	  the	  tamoxifen-­‐resistant	  cell	  lines	  (n	  =	  3,	  p	  ≤	  0.001).102	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Figure	  3.2:	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment	  Decreases	  Proliferation	  in	  
TMX2-­‐28.	  	  Proliferation,	  determined	  by	  MTS	  assay,	  in	  control	  and	  120-­‐hour	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  cells	  (n	  =	  8).	  Data	  represented	  as	  percentage	  of	  control,	  for	  the	  parental	  line,	  MCF-­‐7,	  and	  the	  ER-­‐Negative	  tamoxifen-­‐resistant	  cell	  line,	  TMX2-­‐28.	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(A)	   	   	   	   	   	   	   	   (B)	  
	  	  
Figure	  3.3:	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment	  Inhibits	  Migration	  in	  Scratch/Wound	  Assay	  in	  TMX2-­‐28.	  	  Images	  from	  the	  MCF-­‐7	  (A)	  and	  TMX2-­‐28	  (B)	  Aza-­‐treated	  and	  control	  wells	  at	  the	  time	  of	  the	  scratch	  (0	  hrs.),	  24	  and	  48	  hrs.	  	  Wound	  boundaries	  are	  marked	  with	  vertical	  blue	  lines	  (cells	  are	  growing	  in	  a	  monolayer	  outside	  the	  lines,	  the	  center	  area	  between	  the	  lines	  is	  the	  location	  of	  the	  wound	  and	  is	  free	  of	  cells).
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(A)	   	   	   	   	   	   (B)	  
	  
Figure	  3.4:	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment	  Results	  in	  Detachment	  of	  Cells	  
Independent	  of	  Scratch.	  	  Schematic	  of	  experimental	  design	  (A).	  	  Average	  number	  of	  floating	  TMX2-­‐28	  cells/well	  (n	  =	  3)	  for	  control	  and	  Aza-­‐treated	  cells	  either	  with	  or	  without	  the	  scratch,	  planned	  t-­‐test	  (B).	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(A)	   	   	   	   	   	   	   (B)	  
	  




Figure	  3.6:	  Schematic	  of	  Experimental	  Design	  for	  5-­‐Aza-­‐2’-­‐deoxycytidine	  
Treatment	  and	  Adhesion	  Assay.	  	  Cells	  were	  seeded	  into	  three	  T-­‐75	  flasks	  (Day	  1).	  	  The	  72-­‐hour	  treatment	  with	  vehicle	  control	  or	  2.5	  μM	  5-­‐Aza-­‐2’-­‐deoxycytidine	  began	  for	  two	  of	  the	  flasks	  on	  Day	  2.	  	  On	  the	  following	  day	  (Day	  3)	  the	  48-­‐hour	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  began	  for	  the	  third	  flask.	  	  Two	  days	  later	  (Day	  5),	  cells	  from	  each	  flask	  were	  harvested,	  counted	  and	  seed	  into	  a	  96-­‐well	  fibronectin-­‐coated	  plate	  at	  20,000	  cells/well.	  	  (Remaining	  cell	  pellets	  were	  saved	  and	  stored	  at	  -­‐80°C).	  	  Cells	  were	  allowed	  to	  adhere	  to	  the	  fibronectin-­‐coated	  plate	  for	  30	  minutes,	  washed	  and	  stained	  with	  crystal	  violet,	  as	  described	  previously.	  	  	  
	  	  





Figure	  3.7:	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment	  Decreases	  Adhesion	  in	  TMX2-­‐




Figure	  3.8:	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment	  Decreases	  Adhesion	  in	  TMX2-­‐28	  
(n	  =	  16).	  	  Adhesion	  to	  fibronectin-­‐coated	  plate	  represented	  as	  percentage	  of	  control	  for	  MCF-­‐7	  and	  TMX2-­‐28	  treated	  with	  control	  DMSO	  or	  5-­‐Aza-­‐2’-­‐deoxycytidine	  for	  48	  or	  72	  hours	  (n	  =	  16).	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Figure	  3.9:	  5-­‐Aza-­‐2’-­‐deoxycytidine	  Treatment	  Decreases	  Promoter	  





THE	  ROLE	  OF	  TROP2	  IN	  REGULATION	  OF	  ADHESION,	  MIGRATION	  AND	  
PROLIFERATION	  IN	  TMX2-­‐28	  	  
Introduction	  According	  to	  the	  Human	  Methylation	  BeadChip,	  the	  TACSTD2	  promoter	  is	  hypermethylated	  in	  TMX2-­‐28	  (Table	  2.8	  and	  Figure	  2.8)	  and	  correspondingly	  TROP2	  expression	  is	  downregulated	  (Figure	  2.9)	  indicating	  that	  promoter	  methylation	  may	  regulate	  gene	  expression	  in	  the	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  line.	  	  Interestingly,	  TACSTD2	  expression	  is	  regulated	  by	  promoter	  methylation	  in	  lung	  adenocarcinoma.	  61	  The	  authors	  found	  that	  treatment	  of	  lung	  cancer	  cell	  lines	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreased	  methylation	  and	  increased	  expression	  of	  TROP2	  in	  lung	  cancer	  cell	  lines.	  	  They	  also	  observed	  TACSTD2	  methylation	  and	  low	  expression	  of	  TROP2	  in	  lung	  adenocarcinoma	  tissue.	  	  Forced	  expression	  of	  TROP2	  inhibited	  AKT	  and	  ERK	  activation,	  inhibiting	  proliferation	  and	  colony	  formation.	  	  
TACSTD2	  also	  appears	  to	  be	  methylated	  in	  primary	  prostate	  tumors103	  and	  stomach	  cancer	  cell	  lines.	  104	  Therefore,	  I	  wanted	  to	  determine	  the	  extent	  to	  which	  expression	  of	  TROP2	  in	  TMX2-­‐28,	  induced	  by	  decreased	  promoter	  methylation,	  was	  responsible	  for	  the	  decrease	  in	  proliferation,	  adhesion	  and	  migration	  in	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  TMX2-­‐28	  cells.	  Previous	  studies	  in	  our	  lab	  have	  shown	  that,	  compared	  to	  the	  parental	  line,	  MCF-­‐7,	  TMX2-­‐28	  cells	  have	  increased	  cell	  cycle	  progression,	  migration	  and	  invasion.74,75	  In	  my	  experiments	  with	  control	  DMSO-­‐	  and	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐
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treated	  cells	  (Figure	  3.8),	  both	  MCF-­‐7	  and	  TMX2-­‐28-­‐DMSO-­‐treated	  cells	  have	  similar	  adhesion	  to	  fibronectin.	  	  However,	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  TMX2-­‐28	  cells	  have	  decreased	  proliferation,	  adhesion	  and	  migration	  (Figures	  3.2,	  3.3	  and	  3.4).	  	  While	  5-­‐Aza-­‐2’-­‐deoxycytidine	  affects	  only	  migration	  of	  MCF-­‐7.	  	  MCF-­‐7	  cells	  treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  have	  increased	  migration	  determined	  by	  scratch-­‐wound	  assay	  (Figure	  3.3).	  	  If	  the	  changes	  in	  proliferation,	  adhesion	  and	  migration	  in	  TMX2-­‐28	  that	  result	  from	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  are	  caused	  by	  the	  increase	  in	  TROP2	  expression,	  I	  predict	  that	  forced	  expression	  of	  TROP2	  in	  TMX2-­‐28	  will	  inhibit	  proliferation,	  adhesion	  and	  migration	  (Table	  4.1).	  	  Subsequently,	  I	  predict	  that	  knockdown	  of	  Trop2	  in	  MCF-­‐7	  will	  increase	  proliferation,	  migration	  and	  adhesion.	  Although	  TROP2	  expression	  seems	  to	  inhibit	  cell	  growth	  and	  proliferation	  in	  lung	  cancer,	  61	  it	  promotes	  growth	  in	  other	  cell	  types.	  	  TROP2	  overexpression	  increases	  growth	  of	  human	  colon	  and	  ovarian	  cancer	  cell	  lines	  and	  knockdown	  inhibits	  growth	  in	  MCF-­‐7	  and	  colon	  cancer	  cell	  lines.	  64	  TROP2	  also	  appears	  to	  be	  involved	  in	  regulating	  cell	  adhesion	  and	  migration.	  	  As	  with	  the	  proliferation	  data	  in	  the	  literature,	  TROP2	  seems	  to	  have	  a	  cell	  type-­‐specific	  effect	  on	  adhesion	  and	  migration.	  	  In	  the	  developing	  mouse	  kidney,	  cells	  with	  high	  TROP2	  expression	  have	  decreased	  adhesion	  to	  collagen-­‐coated	  plates	  along	  with	  decreased	  motility.	  105	  However,	  TROP2	  acts	  to	  promote	  detachment	  from	  the	  extracellular	  matrix	  (ECM)	  and	  increase	  migration	  in	  prostate	  cancer	  cells.	  64,106	  In	  these	  cells,	  TROP2	  interacts	  with	  α5β1	  integrin,	  causing	  α5β1	  integrin	  and	  talin	  to	  relocalize	  from	  focal	  adhesions	  to	  the	  leading	  edge	  of	  the	  cell.	  	  This	  results	  in	  increased	  Ras-­‐related	  C3	  botulinum	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toxin	  substrate	  1	  (Rac1)	  GTPase	  and	  p21	  protein	  (Cdc42/Rac)-­‐activated	  kinase	  4	  (PAK4)	  activity,	  which	  increases	  focal	  adhesion	  turnover	  and	  promotes	  migration.	  64	  Cell	  migration	  requires	  the	  cyclic	  assembly,	  maturation	  and	  disassembly	  of	  focal	  adhesions	  and	  involves	  a	  variety	  of	  proteins	  and	  signaling	  molecules,	  which	  facilitate	  integrin	  attachment	  to	  the	  ECM	  and	  the	  regulation	  of	  tension	  in	  the	  cytoskeleton.	  107	  TROP2	  also	  appears	  to	  promote	  migration	  in	  the	  human	  laryngeal	  carcinoma	  cell	  line,	  Hep2,	  as	  knockdown	  inhibits	  migration	  and	  invasion.	  108	  TROP2	  promotes	  migration	  and	  anchorage	  independent	  growth	  in	  mouse	  pancreatic	  cells.59	  Given	  the	  variable	  results	  in	  the	  literature,	  I	  wanted	  to	  determine	  how	  TROP2	  affects	  proliferation,	  adhesion	  and	  migration	  in	  our	  model	  of	  tamoxifen	  resistance.	  	  Specifically,	  I	  wanted	  to	  test	  the	  hypothesis	  that	  increased	  TROP2	  expression	  in	  TMX2-­‐28,	  induced	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  was	  responsible	  for	  the	  decrease	  in	  proliferation,	  adhesion	  and	  migration.	  To	  test	  this	  hypothesis,	  I	  first	  generated	  stable	  cells	  with	  either	  increased	  TROP2	  expression	  or	  decreased	  TROP2	  expression.	  	  Increasing	  TROP2	  expression	  in	  TMX2-­‐28,	  which	  has	  low	  endogenous	  TROP2	  expression,	  should	  mimic	  the	  effect	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment,	  which	  increases	  TROP2	  expression	  as	  a	  result	  of	  decreased	  promoter	  methylation.	  	  Knockdown	  of	  TROP2	  in	  the	  parental	  cell	  line,	  MCF-­‐7,	  will	  help	  to	  validate	  the	  role	  of	  TROP2	  in	  regulating	  proliferation,	  adhesion	  and	  migration.	  	  Next,	  I	  quantifed	  proliferation,	  adhesion	  and	  migration	  in	  the	  overexpression,	  knockdown	  and	  control	  vector-­‐transfected	  cell	  lines.	  	  I	  predicted	  that	  the	  TMX2-­‐28	  cell	  line	  with	  increased	  expression	  of	  TROP2	  would	  have	  decreased	  proliferation,	  adhesion	  and	  migration	  while	  knockdown	  of	  TROP2	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expression	  would	  increase	  proliferation,	  adhesion	  and	  migration	  in	  MCF-­‐7	  cells	  (Table	  4.1).	  Additionally,	  I	  examined	  TACSTD2	  methylation	  and	  TROP2	  expression	  in	  clinical	  breast	  cancer	  samples.	  	  The	  results	  from	  the	  clinical	  samples	  will	  indicate	  whether	  the	  tissue	  culture	  model	  is	  an	  accurate	  representation	  of	  methylation	  and	  expression	  patterns	  in	  human	  disease.	  	  Human	  tissue	  samples	  were	  collected	  in	  collaboration	  with	  Baystate	  Medical	  Center	  (Springfield,	  MA)	  and	  analyzed	  on	  the	  Human	  Illumina	  450	  BeadChip	  for	  DNA	  methylation	  and	  formalin-­‐fixed	  paraffin-­‐embedded	  (FFPE)	  tumor	  blocks	  were	  analyzed	  for	  protein	  expression	  of	  hormone	  receptors	  (ER,	  PR	  and	  HER2),	  the	  proliferation	  marker,	  Ki67,	  and	  TROP2.	  	  Based	  on	  the	  methylation	  data	  for	  TACSTD2	  in	  the	  cell	  lines,	  I	  predict	  that	  ER-­‐positive	  primary	  tumors	  that	  recur	  as	  ER-­‐negative	  tumors	  will	  have	  methylation	  and	  expression	  of	  TROP2	  similar	  to	  that	  of	  TMX2-­‐28	  (Table	  4.2).	  	  This	  is	  because	  TMX2-­‐28	  cells	  were	  derived	  from	  the	  ER-­‐positive,	  MCF-­‐7	  cell	  line,	  treated	  with	  tamoxifen	  and	  subsequently	  lost	  ER	  expression.	  	  If	  TROP2	  expression	  is	  regulated	  by	  promoter	  methylation	  as	  seen	  in	  the	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  line,	  TMX2-­‐28,	  I	  predict	  samples	  with	  high	  promoter	  methylation	  will	  have	  low	  protein	  expression.	  	  Conversely,	  I	  predict	  samples	  will	  low	  promoter	  methylation	  will	  have	  high	  protein	  expression.	  	  	  There	  is	  some	  evidence	  that	  TROP2	  expression	  in	  clinical	  samples	  is	  associated	  with	  prognosis,	  tumor	  grade	  and	  proliferative	  index.	  	  In	  breast	  cancer,	  membrane	  localization	  of	  TROP2	  (indicative	  of	  mature	  glycosylation)	  is	  associated	  with	  a	  poor	  prognosis.	  65	  In	  the	  same	  study,	  researchers	  found	  that	  intracellular	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TROP2	  localization	  was	  associated	  with	  a	  favorable	  prognosis.	  65	  A	  study	  that	  examined	  32	  breast	  cancer	  samples	  found	  that	  TROP2	  expression	  was	  significantly	  higher	  in	  the	  ER-­‐negative/HER2-­‐positive	  tumors.	  109	  However,	  another	  study	  analyzing	  TROP2	  expression	  in	  423	  breast	  cancer	  patients	  found	  TROP2	  expression	  was	  associated	  with	  ER	  and	  HER2	  expression.	  	  These	  authors	  also	  found	  TROP2	  expression	  was	  correlated	  with	  expression	  of	  genes	  that	  promote	  cell	  cycle	  progression.	  60	  Similarly,	  high	  TROP2	  expression	  is	  associated	  with	  high	  Ki-­‐67	  expression	  in	  the	  fetal	  rat	  lung110	  and	  human	  cervical	  cancer111	  and	  high	  grade	  gliomas.	  112	  Therefore,	  I	  predict	  tumors	  with	  high	  levels	  of	  Ki67	  will	  have	  high	  expression	  of	  TROP2.	  	  Similarly,	  high	  TROP2	  expression	  is	  linked	  to	  disease	  progression	  in	  colon	  cancer.	  113	  Analogously,	  a	  study	  examining	  TROP2	  expression	  in	  invasive	  ductal	  carcinoma	  and	  adjacent	  normal	  tissue	  found	  high	  TROP2	  expression	  was	  correlated	  with	  CyclinD1	  expression,	  high	  tumor	  grade,	  lymph	  node	  metastasis	  and	  distant	  metastasis.	  114	  Similar	  studies	  in	  colon	  cancer	  found	  high	  TROP2	  expression	  was	  associated	  with	  liver	  metastasis115	  and	  decreased	  survival.116	  Therefore,	  I	  predict	  the	  recurrent	  breast	  cancer	  samples	  will	  have	  increased	  expression	  of	  TROP2	  while	  the	  non-­‐recurrent	  samples	  should	  have	  decreased	  expression	  of	  TROP2.	  	  My	  predictions	  for	  the	  tumor	  samples	  based	  on	  the	  literature	  are	  outlined	  in	  Table	  4.3.	  Examination	  of	  TACSTD2	  methylation	  and	  expression	  patterns	  of	  TROP2	  in	  clinical	  breast	  cancer	  samples	  will	  validate	  the	  tissue	  culture	  study	  experiments.	  	  This	  will	  help	  determine	  whether	  the	  same	  trends	  in	  our	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  line	  model	  are	  also	  present	  in	  clinical	  samples.	  	  This	  will	  confirm	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whether	  targeting	  TROP2	  and	  TACSTD2	  methylation	  should	  be	  investigated	  as	  a	  therapeutic	  option	  for	  tamoxifen-­‐resistant	  disease.	  	  
Materials	  and	  Methods	  Cell	  culture:	  	  MCF-­‐7	  cells	  were	  purchased	  from	  the	  American	  Type	  Culture	  Collection	  (ATCC).	  	  TMX2-­‐28	  cells	  were	  provided	  by	  John	  Gierthy	  (Wadsworth	  Center	  Albany,	  NY).	  	  Cells	  were	  grown	  in	  Dulbecco’s	  modified	  eagle	  medium	  (without	  phenol	  red).	  	  Medium	  was	  supplemented	  with	  5%	  cosmic	  calf	  serum	  (Hyclone	  Cat.	  No.	  SH30087.03),	  2.0	  mM	  of	  L-­‐glutamine,	  0.1	  mM	  of	  nonessential	  amino	  acids	  and	  250	  ng/mL	  of	  insulin.	  	  Cells	  transfected	  with	  the	  TROP2	  knockdown	  or	  overexpression	  constructs	  were	  maintained	  in	  medium	  as	  described	  above	  supplemented	  with	  300	  μg/mL	  G418	  disulfate	  salt	  (Sigma	  Aldrich,	  Cat	  no.	  A1720).	  	  Cells	  were	  maintained	  at	  37°C,	  5%	  CO2	  in	  a	  humidified	  incubator	  and	  passaged	  at	  subconfluence	  or	  media	  exchanged	  every	  2	  days.	  Bacterial	  Transformation:	  	  The	  following	  vectors	  were	  received	  from	  the	  Alberti	  Lab:	  pSUPER	  (empty,	  control	  vector),	  hTrop-­‐2siRNA#19	  (knockdown	  construct),	  pΔEYFP-­‐N1	  (empty,	  control	  vector)	  and	  hTrop2	  in	  	  pΔEYFP-­‐N1	  (overexpression	  construct).	  	  The	  vectors	  were	  reconstituted	  in	  100	  μL	  of	  TE	  buffer.	  	  One	  Shot	  TOP10	  Chemically	  Competent	  E.	  coli	  (Invitrogen	  /	  Life	  Technologies,	  Carlsbad,	  CA)	  were	  transformed	  according	  to	  manufacturer’s	  protocol.	  	  Briefly,	  cells	  were	  thawed	  on	  ice.	  	  1	  μL	  of	  DNA	  was	  added	  to	  20	  μL	  of	  competent	  cells	  and	  incubated	  on	  ice	  for	  20	  min.	  	  The	  cells	  were	  then	  heat	  shocked	  for	  30	  sec.	  at	  42°C	  and	  incubated	  on	  ice	  for	  2	  min.	  	  250	  μL	  of	  pre-­‐warmed	  S.O.C.	  medium	  was	  added	  to	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each	  vial	  and	  the	  vials	  were	  incubated	  at	  37°C	  in	  a	  shaking	  incubator	  for	  30	  min.	  	  50-­‐70	  μL	  of	  transformation	  was	  plated	  on	  a	  pre-­‐warmed	  selective	  plate	  and	  incubated	  overnight	  at	  37°C.	  	  Single	  colonies	  were	  selected	  and	  grown	  in	  2	  mL	  LB	  broth	  supplemented	  with	  antibiotic	  overnight	  in	  a	  shaking	  incubator	  at	  37°C.	  	  DNA	  was	  isolated	  using	  the	  STET	  Miniplasmid	  Prep	  Protocol.	  STET	  Miniplasmid	  Prep:	  	  1,500	  μL	  of	  bacterial	  suspension	  was	  transferred	  to	  a	  new	  tube	  and	  centrifuged	  for	  2	  min.	  at	  15,000	  rpm.	  	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  resuspended	  in	  140	  μL	  of	  STET	  buffer	  (8%	  sucrose,	  5%	  Triton-­‐X,	  50	  mM	  EDTA	  and	  50	  mM	  Tris-­‐HCl,	  pH8)	  and	  vortexed.	  	  10	  μL	  of	  lysozyme	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO)	  (10mg/mL)	  was	  added	  and	  samples	  were	  boiled	  for	  60	  sec.	  	  Samples	  were	  then	  centrifuged	  for	  10	  min.	  at	  15,000	  rpm.	  	  A	  toothpick	  was	  used	  to	  remove	  and	  discard	  the	  pellet	  then	  150	  μL	  of	  isopropyl	  alcohol	  was	  added	  and	  vortexed.	  	  The	  samples	  were	  centrifuged	  for	  10	  min.	  at	  15,00	  rpm	  and	  the	  supernatant	  was	  discarded.	  	  The	  pellet	  was	  resuspended	  in	  70%	  ethanol	  and	  centrifuged	  for	  10	  min.	  at	  15,000	  rpm.	  	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  resuspended	  in	  30	  μL	  of	  water.	  Restriction	  Enzyme	  Digest	  and	  Gel	  Electrophoresis:	  	  A	  single	  restriction	  digest	  was	  used	  to	  determine	  the	  approximate	  size	  of	  the	  plasmid	  isolated	  from	  each	  bacterial	  colony.	  	  XbaI	  with	  NEB4	  and	  BSA	  (New	  England	  Biolabs,	  Ipswich,	  MA)	  was	  used	  for	  pSUPER	  plasmids.	  	  StuI	  with	  NEB4	  was	  used	  for	  pΔEYFP-­‐N1	  plasmids.	  	  0.5	  μL	  of	  RNaseA	  (20	  mg/mL)(Invitrogen,	  Carlsbad,	  CA)	  or	  1	  μL	  of	  RNaseA	  (10	  mg/mL)(Thermo	  Scientific,	  Waltham,	  MA)	  was	  added	  to	  each	  50	  μL	  sample	  after	  the	  
	  109	  
digest	  was	  complete.	  	  Products	  from	  the	  restriction	  enzyme	  digest	  were	  run	  on	  a	  1%	  agarose	  gel	  at	  100	  V	  for	  1	  hr.	  30	  min.	  TROP2	  Knockdown/Overexpression:	  	  TMX2-­‐28	  or	  MCF-­‐7	  cells	  were	  seeded	  one	  day	  prior	  to	  the	  transfection	  in	  a	  6-­‐well	  plate	  such	  that	  they	  reached	  40%	  confluence	  on	  the	  day	  of	  the	  transfection.	  	  MCF-­‐7	  cells	  were	  transfected	  with	  5	  μg	  of	  either	  pSUPER	  (empty,	  control	  vector)	  or	  hTrop2-­‐siRNA#19	  (knockdown	  construct)	  plus	  200	  ng	  of	  pΔEYFP-­‐N1	  (contains	  G418	  selection	  marker).	  	  TMX2-­‐28	  cells	  were	  transfected	  with	  2	  μg	  of	  pΔEYFP-­‐N1	  (empty,	  control	  vector)	  or	  pΔEYFP-­‐N1-­‐hTrop2	  with	  SuperFect	  (Qiagen	  no.	  301305)	  per	  manufacturers	  instructions.	  	  Briefly,	  2-­‐5	  μg	  of	  DNA	  were	  diluted	  in	  100	  μL	  serum-­‐free	  media.	  	  SuperFect	  transfection	  reagent	  was	  then	  added	  to	  the	  DNA	  solution	  and	  vortexed	  for	  10	  sec.,	  the	  solution	  was	  then	  incubated	  at	  room	  temperature	  for	  5-­‐10	  min.	  to	  allow	  for	  complex	  formation.	  	  Then	  600	  μL	  of	  regular	  growth	  medium	  was	  added	  to	  the	  complex	  solution,	  mixed	  by	  pipetting	  up	  and	  down	  twice	  and	  transferred	  directly	  to	  the	  cells	  (which	  were	  rinsed	  with	  PBS	  prior	  to	  addition).	  	  The	  cells	  were	  incubated	  with	  the	  transfection	  complexes	  for	  2-­‐3	  hours	  at	  37°C,	  5%	  CO2	  in	  a	  humidified	  incubator.	  	  Then	  fresh	  regular	  growth	  medium	  was	  added	  to	  each	  well	  and	  the	  cells	  were	  allowed	  to	  grow	  for	  24	  –	  48	  hours.	  	  After	  this	  time,	  the	  spent	  medium	  was	  exchanged	  with	  selective	  media	  containing	  300	  μg/mL	  of	  G418	  disulfate	  salt	  (Sigma	  Aldrich,	  Cat	  no.	  A1720).	  	  Cells	  were	  maintained	  in	  G418	  selection	  media	  until	  there	  was	  a	  sufficient	  amount	  to	  count	  and	  seed	  for	  colony	  isolation	  with	  the	  medium	  exchanged	  every	  2-­‐3	  days.	  Colony	  Isolation	  with	  Cloning	  Cylinders:	  	  Cells	  were	  seeded	  in	  a	  6-­‐well	  plate	  at	  a	  density	  of	  1,000	  –	  2,000	  cells/well	  and	  cultured	  in	  selective	  media	  until	  colonies	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were	  a	  sufficient	  size	  to	  harvest	  and	  visible	  by	  eye	  (300+	  cells).	  	  Desired	  colonies	  were	  isolated	  using	  cloning	  cylinders.	  	  Briefly,	  colonies	  were	  marked	  on	  the	  bottom	  of	  the	  plate	  with	  a	  marker	  and	  spent	  media	  from	  the	  well	  was	  aspirated,	  wells	  were	  rinsed	  with	  PBS.	  	  After	  rinsing	  and	  aspirating	  PBS,	  a	  cloning	  cylinder	  with	  vacuum	  grease	  on	  the	  edge	  was	  placed	  around	  the	  colony.	  	  Cells	  were	  harvested	  with	  trypsin	  and	  transferred	  to	  a	  single	  well	  of	  a	  96-­‐well	  plate	  containing	  200	  μL	  of	  selection	  media	  and	  cultured	  overnight	  at	  37°C,	  5%	  CO2	  in	  a	  humidified	  incubator.	  	  On	  the	  following	  day,	  the	  spent	  media	  was	  exchanged	  for	  fresh	  selective	  media	  and	  cells	  were	  cultured	  until	  confluent,	  with	  media	  exchanged	  as	  needed.	  	  Cells	  were	  then	  transferred	  to	  successively	  larger	  growth-­‐area	  plates	  until	  there	  were	  enough	  cells	  to	  transfer	  to	  flasks	  for	  RNA	  isolation	  or	  cryopreservation.	  RNA	  Isolation:	  RNA	  was	  isolated	  per	  manufacturers	  protocol	  using	  TriReagent	  (Molecular	  Research	  Center,	  Inc.	  Cat.	  No.	  TR118).	  	  Purified	  RNA	  was	  quantified	  using	  a	  NanoDrop	  8000	  (Thermo	  Scientific).	  Two-­‐Step	  Reverse	  Transcriptase	  PCR	  (RT-­‐PCR):	  	  Changes	  in	  gene	  expression	  were	  confirmed	  by	  two-­‐step	  RT-­‐PCR.	  	  RNA	  was	  reverse	  transcribed	  using	  the	  High-­‐Capacity	  cDNA	  Reverse	  Transcription	  Kit	  (Applied	  Biosytems)	  supplemented	  with	  the	  RNase	  Inhibitor,	  RNasin	  (Promega).	  	  cDNA	  was	  quantified	  using	  a	  NanoDrop	  8000	  (Thermo	  Scientific)	  and	  diluted	  to	  50	  ng/μL.	  	  Primers	  for	  RT-­‐PCR	  were	  designed	  to	  span	  an	  exon-­‐exon	  junction	  using	  Primer-­‐BLAST	  (NIH)	  (Table	  2.1).	  	  RT-­‐PCR	  was	  conducted	  using	  the	  FastStart	  Universal	  SYBR	  Green	  Master	  (with	  Rox	  Reference	  Dye)	  (Roche)	  on	  the	  Stratagene	  MxPro	  (Mx3005P,	  Agilent).	  	  Relative	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mRNA	  expression	  will	  be	  quantified	  using	  the	  Standard	  Curve	  Method	  normalized	  to	  beta-­‐actin	  or	  by	  comparison	  of	  cycle	  thresholds.	  Proliferation	  Assay:	  Cells	  were	  seeded	  in	  a	  96-­‐well	  plate	  at	  5,000	  cells/well.	  	  At	  the	  time	  of	  the	  assay,	  20	  μL	  of	  Cell	  Titer	  96®	  Aqueous	  One	  Solution	  (Promega,	  Madison,	  WI)	  was	  added	  to	  each	  well	  containing	  100	  μL	  of	  growth	  media.	  	  The	  plate	  was	  then	  incubated	  at	  37°C,	  5%	  CO2	  for	  1	  hr.	  30	  min.	  	  Absorbance	  at	  490	  nm	  was	  read	  on	  a	  VersaMax	  Tunable	  Microplate	  reader	  (Molecular	  Devices,	  Sunnyvale,	  CA).	  	  Cell	  proliferation	  was	  quantified	  as	  a	  percentage	  of	  the	  control	  for	  each	  cell	  line.	  Migration	  Assay:	  Cells	  (5	  x	  104	  total,	  n	  =	  3)	  were	  seeded	  in	  basal	  medium	  (DMEM)	  in	  the	  top	  chamber	  of	  the	  transwell	  inserts	  (BD	  8	  μm	  pore	  size	  PET	  track-­‐etched	  membranes,	  Becton	  Dickinson,	  Franklin	  Lakes,	  NJ).	  	  Rich	  medium	  (DMEM	  supplemented	  with	  10%	  FBS)	  was	  added	  to	  the	  bottom	  of	  the	  chamber	  as	  a	  chemoattractant.	  	  Cells	  were	  maintained	  for	  28-­‐30	  hours	  at	  37°C,	  5%	  CO2	  in	  a	  humidified	  incubator.	  	  Media	  was	  removed	  from	  the	  top	  of	  the	  inserts	  and	  the	  inserts	  were	  washed	  by	  dunking	  in	  PBS	  twice.	  	  Non-­‐migratory	  cells	  were	  removed	  from	  the	  top	  of	  the	  membrane	  insert	  using	  a	  Q-­‐tip	  soaked	  in	  PBS,	  the	  stick-­‐end	  of	  a	  Q-­‐tip	  cut	  in	  half	  soaked	  in	  PBS	  and	  a	  dry	  Q-­‐tip.	  	  The	  migratory	  cells	  on	  the	  bottom	  of	  the	  insert	  were	  then	  fixed	  for	  10	  min.	  in	  cold	  methanol	  at	  -­‐20°C	  and	  washed	  by	  dunking	  in	  PBS	  twice.	  	  The	  cells	  were	  then	  stained	  with	  Hematoxylin	  QS	  (Vector	  Laboratories,	  Burlingame,	  CA,	  Cat.	  No.	  H-­‐3404)	  for	  8	  min	  and	  washed	  by	  dunking	  in	  3	  separate	  beakers	  of	  tap	  water,	  leaving	  them	  in	  each	  one	  for	  a	  few	  seconds.	  	  The	  inserts	  were	  then	  allowed	  to	  dry	  for	  approximately	  15	  min.	  	  After	  15	  min.,	  the	  membranes	  were	  carefully	  cut	  out	  using	  a	  razor	  blade	  and	  mounted	  to	  slides	  using	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Cytoseal	  XYL	  (Thermo	  Fisher	  Scientific,	  Waltham,	  MA,	  Cat.	  No.	  8312-­‐4).	  	  Numbers	  of	  migratory	  cells	  were	  determined	  from	  four	  non-­‐overlapping	  images	  of	  each	  membrane	  (10x	  objective).	  Adhesion	  Assay	  (pre-­‐coated	  plates):	  Cells	  were	  seeded	  in	  a	  96-­‐well	  plate	  pre-­‐coated	  with	  human	  fibronectin	  (Corning,	  Bedford,	  MA)	  at	  20,000	  cells/well	  and	  incubated	  at	  37°C,	  5%	  CO2	  for	  1	  hour.	  	  Shaking	  the	  plate	  on	  a	  plate	  shaker	  for	  10-­‐15	  sec	  displaced	  non-­‐adherent	  cells.	  	  The	  cell	  suspension	  was	  then	  removed	  and	  the	  wells	  were	  washed	  three	  times	  with	  100	  μL	  of	  wash	  buffer	  (0.1%	  BSA	  in	  serum-­‐free	  media).	  	  The	  cells	  were	  fixed	  by	  incubating	  with	  100	  μL	  of	  4%	  paraformaldehyde	  in	  PBS	  for	  10-­‐15	  min.	  	  The	  wells	  were	  then	  washed	  with	  wash	  buffer,	  which	  was	  removed	  by	  dumping	  out	  and	  tapping	  the	  plate	  on	  the	  bench.	  	  The	  cells	  were	  stained	  with	  5	  mg/mL	  crystal	  violet	  in	  2%	  ethanol	  for	  10	  min.	  	  The	  staining	  solution	  was	  removed	  and	  the	  plates	  were	  washed	  three	  times	  by	  submerging	  in	  water	  and	  discarding	  the	  wash.	  	  Excess	  water	  was	  removed	  by	  tapping	  the	  plate	  on	  the	  bench	  and	  the	  plate	  was	  dried	  for	  at	  least	  24	  hours.	  	  After	  the	  plate	  dried,	  100	  μL	  of	  1%	  SDS	  was	  added	  to	  each	  well	  and	  incubated	  at	  room	  temperature	  for	  30	  min.	  	  Absorbance	  at	  550	  nm	  was	  read	  on	  a	  VersaMax	  Tunable	  Microplate	  reader	  (Molecular	  Devices,	  Sunnyvale,	  CA).	  	  Cell	  adhesion	  to	  fibronectin	  was	  quantified	  as	  a	  percentage	  of	  the	  control	  for	  each	  cell	  line.	  Immunohistochemistry	  (IHC):	  	  Cells	  were	  seeded	  on	  poly-­‐L-­‐lysine	  (PLL)-­‐coated	  slides	  (Polysciences,	  Cat.	  No.	  22247,	  Warrington,	  PA)	  at	  a	  density	  of	  approximately	  2	  x	  105	  cells/mL/slide.	  	  Cells	  were	  maintained	  at	  37°C,	  5%	  CO2	  in	  a	  humidified	  incubator	  overnight	  and	  fixed	  approximately	  24	  hours	  later.	  	  First,	  the	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slides	  were	  rinsed	  with	  cold	  phosphate-­‐buffered	  saline	  solution	  (PBS)	  twice	  and	  then	  fixed	  in	  ice	  cold	  100%	  methanol	  for	  10	  min.	  	  The	  slides	  were	  then	  allowed	  to	  dry	  and	  stored	  at	  -­‐20°C	  until	  stained.	  	  Immunohistochemical	  staining	  was	  performed	  at	  Baystate.	  	  The	  slides	  were	  stained	  for	  TROP2	  (Human	  TROP-­‐2	  affinity	  purified	  polyclonal	  antibody,	  R&D	  Systems,	  Cat.	  No.	  AF650)	  using	  the	  HRP-­‐DAB	  Cell	  and	  Tissue	  Staining	  kit	  (R&D	  Systems,	  Cat.	  No.	  CTS008).	  	  	  Formalin-­‐fixed	  paraffin-­‐embedded	  (FFPE)	  tissue	  blocks	  were	  prepared	  from	  the	  breast	  tumor	  samples.	  	  The	  blocks	  were	  sectioned	  (5μm	  thick)	  and	  placed	  on	  slides.	  	  Using	  the	  UltraView	  Universal	  DAB	  Detection	  Kit	  on	  the	  BenchMark	  Ultra	  platform,	  the	  slides	  were	  stained	  for	  ER,	  PR	  and	  HER2.	  	  The	  slides	  were	  stained	  for	  TROP2	  (Human	  TROP-­‐2	  affinity	  purified	  polyclonal	  antibody,	  R&D	  Systems,	  Cat.	  No.	  AF650)	  using	  the	  HRP-­‐DAB	  Cell	  and	  Tissue	  Staining	  kit	  (R&D	  Systems,	  Cat.	  No.	  CTS008).	  	  	  Hematoxylin	  and	  eosin	  (H&E)	  slides	  were	  prepared	  and	  used	  for	  tumor	  verification.	  	  The	  antibodies	  used	  for	  ER,	  PR	  and	  HER2	  were	  previously	  optimized:	  ER	  (Ventana	  anti-­‐estrogen	  receptor	  SP1	  rabbit	  monoclonal	  primary	  antibody),	  PR	  (Ventana	  anti-­‐progesterone	  receptor	  1E2	  rabbit	  monoclonal	  primary	  antibody)	  and	  HER2	  (Ventana	  PATHWAY	  anti-­‐hER2/neu	  antibody	  4B5	  rabbit	  monoclonal	  antibody).	  	  Ethanol	  was	  used	  to	  dehydrate	  the	  slides	  followed	  by	  xylene	  post-­‐staining	  and	  addition	  of	  coverslips.	  	  The	  Ki67	  data	  were	  obtained	  from	  the	  pathology	  records.	  Review	  of	  Pathology:	  	  Scoring	  of	  slides	  was	  conducted	  by	  one	  anatomic	  pathologist	  (Rahul	  Jawale).	  	  Slides	  were	  scored	  blindly	  for	  immunoreactivity	  of	  5	  antigens;	  approximate	  number	  of	  positive	  cells	  was	  recorded	  (%)	  and	  intensity	  of	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immunoreactivity	  was	  reported.	  	  For	  ER	  and	  PR,	  Allred	  scored	  were	  recorded	  ranging	  from	  0-­‐8.	  	  Tumors	  with	  a	  score	  of	  3	  or	  greater	  were	  considered	  positive	  for	  receptor	  status	  and	  tumors	  were	  considered	  HER2	  positive	  when	  30%	  of	  the	  cells	  contained	  3+	  membrane	  staining.	  	  Ki67	  scored	  ranged	  from	  0-­‐100%	  as	  the	  percentage	  of	  positive	  cells	  within	  the	  area	  of	  invasive	  cells.	  	  For	  TROP2,	  the	  scale	  for	  percent	  positive	  cells	  was	  0:	  negative,	  1:	  1-­‐33%,	  2:	  34-­‐66%	  and	  3:67-­‐100%	  and	  the	  intensity	  was	  reported	  as	  a	  score	  from	  0	  (negative)	  to	  3	  (strong),	  this	  was	  recorded	  for	  both	  membrane-­‐localized	  TROP2	  and	  cytoplasmic	  TROP2.	  	  The	  overall	  score	  for	  membrane-­‐localized	  TROP2	  was	  determined	  by	  multiplying	  the	  percent	  positive	  score	  by	  the	  intensity	  score	  (range	  0-­‐9).	  	  Scoring	  of	  TROP2	  was	  completed	  in	  one	  session	  with	  a	  single	  observer	  documenting	  records	  (SZ).	  	  One	  of	  the	  tumor	  samples	  was	  scored	  twice	  for	  TROP2	  with	  similar	  results.	  
	  
Results	  
Overexpression	  of	  TROP2	  Alters	  Adhesion	  and	  Migration	  in	  TMX2-­‐28,	  Not	  
Proliferation	  	   To	  mimic	  the	  effect	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  on	  TMX2-­‐28	  and	  increase	  TROP2	  expression,	  a	  stable	  cell	  line	  with	  increased	  TROP2	  mRNA	  expression	  (TMX2-­‐28-­‐Trop2)	  was	  generated	  as	  described	  above.	  	  	  A	  stable	  cell	  line	  expressing	  the	  control	  vector	  without	  the	  TROP2	  coding	  sequence	  was	  also	  generated	  (TMX2-­‐28-­‐Control).	  	  As	  determined	  by	  RT-­‐PCR,	  TROP2	  mRNA	  expression	  increased	  by	  more	  than	  100%	  in	  TMX2-­‐28-­‐Trop2	  compared	  to	  TMX2-­‐28-­‐Control	  (Figure	  4.1,	  A).	  	  TROP2	  expression	  in	  the	  cloned	  cell	  lines	  was	  examined	  by	  IHC.	  	  As	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predicted,	  the	  MCF-­‐7-­‐Control	  cell	  line	  has	  higher	  expression	  of	  TROP2	  than	  the	  TMX2-­‐28-­‐Control	  cell	  line.	  	  Transfection	  of	  MCF-­‐7	  with	  the	  TROP2	  knockdown	  construct	  resulted	  in	  decreased	  TROP2	  expression	  in	  the	  MCF-­‐7-­‐Trop2-­‐Knockdown	  (MCF-­‐7-­‐Trop2-­‐Kd)	  cell	  line.	  	  While	  transfection	  of	  TMX2-­‐28	  with	  the	  TROP2	  expression	  construct	  resulted	  in	  increased	  expression	  of	  TROP2	  in	  the	  TMX2-­‐28-­‐Trop2	  cell	  line	  (Figure	  4.1,	  B	  and	  C).	  	  If	  TROP2	  is	  involved	  in	  the	  phenotype	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment,	  I	  predict	  TMX2-­‐28-­‐Trop2	  to	  have	  decreased	  proliferation,	  adhesion	  and	  migration	  compared	  to	  TMX2-­‐28-­‐Control.	  	  Proliferation,	  adhesion	  and	  migration	  assays	  were	  carried	  out	  as	  described	  above.	  	  TMX2-­‐28-­‐Trop2	  proliferation	  is	  slightly	  lower	  than	  TMX2-­‐28-­‐Control,	  but	  the	  difference	  was	  not	  significant	  (Figure	  4.2).	  	  This	  experiment	  was	  repeated	  two	  times	  with	  similar	  results,	  representative	  data	  shown.	  	  However,	  there	  was	  a	  significant	  difference	  in	  adhesion	  to	  fibronectin	  with	  increased	  TROP2	  expression.	  	  The	  TMX2-­‐28-­‐Trop2	  cell	  line	  has	  increased	  adhesion	  to	  fibronectin	  (26%)	  compared	  to	  TMX2-­‐28-­‐Control	  (Figure	  4.3).	  	  This	  experiment	  was	  repeated	  three	  times	  with	  similar	  results,	  representative	  data	  shown.	  	  Next,	  a	  transwell	  migration	  experiment	  was	  used	  to	  determine	  whether	  TROP2	  overexpression	  affects	  cell	  migration.	  	  The	  TMX2-­‐28-­‐Trop2	  cell	  line	  has	  over	  6	  times	  more	  migratory	  cells	  per	  membrane	  than	  TMX2-­‐28-­‐Control	  (Figure	  4.4).	  	  This	  experiment	  was	  repeated	  twice	  with	  a	  similar	  trend	  in	  results,	  representative	  data	  shown.	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Knockdown	  of	  TROP2	  in	  MCF-­‐7	  Alters	  Proliferation	  Only	  To	  further	  examine	  the	  role	  of	  TROP2	  in	  regulating	  proliferation,	  adhesion	  and	  migration,	  stable	  cell	  lines	  were	  generated	  as	  described	  above	  by	  transfecting	  MCF-­‐7	  cells	  with	  either	  a	  vector	  containing	  the	  scrambled	  control	  shRNA	  (MCF-­‐7-­‐Control)	  or	  the	  shRNA	  sequence	  targeting	  TROP2	  (MCF-­‐7-­‐Trop2-­‐Kd).	  	  As	  determined	  by	  RT-­‐PCR,	  transfection	  with	  the	  shRNA	  vector	  against	  TROP2	  resulted	  in	  an	  80%	  knockdown	  of	  TROP2	  mRNA	  compared	  to	  MCF-­‐7-­‐Control	  (Figure	  4.1).	  	  The	  knockdown	  was	  approximately	  50%	  compared	  to	  non-­‐transfected	  MCF-­‐7.	  	  Decreasing	  TROP2	  expression	  in	  MCF-­‐7	  cells	  should	  cause	  them	  to	  behave	  similar	  to	  TMX2-­‐28.	  	  Knockdown	  of	  TROP2	  in	  MCF-­‐7	  increased	  proliferation	  (25%),	  compared	  to	  MCF-­‐7-­‐Control	  (Figure	  4.5).	  	  This	  assay	  was	  repeated	  twice	  with	  similar	  results,	  representative	  data	  shown.	  	  TROP2	  knockdown	  in	  MCF-­‐7	  had	  a	  variable	  result	  on	  adhesion	  to	  fibronectin.	  	  In	  two	  out	  of	  three	  of	  the	  experiments,	  MCF-­‐7-­‐Trop2-­‐Kd	  had	  decreased	  adhesion	  to	  fibronectin	  compared	  to	  MCF-­‐7-­‐Control.	  	  However	  in	  the	  third	  experiment,	  MCF-­‐7-­‐Trop2-­‐Kd	  had	  increased	  adhesion	  to	  fibronectin	  (Figure	  4.6).	  	  Therefore,	  the	  results	  from	  these	  experiments	  are	  inconclusive.	  	  Knockdown	  of	  TROP2	  did	  not	  affect	  migration	  of	  MCF-­‐7	  cells,	  as	  there	  were	  only	  two	  migratory	  cells	  in	  the	  MCF-­‐7-­‐Control	  and	  two	  in	  the	  MCF-­‐7-­‐Trop2-­‐Kd	  samples	  (n	  =	  3)	  (data	  not	  shown).	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Analysis	  of	  TACSTD2	  Methylation	  and	  TROP2	  Expression	  in	  Clinical	  Samples	  
Patient	  Demographics	  	   A	  total	  of	  86	  human	  breast	  tumor	  samples	  were	  identified	  in	  the	  repository	  of	  the	  pathology	  department	  at	  Baystate	  Medical	  Center.	  	  There	  were	  70	  primary	  and	  recurrent	  tumor	  samples	  collected	  from	  patients	  where	  the	  isolated	  DNA	  passed	  the	  quality	  control	  tests	  and	  was	  analyzed	  for	  DNA	  methylation	  on	  the	  Human	  450	  BeadChip.	  	  Therefore,	  I	  will	  limit	  my	  analysis	  to	  the	  70	  tumor	  samples	  (34	  primary	  tumors	  and	  36	  recurrent)	  for	  which	  we	  have	  methylation	  data.	  	  Patient	  demographics	  are	  summarized	  in	  Table	  4.4.	  	  The	  average	  age	  of	  the	  women	  at	  the	  diagnosis	  of	  the	  primary	  tumor	  was	  56.6	  years	  and	  the	  average	  age	  at	  recurrence	  was	  64.1	  years,	  with	  the	  average	  time	  to	  recurrence	  being	  67.8	  months	  (approximately	  5.5	  years).	  	  Tumor	  blocks	  were	  sectioned	  for	  IHC	  analysis	  of	  hormone	  receptors	  (ER,	  PR	  and	  HER2),	  the	  proliferation	  marker,	  Ki67,	  and	  TROP2.	  	  The	  majority	  (76.5%)	  of	  primary	  tumors	  are	  ER-­‐positive,	  while	  only	  52.8%	  of	  recurrent	  tumors	  are	  ER-­‐positive.	  	  PR	  and	  HER2	  status	  are	  summarized	  in	  Table	  4.4.	  	  Data	  on	  hormone	  therapy	  was	  available	  for	  23	  of	  the	  34	  (68%)	  primary	  tumor	  samples.	  	  Sixteen	  patients	  (69.5%)	  received	  anti-­‐hormonal	  therapy.	  	  Of	  those	  women	  treated	  with	  anti-­‐hormonal	  therapy,	  nine	  received	  either	  tamoxifen	  alone	  or	  tamoxifen	  in	  combination	  with	  an	  aromatase	  inhibitor.	  	   The	  tumor	  samples	  were	  organized	  into	  four	  groups	  based	  on	  the	  ER	  status	  of	  their	  primary	  and	  recurrent	  tumors	  (Table	  4.5).	  	  The	  women	  in	  the	  first	  group	  had	  primary	  tumors	  that	  were	  ER-­‐positive	  and	  recurrent	  tumors	  that	  were	  also	  ER-­‐positive.	  	  The	  second	  group	  contains	  patients	  whose	  primary	  tumor	  was	  ER-­‐
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negative	  and	  their	  recurrent	  tumor	  was	  also	  ER-­‐negative.	  	  The	  next	  group	  consists	  of	  patients	  whose	  primary	  tumor	  was	  ER-­‐positive	  and	  their	  recurrent	  tumor	  was	  ER-­‐negative.	  	  There	  are	  8	  women	  who	  did	  not	  have	  a	  recurrence	  as	  of	  December	  2015,	  6	  had	  ER-­‐positive	  tumors	  and	  2	  had	  ER-­‐negative	  tumors.	  	  	  
TACSTD2	  Methylation	  in	  Clinical	  Samples	  	   To	  determine	  whether	  the	  trend	  of	  increased	  TACSTD2	  methylation	  observed	  in	  the	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  line,	  TMX2-­‐28,	  was	  consistent	  in	  the	  clinical	  samples,	  I	  examined	  methylation	  of	  TACSTD2	  in	  the	  human	  tumor	  samples.	  	  Average	  beta	  values	  from	  the	  450	  BeadChip	  were	  obtained	  for	  the	  CpG	  sites	  in	  
TACSTD2.	  	  If	  TMX2-­‐28	  is	  an	  accurate	  model	  of	  ER-­‐negative,	  recurrent	  disease,	  I	  predict	  promoter	  methylation	  to	  be	  high	  in	  ER-­‐negative	  recurrent	  tumors	  that	  were	  initially	  ER-­‐positive	  primary	  tumors.	  	   I	  first	  examined	  methylation	  for	  all	  TACSTD2	  CpG	  sites	  on	  the	  450	  BeadChip	  in	  all	  tumor	  samples.	  	  Comparing	  ER-­‐positive	  tumors	  to	  ER-­‐negative	  tumors,	  there	  is	  no	  difference	  in	  methylation.	  	  The	  mean	  beta	  values	  for	  all	  TACSTD2	  CpG	  sites	  in	  ER-­‐positive	  tumors	  and	  ER-­‐negative	  tumors	  is	  0.183	  and	  0.180,	  respectively	  (Figure	  4.7,	  A	  and	  Table	  4.6).	  	  Because	  there	  was	  little	  difference	  in	  methylation	  of	  all	  TACSTD2	  CpG	  sites	  on	  the	  chip,	  I	  did	  the	  same	  comparison	  using	  only	  CpGs	  in	  the	  promoter	  of	  
TACSTD2	  (TSS200	  or	  TSS1500)	  (Figure	  4.7,	  B	  and	  Table	  4.6).	  	  There	  was	  no	  difference	  in	  TACSTD2	  promoter	  methylation	  between	  ER-­‐positive	  and	  ER-­‐negative	  tumors.	  	  The	  mean	  beta	  value	  for	  promoter	  CpGs	  in	  ER-­‐positive	  tumors	  and	  ER-­‐negative	  tumors	  is	  0.206	  and	  0.200,	  respectively.	  	  	  Next	  I	  compared	  methylation	  of	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all	  TACSTD2	  CpG	  sites	  and	  promoter	  CpG	  sites	  between	  primary	  and	  recurrent	  tumors.	  	  The	  mean	  beta	  value	  for	  all	  TACSTD2	  CpG	  sites	  in	  primary	  tumors	  and	  recurrent	  tumors	  is	  0.183	  and	  0.181,	  respectively	  (Figure	  4.8,	  A	  and	  Table	  4.6).	  	  The	  mean	  beta	  value	  for	  promoter	  CpGs	  in	  primary	  tumors	  and	  recurrent	  tumors	  is	  0.207	  and	  0.200,	  respectively	  (Figure	  4.8,	  B	  and	  Table	  4.6).	  	  Because	  there	  were	  no	  differences	  in	  methylation	  by	  ER	  status	  or	  primary	  vs.	  recurrent	  tumors,	  I	  examined	  methylation	  of	  only	  the	  3	  TACSTD2	  CpGs	  identified	  as	  differentially	  methylated	  and	  altered	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  in	  the	  cell	  lines.	  Based	  on	  the	  methylation	  data	  from	  the	  cells	  lines,	  I	  predict	  that	  TACSTD2	  promoter	  methylation	  will	  be	  low	  in	  ER-­‐positive	  primary	  tumors	  and	  high	  in	  ER-­‐negative	  recurrent	  tumors	  that	  were	  initially	  ER-­‐positive.	  	  Specifically,	  I	  examined	  methylation	  of	  the	  3	  CpGs	  identified	  as	  differentially	  methylated	  between	  MCF-­‐7	  and	  TMX2-­‐28	  and	  altered	  by	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  in	  TMX2-­‐28	  (MAPINFO	  numbers	  59043370:	  CpG	  1,	  59043280:	  CpG	  2	  and	  59043255:	  CpG	  3)	  in	  the	  tumor	  samples	  (see	  Tables	  2.5	  and	  2.8).	  	  Although	  the	  average	  beta	  values	  for	  each	  site	  were	  much	  lower	  than	  those	  in	  the	  cell	  lines,	  mean	  methylation	  of	  each	  site	  in	  the	  recurrent	  tumor	  was	  higher	  than	  the	  mean	  methylation	  in	  the	  primary	  tumors	  for	  patients	  in	  this	  group	  (Figure	  4.9,	  A).	  	  The	  difference	  in	  beta	  values	  was	  statistically	  significant	  for	  CpG	  1(one-­‐tail	  p-­‐value	  =	  0.047,	  two-­‐tail	  p-­‐value	  =	  094).	  	  CpG	  sites	  2	  and	  3	  followed	  the	  same	  trend	  with	  the	  ER-­‐negative	  recurrent	  tumor	  having	  a	  higher	  average	  beta	  value	  than	  the	  ER-­‐positive	  primary	  tumor	  (one-­‐tail	  p-­‐values	  of	  0.27	  and	  0.075,	  two-­‐tail	  p-­‐values	  of	  0.53	  and	  0.15,	  respectively).	  	  For	  each	  of	  the	  three	  CpGs,	  the	  mean	  average	  beta	  values	  were	  higher	  in	  the	  ER-­‐negative	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recurrent	  tumor	  than	  the	  ER-­‐positive	  primary	  tumor.	  	  This	  result	  is	  in	  agreement	  with	  my	  prediction	  based	  on	  DNA	  methylation	  in	  TMX2-­‐28.	  Interestingly,	  there	  was	  no	  difference	  in	  the	  mean	  average	  beta	  value	  of	  these	  three	  CpGs	  in	  the	  group	  with	  ER-­‐positive	  primary	  tumors	  that	  recurred	  as	  ER-­‐positive	  (Figure	  4.9,	  B).	  	  Methylation	  was	  lower	  in	  the	  ER-­‐positive	  recurrent	  tumor	  than	  the	  ER-­‐positive	  primary	  tumor	  for	  CpG	  1	  however;	  the	  difference	  was	  not	  statistically	  significant.	  	  Mean	  beta	  values	  for	  CpGs	  2	  and	  3	  were	  similar	  between	  primary	  and	  recurrent	  tumors	  for	  this	  group.	  
TACSTD2	  methylation	  values	  were	  also	  similar	  in	  the	  group	  with	  ER-­‐negative	  tumors	  that	  recurred	  as	  ER-­‐negative	  (Figure	  4.9,	  C).	  	  The	  ER-­‐negative	  recurrent	  samples	  had	  lower	  methylation	  than	  the	  ER-­‐positive	  primary	  samples	  for	  CpG	  3	  however;	  the	  difference	  was	  not	  statistically	  significant	  (two-­‐tail	  p-­‐value	  =	  0.064).	  	   There	  were	  eight	  patients	  who	  did	  not	  have	  a	  recurrence.	  	  Six	  of	  these	  tumor	  samples	  were	  ER-­‐positive	  and	  two	  were	  ER-­‐negative.	  	  The	  mean	  average	  beta	  values	  for	  CpGs	  1,	  2	  and	  3	  for	  the	  non-­‐recurrent	  samples	  were	  0.0856,	  0.2229	  and	  0.1214,	  (standard	  deviations	  were	  0.027,	  0.080	  and	  0.046),	  respectively.	  	  Average	  beta	  values	  ranged	  from	  0.054	  to	  0.11	  for	  CpG	  1,	  0.10	  to	  0.31	  for	  CpG	  2	  and	  0.070	  to	  0.19	  for	  CpG	  3.	  	  
	  
Expression	  of	  TROP2	  in	  Clinical	  Samples	  and	  Correlation	  with	  Promoter	  
Methylation	  
	   Protein	  expression	  and	  localization	  (cytoplasmic	  and/or	  membrane)	  of	  TROP2	  was	  determined	  in	  the	  tumor	  samples	  by	  IHC.	  	  TROP2	  IHC	  data	  was	  obtained	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for	  66	  of	  the	  70	  tumor	  samples	  for	  which	  we	  also	  have	  methylation	  data.	  	  There	  was	  not	  enough	  tumor	  block	  to	  score	  the	  remaining	  four	  samples.	  	  Examples	  of	  cytoplasmic	  and	  membrane	  TROP2	  staining	  from	  two	  patients	  are	  shown	  in	  Figure	  4.10.	  	  Expression	  of	  membrane-­‐localized	  TROP2	  was	  detected	  in	  59	  (89%)	  of	  the	  samples.	  	  The	  membrane	  TROP2	  scores	  ranged	  from	  0	  to	  9	  (mean,	  5.1)	  (descriptive	  statistics	  are	  summarized	  in	  Table	  4.7)	  (Figure	  4.11,	  A).	  	  Cytoplasmic	  TROP2	  was	  found	  in	  65	  (98%)	  of	  samples.	  	  The	  scores	  for	  cytoplasmic	  TROP2	  ranged	  from	  0	  to	  9	  (mean,	  4.3)	  (descriptive	  statistics	  are	  summarized	  in	  Table	  4.8)	  (Figure	  4.11,	  B).	  	  If	  methylation	  regulates	  expression	  of	  TROP2	  in	  human	  tissue,	  I	  predict	  that	  tumor	  samples	  will	  have	  an	  inverse	  correlation	  between	  methylation	  and	  protein	  expression.	  	   To	  determine	  whether	  promoter	  methylation	  of	  the	  3	  CpGs	  identified	  as	  differentially	  methylated	  in	  TMX2-­‐28	  and	  altered	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  was	  correlated	  with	  TROP2	  expression,	  I	  examined	  the	  correlation	  between	  the	  mean	  average	  beta	  value	  of	  CpGs	  1,	  2	  and	  3	  and	  membrane-­‐localized	  TROP2	  expression	  for	  all	  of	  the	  tumor	  samples.	  	  I	  chose	  to	  test	  membrane	  TROP2	  only	  because	  there	  was	  greater	  variability	  in	  membrane	  TROP2	  expression	  between	  tumor	  samples	  and	  because	  membrane-­‐localized	  TROP2	  has	  been	  shown	  to	  have	  prognostic	  value	  in	  breast	  cancer.	  65	  There	  was	  no	  linear	  relationship	  between	  mean	  methylation	  of	  the	  three	  CpGs	  and	  expression	  of	  membrane-­‐localized	  TROP2	  (R	  squared	  =	  0.0006).	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TROP2	  Expression	  in	  Clinical	  Samples	  Although	  there	  was	  no	  correlation	  between	  mean	  methylation	  of	  CpGs	  1,	  2	  and	  3	  and	  membrane	  TROP2	  expression,	  I	  know	  that	  the	  ER-­‐negative	  recurrent	  tumors	  had	  increased	  methylation	  at	  these	  three	  CpGs	  compared	  to	  their	  ER-­‐positive	  primary	  tumors	  (Figure	  4.9,	  A).	  	  If	  TROP2	  expression	  is	  regulated	  by	  promoter	  methylation,	  I	  would	  predict	  the	  ER-­‐positive	  primary	  tumors	  in	  this	  group	  to	  have	  higher	  expression	  of	  TROP2	  than	  the	  ER-­‐negative	  recurrent	  tumors.	  	  Therefore,	  I	  wanted	  to	  determine	  whether	  expression	  of	  membrane-­‐localized	  TROP2	  was	  different	  between	  the	  ER-­‐negative	  recurrent	  tumors	  and	  the	  ER-­‐positive	  primary	  tumors	  for	  this	  group.	  	  However,	  there	  was	  no	  difference	  in	  expression	  of	  membrane-­‐localized	  TROP2	  between	  the	  ER-­‐positive	  primary	  tumors	  and	  their	  ER-­‐negative	  recurrent	  tumors	  (mean	  membrane	  TROP2	  scores	  of	  5	  and	  4.7,	  respectively)	  (Figure	  4.12).	  Next,	  I	  wanted	  to	  examine	  expression	  of	  membrane-­‐	  and	  cytoplasmic-­‐localized	  TROP2	  by	  ER/HER2	  status.	  	  A	  previous	  report	  found	  that	  ER-­‐negative/HER2-­‐positive	  breast	  tumors	  had	  higher	  expression	  of	  TROP2	  than	  ER-­‐positive/HER2-­‐negative	  tumors.	  109	  They	  did	  not	  distinguish	  between	  membrane	  and	  cytoplasmic	  localization.	  	  Therefore,	  I	  predict	  that	  TROP2	  expression	  will	  be	  high	  in	  tumors	  that	  are	  ER-­‐negative/HER2-­‐positive.	  	  First	  I	  categorized	  the	  samples	  into	  groups	  based	  on	  ER/HER2	  status:	  ER-­‐negative/HER2-­‐negative	  (n	  =	  18),	  ER-­‐negative/HER2-­‐positive	  (n	  =	  5),	  ER-­‐positive/HER2-­‐negative	  (n	  =	  37)	  and	  ER-­‐postive/HER2-­‐positive	  (n	  =	  6).	  	  Then	  I	  compared	  membrane	  and	  cytoplasmic	  TROP2	  scores	  separately	  between	  the	  groups	  using	  one-­‐way	  ANOVA.	  	  As	  predicted,	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the	  ER-­‐negative/HER2-­‐positive	  tumor	  samples	  had	  higher	  expression	  of	  membrane-­‐localized	  TROP2	  (mean	  membrane	  TROP2	  score	  of	  7.4	  compared	  to	  4.3,	  5.3	  and	  4.3),	  however	  the	  results	  from	  the	  one-­‐way	  ANOVA	  were	  not	  statistically	  significant	  (p-­‐value	  =	  0.28)	  (Figure	  4.13,	  A).	  	  Because	  I	  predicted	  that	  ER-­‐negative/HER2-­‐positive	  tumors	  would	  have	  higher	  TROP2	  expression	  than	  ER-­‐positive/HER2-­‐negative	  tumors,	  I	  compared	  the	  membrane	  TROP2	  scores	  between	  these	  two	  groups	  using	  a	  student’s	  t-­‐test.	  	  There	  is	  a	  trend	  in	  the	  direction	  I	  predicted	  that	  the	  ER-­‐negative/HER2-­‐positive	  samples	  have	  higher	  membrane	  TROP2	  expression	  than	  ER-­‐positive/HER2-­‐negative	  samples	  (one-­‐tail	  p-­‐value	  =	  0.103).	  	  However,	  there	  was	  no	  difference	  in	  cytoplasmic	  TROP2	  expression	  between	  the	  groups	  (one-­‐way	  ANOVA	  p-­‐value	  =	  0.21)	  (Figure	  4.13,	  B).	  	  
TROP2	  Expression	  and	  Recurrence	   	  Based	  on	  previous	  reports	  that	  TROP2	  expression	  is	  associated	  with	  disease	  progression,	  113	  metastasis115	  and	  recurrence116	  in	  colon	  cancer,	  metastasis	  in	  breast	  cancer114	  and	  membrane-­‐localized	  TROP2	  indicates	  a	  poor	  prognosis	  in	  breast	  cancer,	  65	  I	  predict	  that	  recurrent	  samples	  will	  have	  increased	  TROP2	  expression	  and	  strong	  expression	  of	  membrane-­‐localized	  TROP2.	  	  I	  then	  wanted	  to	  determine	  whether	  TROP2	  expression	  could	  be	  used	  to	  predict	  recurrence	  or	  earlier	  recurrence.	  	  First,	  I	  compared	  both	  membrane	  and	  cytoplasmic	  TROP2	  expression	  in	  the	  non-­‐recurrent	  tumor	  samples	  (n	  =	  8)	  to	  the	  primary	  tumors	  that	  recur	  (n	  =	  26).	  	  Surprisingly,	  expression	  of	  membrane-­‐localized	  TROP2	  was	  higher	  in	  the	  non-­‐recurrent	  samples	  than	  in	  the	  primary	  samples	  that	  recur	  (mean	  membrane	  TROP2	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score	  of	  8.4	  compared	  to	  4.4,	  respectively,	  two-­‐tail	  p-­‐value	  <	  0.01)	  (Figure	  4.14,	  A).	  	  Meanwhile,	  there	  was	  no	  difference	  in	  cytoplasmic	  TROP2	  score	  between	  the	  non-­‐recurrent	  samples	  and	  the	  primary	  samples	  that	  recur	  (Figure	  4.14,	  B).	  Because	  there	  is	  a	  wide	  range	  of	  TROP2	  scores	  in	  the	  primary	  samples	  that	  recur,	  I	  wanted	  to	  determine	  whether	  TROP2	  expression	  levels	  were	  correlated	  with	  time	  to	  recurrence.	  	  Linear	  regression	  analysis	  shows	  that	  for	  all	  primary	  tumors	  that	  have	  a	  recurrence	  (n	  =	  26),	  there	  is	  no	  correlation	  with	  membrane	  or	  cytoplasmic	  TROP2	  expression	  and	  time	  to	  recurrence	  in	  months	  (R	  squared	  =	  0.006	  and	  0.02,	  respectively).	  	  All	  of	  the	  patients	  without	  a	  recurrence	  were	  diagnosed	  in	  either	  2008	  or	  2009	  and	  have	  a	  time	  to	  recurrence	  (current	  through	  December	  2015)	  ranging	  from	  85	  to	  95	  months.	  	  Interestingly,	  they	  have	  high	  membrane	  TROP2	  expression	  (mean	  =	  8.4)	  but	  moderate	  cytoplasmic	  TROP2	  expression	  (mean	  =	  4.6).	  	  
TROP2	  Expression,	  Tumor	  Grade	  and	  Ki67	  Status	  Several	  published	  studies	  indicate	  that	  TROP2	  expression	  may	  be	  correlated	  with	  high	  tumor	  grade	  and	  increased	  proliferation.	  60,110-­‐114	  Therefore,	  I	  wanted	  to	  investigate	  the	  relationship	  between	  TROP2	  expression	  and	  tumor	  grade	  and	  Ki67	  status.	  	  For	  these	  analyses,	  I	  considered	  only	  membrane-­‐localized	  TROP2	  because	  there	  was	  more	  variability	  in	  membrane-­‐localized	  TROP2	  expression	  than	  cytoplasmic.	  	  First,	  I	  categorized	  membrane	  TROP2	  expression	  as	  low	  (IHC	  score	  ≤	  3)	  or	  high	  (IHC	  score	  >	  3)	  (Figure	  4.15,	  A).	  	  Then	  I	  compared	  tumor	  grade	  (Figure	  4.15,	  B)	  and	  Ki67	  score	  (Figure	  4.15,	  C)	  for	  the	  two	  categories	  of	  membrane	  TROP2	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expression.	  	  There	  was	  no	  difference	  between	  tumors	  with	  low	  and	  high	  expression	  of	  membrane	  TROP2	  according	  to	  tumor	  grade	  (n	  =	  22	  and	  40,	  respectively)	  or	  Ki67	  score	  (n	  =	  25	  and	  41,	  respectively)	  (student’s	  t-­‐test	  p-­‐values	  =	  0.30	  and	  0.66,	  respectively).	  	  
Discussion	  	   Sustaining	  proliferation,	  promoting	  migration	  and	  altering	  cell	  adhesion	  are	  important	  characteristics	  of	  cancer	  cells	  involved	  in	  promoting	  tumor	  growth	  and	  facilitating	  invasion	  and	  migration.	  	  TROP2	  is	  known	  to	  regulate	  several	  aspects	  of	  these	  processes	  in	  various	  cell	  types.	  	  The	  primary	  objective	  of	  this	  study	  was	  to	  determine	  whether	  TROP2	  is	  involved	  in	  regulating	  proliferation,	  adhesion	  and	  migration	  in	  our	  cell	  line	  model	  of	  tamoxifen	  resistance.	  	  To	  accomplish	  this,	  a	  stable	  TMX2-­‐28	  cell	  line	  was	  generated	  with	  increased	  expression	  of	  TROP2	  and	  a	  stable	  MCF-­‐7	  cell	  line	  was	  generated	  with	  decreased	  TROP2	  expression.	  	  Next,	  I	  quantified	  cell	  proliferation,	  adhesion	  to	  fibronectin	  and	  migration	  for	  each	  of	  these	  cell	  lines	  compared	  to	  their	  respective	  control	  vector	  transfected	  cell	  line.	  	  The	  results	  from	  these	  experiments	  will	  help	  determine	  whether	  TROP2	  mediates	  the	  effects	  of	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  These	  experiments	  will	  also	  help	  determine	  whether	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  would	  be	  beneficial	  for	  women	  with	  tamoxifen	  resistant	  breast	  cancer,	  since	  5-­‐Aza-­‐2’-­‐deoxycytidine	  increases	  TROP2	  expression	  in	  TMX2-­‐28.	  Increasing	  TROP2	  expression	  in	  TMX2-­‐28	  is	  predicted	  to	  mimic	  the	  effect	  of	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  and	  therefore	  inhibit	  proliferation,	  adhesion	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and	  migration.	  	  However,	  TROP2	  overexpression	  did	  not	  affect	  proliferation	  (Figure	  4.2),	  there	  was	  only	  a	  slight	  decrease	  in	  proliferation	  of	  TMX2-­‐28-­‐Trop2.	  	  This	  agrees	  somewhat	  with	  a	  2012	  paper	  stating	  that	  lung	  cancer	  cells	  had	  decreased	  proliferation	  as	  a	  result	  of	  decreased	  AKT	  and	  ERK	  activation	  in	  response	  to	  increased	  TROP2	  expression.	  61	  Although,	  there	  was	  only	  a	  slight	  decrease	  in	  TMX2-­‐28-­‐Trop2	  proliferation,	  this	  could	  indicate	  that	  TMX2-­‐28-­‐Trop2	  cells	  have	  a	  slight	  decrease	  in	  AKT	  and	  ERK	  signaling.	  	  This	  however,	  is	  in	  contrast	  to	  several	  other	  papers	  in	  the	  literature	  that	  found	  increased	  TROP2	  expression	  promotes	  growth	  and	  proliferation.	  	  Increased	  TROP2	  expression	  has	  been	  shown	  to	  promote	  the	  growth	  of	  colon	  and	  ovarian	  cancer	  cell	  lines	  as	  well	  as	  fibroblasts	  isolated	  from	  the	  fetal	  rat	  lung.	  64,110	  Increased	  TROP2	  expression	  was	  also	  found	  to	  promote	  cell	  cycle	  progression	  via	  phosphorylation	  of	  ERK1/2	  in	  mouse	  pancreatic	  cancer	  cells	  and	  cervical	  cancer	  cell	  lines.	  59,111	  Overall	  the	  results	  from	  this	  experiment	  indicate	  that	  TROP2	  and	  TROP2-­‐induced	  signaling	  does	  not	  affect	  proliferation	  of	  TMX2-­‐28.	  	  Therefore,	  the	  decreased	  proliferation	  of	  TMX2-­‐28	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  is	  not	  due	  to	  increased	  expression	  of	  TROP2.	  	  This	  indicates	  that	  TMX2-­‐28	  cells	  utilize	  a	  mechanism	  that	  is	  independent	  of	  TROP2	  signaling	  to	  sustain	  proliferative	  signals.	  	  	  	  Opposite	  of	  predicted	  results,	  increased	  TROP2	  expression	  promotes	  adhesion	  and	  migration	  of	  TMX2-­‐28	  cells	  (Figure	  4.3	  and	  4.4).	  	  This	  indicates	  that	  TROP2	  is	  not	  responsible	  for	  the	  decrease	  in	  adhesion	  and	  migration	  of	  TMX2-­‐28	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  The	  results	  do	  however	  agree	  with	  the	  majority	  of	  results	  in	  the	  literature.	  	  TROP2	  is	  required	  for	  invasion	  of	  colon	  cancer	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cells.	  117	  Similarly,	  TROP2	  promotes	  migration	  of	  mouse	  pancreatic	  cancer	  cells,	  59	  fibroblasts	  isolated	  from	  fetal	  rat	  lung62	  and	  cervical	  cancer	  cells.	  111	  In	  prostate	  cancer	  cells	  TROP2	  increases	  migration	  on	  fibronectin	  via	  interacting	  with	  β1	  integrin	  and	  increasing	  focal	  adhesion	  turnover.	  57	  It	  is	  not	  known	  whether	  TROP2	  interacts	  with	  β1	  integrin	  in	  TMX2-­‐28-­‐TROP2	  cells.	  	  However,	  a	  more	  recent	  paper	  found	  that	  knockdown	  of	  TROP2	  in	  prostate	  cancer	  cells	  increases	  FAK	  signaling	  and	  turnover	  of	  focal	  adhesions.	  118	  Therefore,	  I	  would	  predict	  that	  increased	  TROP2	  expression	  would	  inhibit	  FAK	  signaling	  and	  promote	  the	  formation	  of	  stable	  focal	  adhesions.	  	  TMX2-­‐28-­‐Trop2	  cells	  do	  have	  increased	  adhesion	  to	  fibronectin,	  but	  also	  increased	  migration,	  which	  requires	  turnover	  of	  focal	  adhesions.	  	  The	  same	  authors	  also	  found	  that	  TROP2	  was	  present	  in	  exosomes,	  endosomal	  vesicles	  that	  are	  involved	  in	  creating	  a	  favorable	  pre-­‐metastatic	  niche	  by	  facilitating	  transfer	  of	  genetic	  material	  and	  signaling	  molecules.	  	  The	  TROP2-­‐positive	  exosomes	  promote	  migration	  of	  cells	  that	  lack	  expression	  of	  TROP2.	  118	  However,	  it	  is	  not	  known	  whether	  TROP2	  is	  recruited	  to	  exosomes	  in	  TMX2-­‐28-­‐Trop2	  cells.	  	  Conflicting	  with	  this	  evidence	  that	  TROP2	  promotes	  migration	  and	  invasion,	  there	  are	  a	  few	  cases	  where	  TROP2	  is	  inhibitory.	  	  Expression	  of	  TROP2	  in	  TROP2-­‐negative	  prostate	  cancer	  cells	  inhibits	  adhesion	  to	  fibronectin.	  106	  Fetal	  mouse	  kidney	  cells	  with	  high	  expression	  of	  TROP2	  have	  decreased	  adhesion	  to	  collagen	  and	  decreased	  motility	  compared	  to	  cells	  with	  low	  TROP2	  expression.	  105	  Although	  TMX2-­‐28-­‐Trop2	  cells	  have	  increased	  adhesion	  to	  fibronectin	  and	  increased	  migration.	  	  Therefore,	  it	  would	  be	  important	  to	  determine	  the	  mechanism	  by	  which	  TROP2	  promotes	  adhesion	  and	  migration	  in	  TMX2-­‐28-­‐Trop2	  cells	  and	  also	  in	  other	  tamoxifen-­‐
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resistant	  cell	  lines.	  	  It	  would	  also	  be	  valuable	  to	  determine	  whether	  TROP2	  interacts	  with	  β1	  integrin	  to	  alter	  focal	  adhesion	  signaling	  and	  dynamics	  as	  well	  as	  whether	  TROP2	  is	  present	  in	  exosomes	  in	  TMX2-­‐28-­‐Trop2	  cells.	  MCF-­‐7	  cells	  with	  low	  TROP2	  expression	  were	  expected	  to	  behave	  similarly	  to	  TMX2-­‐28	  cells,	  which	  normally	  have	  low	  TROP2	  expression.	  	  Our	  lab	  has	  established	  that	  compared	  to	  MCF-­‐7,	  TMX2-­‐28	  cells	  have	  increased	  proliferation,	  migration	  and	  invasion.	  74,75	  Additionally,	  knockdown	  of	  TROP2	  in	  lung	  cancer	  cells	  increases	  activation	  of	  AKT,	  promoting	  tumor	  growth.	  61	  Therefore,	  my	  prediction	  was	  that	  knockdown	  of	  TROP2	  in	  MCF-­‐7	  would	  increase	  proliferation	  and	  migration.	  	  MCF-­‐7-­‐Trop2-­‐Kd	  cells	  indeed	  had	  increased	  proliferation	  (Figure	  4.5)	  however;	  there	  was	  no	  change	  in	  migration.	  	  I	  would	  therefore	  predict	  that	  MCF-­‐7-­‐Trop2-­‐Kd	  cells	  have	  increased	  AKT	  activation.	  	  Contradictory	  to	  these	  results,	  there	  are	  several	  groups	  that	  present	  evidence	  that	  knockdown	  of	  TROP2	  decreases	  proliferation.	  	  Previously,	  knockdown	  of	  TROP2	  was	  found	  to	  inhibit	  growth	  of	  MCF-­‐7	  cells	  and	  colon	  cancer	  cells.	  64	  This	  is	  in	  direct	  contradiction	  to	  the	  results	  presented	  here	  and	  could	  be	  a	  result	  of	  differences	  in	  tissue	  culture	  conditions.	  	  The	  MCF-­‐7	  cells	  in	  their	  study	  were	  grown	  in	  RPMI-­‐1640	  growth	  medium	  and	  it	  is	  not	  clear	  whether	  the	  medium	  contained	  phenol	  red,	  which	  can	  have	  estrogenic	  activity.	  	  The	  growth	  medium	  used	  in	  the	  experiments	  presented	  here	  did	  not	  contain	  phenol	  red.	  	  Knockdown	  of	  TROP2	  also	  decreases	  proliferation	  in	  fetal	  rat	  lung	  cells,	  cervical	  cancer	  cells	  and	  laryngeal	  carcinoma	  cells.	  62,108,110,111	  Therefore,	  it	  would	  be	  interesting	  to	  compare	  the	  activity	  of	  signaling	  molecules	  downstream	  of	  TROP2	  in	  these	  cell	  types,	  such	  as	  AKT	  and	  ERK.	  54	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In	  two	  out	  of	  three	  adhesion	  assay	  experiments,	  MCF-­‐7-­‐Trop2-­‐Kd	  had	  decreased	  adhesion	  to	  fibronectin	  (Figure	  4.6).	  	  However,	  knockdown	  of	  TROP2	  in	  MCF-­‐7	  increased	  adhesion	  in	  the	  third	  experiment.	  	  Therefore,	  I	  conclude	  that	  the	  results	  were	  inconclusive	  and	  knockdown	  of	  TROP2	  has	  variable	  results	  on	  adhesion	  of	  MCF-­‐7	  cells	  to	  fibronectin.	  	  Experiments	  in	  prostate	  cancer	  cells	  in	  which	  TROP2	  expression	  is	  knocked	  down	  found	  the	  cells	  had	  increased	  adhesion	  to	  fibronectin,	  indicating	  that	  TROP2	  inhibits	  adhesion.	  106	  Similarly,	  cells	  in	  the	  fetal	  mouse	  kidney	  with	  high	  TROP2	  expression	  had	  low	  adhesion	  to	  collagen-­‐coated	  plates.	  105	  Therefore,	  I	  predicted	  MCF-­‐7-­‐Trop2-­‐Kd	  cells	  to	  have	  increased	  adhesion	  to	  fibronectin.	  	  However,	  my	  results	  indicate	  that	  TROP2	  knockdown	  does	  not	  alter	  or	  has	  a	  variable	  effect	  on	  adhesion	  in	  MCF-­‐7.	  	  TROP2	  is	  also	  known	  to	  affect	  FAK	  signaling,	  which	  is	  involved	  in	  regulating	  focal	  adhesion	  turnover.	  	  However,	  knockdown	  of	  TROP2	  in	  prostate	  cancer	  cells	  results	  in	  an	  increase	  in	  the	  number	  of	  FAK-­‐containing	  focal	  adhesions	  but	  not	  the	  total	  number	  of	  focal	  adhesions.	  118	  Therefore,	  I	  would	  expect	  to	  find	  more	  FAK-­‐containing	  focal	  adhesions	  in	  MCF-­‐7-­‐Trop2-­‐Kd	  cells	  and	  therefore	  increased	  FAK	  signaling	  leading	  to	  increased	  focal	  adhesion	  turn-­‐over	  and	  slight	  decrease	  in	  adhesion	  because	  the	  cells	  are	  more	  migratory.	  	  However,	  it	  is	  not	  known	  whether	  knockdown	  of	  TROP2	  in	  MCF-­‐7	  results	  in	  an	  increase	  in	  the	  number	  of	  focal	  adhesions	  that	  contain	  FAK.	  	   Although	  TACSTD2	  expression	  appears	  to	  be	  regulated	  by	  promoter	  methylation	  in	  the	  cell	  lines,	  expression	  of	  TROP2	  does	  not	  appear	  to	  be	  regulated	  by	  promoter	  methylation	  in	  the	  tumor	  samples,	  as	  there	  was	  no	  correlation	  between	  promoter	  methylation	  and	  expression	  determined	  by	  IHC.	  	  However,	  similarly	  to	  the	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methylation	  results	  from	  the	  cell	  line	  model,	  methylation	  of	  the	  three	  CpGs	  in	  the	  
TACSTD2	  promoter	  identified	  in	  the	  cell	  line	  model	  was	  higher	  in	  the	  ER-­‐negative	  recurrent	  tumors	  compared	  to	  their	  ER-­‐positive	  primary	  tumors	  (Figure	  4.9,	  A).	  	  Despite	  the	  small	  sample	  size	  of	  this	  study,	  the	  difference	  in	  methylation	  between	  the	  ER-­‐positive	  primary	  tumors	  and	  their	  ER-­‐negative	  recurrent	  tumors	  was	  significant	  for	  CpG	  1.	  	  In	  general,	  TACSTD2	  methylation	  for	  the	  tumor	  samples	  is	  much	  lower	  than	  the	  methylation	  values	  seen	  in	  the	  cell	  lines.	  	  However,	  these	  low	  methylation	  values	  may	  still	  be	  important	  for	  regulating	  gene	  expression,	  as	  they	  are	  within	  the	  range	  of	  previously	  reported	  differentially	  methylated	  CpGs	  in	  breast	  cancer.	  119,120	  It	  would	  be	  important	  to	  confirm	  these	  findings	  with	  a	  larger	  sample	  size.	  	  	   Expression	  of	  membrane-­‐	  and	  cytoplasmic-­‐localized	  TROP2	  was	  detected	  in	  nearly	  all	  tumor	  samples	  (89%	  and	  98%,	  respectively).	  	  Despite	  a	  previous	  report	  indicating	  that	  membrane	  localization	  of	  TROP2	  was	  associated	  with	  a	  poor	  prognosis	  for	  breast	  cancer	  patients	  and	  intracellular	  TROP2	  was	  associated	  with	  better	  survival,	  65	  this	  was	  not	  the	  case	  in	  our	  sample	  cohort.	  	  Non-­‐recurrent	  tumors	  had	  higher	  levels	  of	  membrane	  TROP2	  than	  primary	  tumors	  with	  a	  recurrence	  (Figure	  4.13,	  A).	  	  There	  was	  no	  difference	  in	  cytoplasmic-­‐localized	  TROP2	  between	  these	  groups	  (Figure	  4.13,	  B).	  	  However,	  the	  sample	  size	  in	  the	  present	  study	  was	  particularly	  small	  especially	  for	  the	  non-­‐recurrent	  tumors.	  	  Therefore,	  it	  would	  be	  important	  to	  verify	  these	  findings	  in	  a	  larger	  sample	  size.	  	  It	  is	  also	  important	  to	  consider	  that	  the	  published	  study	  used	  different	  antibodies	  to	  recognize	  TROP2	  post-­‐translational	  modifications	  and	  therefore	  distinguish	  between	  membrane-­‐
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targeted	  and	  intracellular	  TROP2.	  65	  In	  the	  present	  study,	  we	  used	  one	  antibody	  and	  visually	  distinguished	  membrane	  versus	  cytoplasmic	  TROP2	  expression	  when	  scoring	  the	  IHC	  samples.	  	  	  	   In	  agreement	  with	  a	  previous	  report	  analyzing	  TROP2	  expression	  in	  32	  breast	  cancer	  samples,	  109	  I	  found	  that	  ER-­‐negative/HER2-­‐positive	  tumors	  had	  higher	  expression	  of	  membrane	  TROP2	  than	  ER-­‐positive/HER2-­‐negative	  tumors.	  	  Although	  the	  increase	  in	  TROP2	  expression	  was	  not	  significant,	  it	  was	  in	  the	  direction	  predicted	  according	  to	  the	  results	  in	  the	  literature.	  	   Several	  studies	  in	  other	  tissues	  found	  high	  TROP2	  expression	  was	  associated	  with	  disease	  progression,	  migration,	  recurrence	  and	  increased	  proliferation.	  110-­‐
113,115,116	  This	  lead	  me	  to	  predict	  that	  tumor	  samples	  with	  high	  TROP2	  expression	  would	  have	  increased	  proliferation,	  high	  tumor	  grade,	  and	  a	  shorter	  time	  to	  recurrence.	  	  However,	  I	  found	  no	  association	  between	  membrane	  TROP2	  expression	  and	  tumor	  grade,	  Ki67	  score	  or	  time	  to	  recurrence	  (Figures	  4.14,	  B	  and	  C).	  	  This	  may	  be	  a	  reflection	  of	  a	  small	  sample	  size	  or	  it	  may	  indicate	  that	  TROP2	  signaling	  is	  acting	  in	  a	  different	  way	  in	  breast	  cancer	  than	  other	  types	  of	  tissue.	  The	  role	  of	  TROP2	  in	  breast	  cancer	  could	  be	  further	  investigated	  by	  analyzing	  expression	  of	  downstream	  signaling	  components	  that	  may	  be	  associated	  with	  disease	  recurrence	  and	  drug	  resistance.	  	  Increased	  TROP2	  expression	  had	  been	  shown	  to	  increase	  expression	  of	  growth	  regulatory	  proteins	  including	  NF-­‐κβ,	  RB,	  STAT1	  and	  STAT3.	  60	  I	  would	  predict	  that	  those	  tumor	  samples	  with	  high	  TROP2	  expression	  would	  also	  have	  increased	  expression	  and	  activity	  of	  these	  downstream	  effectors.	  	  However,	  the	  expression	  levels	  of	  these	  proteins	  in	  the	  tumor	  samples	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analyzed	  here	  are	  not	  known.	  	  Given	  the	  discrepancy	  between	  the	  results	  presented	  here	  and	  some	  of	  those	  in	  the	  literature,	  it	  appears	  that	  TROP2	  may	  have	  tissue-­‐specific	  roles	  in	  carcinogenesis.	  	  Therefore,	  it	  will	  be	  important	  in	  the	  future	  to	  determine	  not	  only	  the	  subcellular	  localization	  of	  TROP2	  but	  also	  expression	  of	  other	  downstream	  signaling	  components	  that	  may	  act	  to	  promote	  growth	  signaling	  in	  cancer	  cells.
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Table	  4.1	  Summary	  of	  Previous	  Results	  and	  Predictions	  










Adhesion	   Migration	  
MCF-­‐7	   Low	   High	   Moderate	   Similar	  to	  TMX2-­‐28	   Low	  TMX2-­‐28	   High	   Low	   Increased	   Similar	  to	  MCF-­‐7	   Increased	  	   	   	   	   	   	  	   	   	   Results	  from	  Chp.	  3	  MCF-­‐7-­‐Aza	   Low	   High	  (no	  change)	   No	  Change	   n/a	   (2D)	  Increase	  TMX2-­‐28-­‐Aza	   Low	   High	   Decrease	   Decrease	   (2D)	  Decrease	  	   	   	   	   	   	  	   	   	   Predictions	  MCF-­‐7-­‐Trop2-­‐Kd	   n/a	   Low	   Increase	   Increase	   Increase	  TMX2-­‐28-­‐Trop2	   n/a	   High	   Decrease	   Decrease	   Decrease	  	   	   	   	   	   	  	   	   	   Results	  from	  Chp.	  4	  MCF-­‐7-­‐Trop2-­‐Kd	   n/a	   Low	   Increase	   No	  change	   No	  change	  TMX2-­‐28-­‐Trop2	   n/a	   High	   No	  change	   Increase	   Increase	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Table	  4.2	  Predictions	  for	  Tumor	  Samples	  Based	  on	  Cell	  Line	  Data	  
	   ER	  +	  Primary	   ER	  -­‐	  Recurrence	  Cell	  line	  model	   MCF-­‐7	   TMX2-­‐28	  
TACSTD2	  promoter	  methylation	   Low	   High	  TROP2	  Expression	   High	   Low	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Table	  4.3	  Predictions	  for	  Tumor	  Samples	  Based	  on	  Literature*	  	   Non-­‐Recurrent	   Recurrent	   ER+/HER2+	  TROP2	  Expression	   Low	   High	   High	  TROP2	  Localization	   Membrane	  absent	   Membrane	   Membrane	  Ki67	  Status	   Low	   High	   High	  Tumor	  Grade	   Low	   High	   High	  	  *	  Predictions	  based	  on	  60,65,110-­‐116	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Table	  4.4	  Patient	  and	  Tumor	  Characteristics	  
Age (in years) mean (SD) range 
    At Primary  56.6 (12.3), 37 - 84 
    At Recurrence 64.1 (12.6), 39 - 90 
Menopausal n (%)  
    At Primary 13 (38%) 
    At Recurrence 21 (58%) 







ER status n (%) 
+ 26 (76.5) 19 (52.8) 
- 8 (23.5) 17 (47.2) 
PR status n (%) 
+ 20 (58.8) 16 (44.4) 
- 14 (41.2) 20 (55.6) 
HER2 status n (%) 
+ 5 (14.7) 9 (25) 
- 29 (85.3)  27 (75) 
Ki67 IHC n (%) 
low (≤15) 26 (76.5) 20 (55.6) 
high (>15) 8 (23.5) 16 (44.4) 
Tumor Grade n (%)3 
0 5 (15.1) 5 (15.1) 
1 5 (15.1) 2 (6.1) 
2 11 (33.3) 5 (15.1) 
3 12 (36.3) 21 (63.6) 
Tumor Type n (%) 
DCIS 5 (14.7) 5 (13.9) 
IDC 23 (67.6) 26 (72.2) 
ILC 4 (11.8) 4 (11.1) 
IDLC 2 (5.9) 1 (2.8) 
Location of Recurrence(s) n (%)4 
Ipsilateral to primary NA 21 (60) 
Contralateral to primary NA 14 (40) 
Tumor Size n (%)3  
≥20 mm 13 (48.2) 13 (52) 
<20 mm 14 (51.8) 12 (48) 
Anti-hormonal Therapy n (%)3 
	  137	  
No 7 (30.4) NA 
Yes, Tam 4 (17.4) NA 
Yes, AI 7 (30.4) NA 
Yes, Tam & AI 5 (21.8) NA 
Chemotherapy Type n (%)3, 5 
AC + paclitaxel 6 (23.1) NA 
AC + docetaxel 3 (11.6) NA 
Other 5 (19.2) NA 
None  12 (46.1) NA 
1TTR = time to recurrence 
2Primary tumors include the 8 non-recurrent tumors 
3Indicates that data are missing for some samples; percentages 
are calculated on the available data 
4Includes second recurrences; missing laterality for one tumor 
5AC = Adriamycin (doxorubicin) and C = cyclophosphamide 
NA = not applicable 










Table	  4.5	  TROP2	  Staining	  in	  Breast	  Tumors	  






ER+ Primary to ER+ Recurrence 
ER+ Primary (n = 14) 3.9 (3.1) 4.8 (2.1) 
ER+ Recurrence (n = 18) 4.9 (3.3) 4.3 (2.1) 
ER- Primary to ER- Recurrence 
ER- Primary (n = 6) 5 (2.7) 3.7 (2.0) 
ER- Recurrence (n = 8) 5 (3.8) 3.5 (2.8) 
ER+ Primary to ER- Recurrence 
ER+ Primary (n = 6) 5 (4.5) 4.5 (1.6) 
ER- Recurrence (n = 6) 4.7 (2.7) 4.6 (1.7) 
Non-Recurrent 
ER+ (n = 6) 9 (0) 4.8 (1.8) 
ER- (n = 2) 6.5 (3.5) 4 (2.8) 
 
ER/HER2 status  
-/- (n = 18) 4.3 (2.8) 3.5 (2.2) 
-/+ (n = 5) 7.4 (2.3) 5.1 (1.3) 
+/- (n = 37) 5.3 (3.5) 4.5 (2.0) 
+/+ (n = 6) 4.3 (3.8) 5 (1.5) 
   
Non-Recurrent (n = 8) 8.4 (1.8) 4.6 (1.9) 
Primaries that Recur (n = 26) 4.4 (3.3)  4.4 (2.0) 
   
See text for scoring of TROP2 	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Table	  4.6	  Descriptive	  Statistics	  for	  Average	  Beta	  Values	  by	  ER	  Status	  
All	  TACSTD2	  CpGs	  






Tumors	  Mean	   0.183	   0.180	   0.183	   0.181	  Minimum	   0.080	   0.089	   0.084	   0.082	  Maximum	   0.706	   0.651	   0.697	   0.678	  Range	   0.626	   0.562	   0.613	   0.600	  Variance	   0.021	   0.018	   0.021	   0.019	  Standard	  Deviation	   0.145	   0.132	   0.144	   0.138	  Median	   0.139	   0.135	   0.145	   0.130	  25th	  Percentile	   0.112	   0.115	   0.105	   0.125	  75th	  Percentile	   0.206	   0.205	   0.209	   0.199	  Interquartile	  Range	   0.095	   0.090	   0.105	   0.074	  
TACSTD2	  Promoter	  CpGs	  	   ER-­‐Positive	  Tumors	   ER-­‐Negative	  Tumors	   Primary	  Tumors	   Recurrent	  Tumors	  Mean	   0.206	   0.200	   0.207	   0.201	  Minimum	   0.090	   0.089	   0.097	   0.082	  Maximum	   0.706	   0.651	   0.697	   0.678	  Range	   0.616	   0.562	   0.600	   0.596	  Variance	   0.037	   0.030	   0.035	   0.034	  Standard	  Deviation	   0.191	   0.174	   0.188	   0.183	  Median	   0.152	   0.146	   0.150	   0.149	  25th	  Percentile	   0.124	   0.126	   0.124	   0.125	  75th	  Percentile	   0.203	   0.204	   0.207	   0.199	  Interquartile	  Range	   0.079	   0.078	   0.083	   0.074	  




Table	  4.7	  Descriptive	  Statistics	  for	  
Membrane	  TROP2	  Scores	  Mean	   5.11	  Minimum	   0	  Maximum	   9	  Range	   9	  Variance	   10.94	  Standard	  Deviation	   3.31	  Mode	   9	  Median	   4.5	  25th	  Percentile	   2.25	  75th	  Percentile	   9	  Interquartile	  Range	   6.75	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Table	  4.8	  Descriptive	  Statistics	  for	  
Cytoplasmic	  TROP2	  Scores	  Mean	   4.33	  Minimum	   0	  Maximum	   9	  Range	   9	  Variance	   4.21	  Standard	  Deviation	   2.05	  Mode	   6	  Median	   3	  25th	  Percentile	   3	  75th	  Percentile	   6	  Interquartile	  Range	   3	  
	  











Figure	  4.1:	  TROP2	  Expression	  in	  the	  Cloned	  Cell	  Lines.	  	  TROP2	  mRNA	  expression	  determined	  by	  RT-­‐PCR	  run	  in	  technical	  triplicate	  for	  MCF-­‐7	  (non-­‐transfected),	  MCF-­‐7-­‐Control,	  MCF-­‐7-­‐Trop2-­‐Knockdown,	  TMX2-­‐28	  (non-­‐transfected),	  TMX2-­‐28-­‐Control	  and	  TMX2-­‐28-­‐Trop2	  cell	  lines	  (A).	  	  Expression	  of	  TROP2	  determined	  by	  IHC	  for	  MCF-­‐7-­‐Control-­‐Clone-­‐B	  and	  MCF-­‐7-­‐Trop2-­‐Knockdown-­‐Clone-­‐A	  (B).	  	  Expression	  of	  TROP2	  determined	  by	  IHC	  for	  TMX2-­‐28-­‐Control-­‐Clone-­‐A	  and	  TMX2-­‐28-­‐Trop2-­‐Clone-­‐B	  (C).	  	  Magnification	  =	  200X.	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Figure	  4.2:	  TROP2	  Overexpression	  Does	  Not	  Affect	  Proliferation	  in	  TMX2-­‐28.	  	  Cell	  proliferation	  determined	  by	  MTS	  assay	  represented	  as	  percent	  of	  control	  for	  TMX2-­‐28-­‐Control	  and	  TMX2-­‐28-­‐Trop2	  cell	  lines	  (n	  =	  16,	  p	  =	  0.29).	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Figure	  4.3:	  TROP2	  Increases	  Adhesion	  to	  Fibronectin	  in	  TMX2-­‐28.	  Adhesion	  to	  fibronectin	  represented	  as	  percent	  of	  control	  for	  TMX2-­‐28-­‐Control	  and	  TMX2-­‐28-­‐Trop2	  cell	  lines	  (n	  =	  16,	  p	  <	  0.0001).	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Figure	  4.4:	  TROP2	  Promotes	  Migration	  of	  TMX2-­‐28.	  	  Number	  of	  migratory	  cells	  per	  transwell	  membrane	  determined	  from	  four	  non-­‐overlapping	  images	  per	  sample	  (n	  =	  3).	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Figure	  4.5:	  Knockdown	  of	  TROP2	  in	  MCF-­‐7	  Increases	  Proliferation.	  Cell	  proliferation	  determined	  by	  MTS	  assay	  represented	  as	  percent	  of	  control	  for	  MCF-­‐7-­‐-­‐Control	  and	  MCF-­‐7-­‐Trop2-­‐Kd	  cell	  lines	  (n	  =	  16,	  p	  <	  0.00001).	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(A)	   	   	   	   	   	   	   	   (B)	   	   	   	   	   	   	   	  
	   	   	  
(C)	  
	   	   	  (Figure	  4.6)	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Figure	  4.6:	  TROP2	  Knockdown	  Has	  Variable	  Results	  on	  MCF-­‐7	  Adhesion	  to	  Fibronectin.	  Adhesion	  to	  fibronectin	  represented	  as	  percent	  of	  control	  for	  MCF-­‐7-­‐Control	  and	  MCF-­‐7-­‐Trop2-­‐Kd	  cell	  lines	  for	  three	  separate	  experiments	  (A)	  n	  =	  16,	  (B)	  n	  =	  8	  and	  (C)	  n	  =	  16.	  	  A	  significant	  decrease	  in	  adhesion	  to	  fibronectin	  in	  MCF-­‐7-­‐Trop2-­‐Kd	  was	  observed	  in	  two	  out	  of	  the	  three	  experiments.	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(A)	   	   	   	   	   	   	   	   	   	   (B)	  
	   	   	  
Figure	  4.7:	  Average	  Methylation	  for	  TACSTD2	  in	  Tumor	  Samples	  by	  ER	  status.	  Boxplots	  indicating	  average	  beta	  values	  for	  all	  TACSTD2	  CpGs	  on	  the	  450	  BeadChip	  for	  the	  tumor	  samples	  by	  ER	  status	  (ER-­‐positive	  v.	  ER-­‐negative)	  (A)	  and	  CpGs	  located	  in	  the	  promoter	  only	  (TSS200	  or	  TSS1500)	  (B).	  	  	  Boxplots	  generated	  in	  Genome	  Studio.
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(A) (B)	  
	   	   	  






	   	  	  (Figure	  4.9)	  































Figure	  4.11:	  Summary	  of	  Membrane	  and	  Cytoplasmic	  TROP2	  IHC	  Scoring	  in	  




Figure	  4.12:	  Expression	  of	  Membrane	  TROP2	  in	  ER-­‐Positive	  Primary	  Tumors	  
that	  Recur	  as	  ER-­‐Negative.	  Mean	  membrane	  TROP2	  scores	  determined	  by	  IHC	  for	  the	  ER-­‐positive	  primary	  tumors	  (n	  =	  6)	  that	  recur	  as	  ER-­‐negative	  tumors	  (n	  =	  6)	  (one-­‐tail	  p-­‐value	  =	  0.44,	  two-­‐tail	  p-­‐value	  =	  0.88).	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(A)	   	   	   	   	   	   	   (B)	  
	   	  
	  
Figure	  4.13:	  Expression	  of	  TROP2	  in	  Tumor	  Samples	  by	  ER/HER2	  Status.	  Mean	  membrane	  (A)	  and	  cytoplasmic	  (B)	  TROP2	  scores	  determined	  by	  IHC	  for	  the	  tumor	  samples	  grouped	  by	  ER/HER2	  status	  (ER-­‐negative/HER2-­‐negative:	  n	  =	  18,	  ER-­‐negative/HER2-­‐positive,	  n	  =	  5,	  ER-­‐positive/HER2-­‐negative,	  n	  =	  37,	  and	  ER-­‐positive/HER2-­‐postitive,	  n	  =	  6).	  	  (One-­‐way	  ANOVA	  p-­‐values	  for	  membrane	  and	  cytoplasmic	  TROP2	  equal	  0.28	  and	  0.21,	  respectively).	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(A)	   	   	   	   	   	   	   (B)	  
	   	  
Figure	  4.14:	  Expression	  of	  TROP2	  in	  Non-­‐Recurrent	  Samples	  and	  Primary	  




(B)	   	   	   	   	   	   	   (C)	  
	   	   	  
Figure	  4.15:	  Tumor	  Grade	  and	  Ki67	  Score	  by	  Expression	  Level	  of	  Membrane	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Introduction	  As	  reviewed	  by	  Karantza,	  121	  the	  cytoskeleton	  is	  composed	  of	  three	  types	  of	  cytoskeletal	  filaments:	  microfilaments,	  intermediate	  filaments	  and	  microtubules	  (Figure	  5.1).	  	  Microfilaments	  (also	  called	  actin	  filaments)	  are	  made	  of	  interlaced	  actin	  chains	  (6nm	  in	  diameter).	  	  They	  function	  to	  maintain	  cellular	  shape,	  resist	  tension,	  form	  cytoplasmic	  protrusions	  and	  are	  involved	  in	  cell-­‐cell	  and	  cell-­‐matrix	  interactions.	  	  Intermediate	  filaments	  (10	  nm	  in	  diameter)	  are	  slightly	  larger	  and	  stronger	  than	  actin	  filaments.	  	  They	  help	  maintain	  the	  internal	  cell	  structure	  by	  preserving	  shape	  and	  bearing	  tension.	  	  Microtubules	  are	  23	  nm	  in	  diameter	  and	  are	  hollow	  cylinders	  made	  of	  13	  protofilaments	  (polymers	  of	  alpha-­‐	  and	  beta-­‐	  tubulin).	  	  Microtubules	  form	  the	  mitotic	  spindle	  and	  are	  important	  for	  intracellular	  transport.	  	  Keratins	  are	  a	  type	  of	  intermediate	  filament	  classified	  according	  to	  the	  amino	  acid	  sequence	  of	  their	  rod-­‐domain.	  	  Expression	  of	  keratins	  has	  a	  tissue-­‐	  and	  differentiation-­‐state-­‐specific	  pattern.	  121	  Therefore,	  keratin	  expression	  patterns	  are	  often	  used	  to	  identify	  tumor	  cells	  from	  carcinomas	  that	  have	  metastasized	  or	  circulating	  tumor	  cells.122	  Keratins	  (also	  known	  as	  cytokeratins)	  are	  classified	  based	  on	  2D	  isoelectric	  focusing	  and	  SDS-­‐polyacrylamide	  gel	  electrophoresis.	  	  Moll	  and	  colleagues	  initially	  characterized	  and	  categorized	  keratins	  from	  human	  cell	  lines,	  normal	  epithelia	  and	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tumors	  in	  this	  manner.	  123	  Keratins	  make	  up	  two	  of	  the	  six	  types	  of	  intermediate	  filaments.	  121,124	  Type	  I	  (acidic)	  and	  Type	  II	  (basic	  or	  neutral)	  keratins	  are	  typically	  expressed	  in	  epithelial	  cells.	  	  Keratin	  filaments	  are	  composed	  of	  heterotypic	  pairs	  of	  Type	  I	  and	  Type	  II	  proteins.	  	  They	  help	  protect	  epithelial	  cells	  from	  both	  mechanical	  and	  non-­‐mechanical	  stress.	  	  In	  addition,	  keratins	  are	  involved	  in	  regulating	  apico-­‐basal	  polarity,	  determining	  cell	  size,	  spacing	  of	  organelles,	  targeting	  of	  membrane	  proteins	  and	  controlling	  protein	  translation.	  121	  Throughout	  tumorigenesis,	  cancer	  cells	  generally	  maintain	  their	  original	  keratin	  expression	  profile.	  124	  Therefore,	  pathologists	  and	  oncologists	  utilize	  keratins	  as	  a	  diagnostic	  tool	  in	  epithelial	  cancers	  by	  using	  their	  expression	  pattern	  to	  classify	  adenocarcinomas	  by	  tissue	  of	  origin	  and	  to	  help	  determine	  the	  best	  treatment	  options	  for	  the	  patient.121	  	   There	  are	  variable	  results	  regarding	  keratin	  expression	  in	  breast	  cancers	  in	  the	  literature,	  depending	  on	  sample	  size	  and	  antibodies	  used.	  	  In	  the	  normal	  breast,	  CK5	  and	  CK14	  are	  expressed	  in	  myoepithelial	  cells	  while	  CK7,	  CK8,	  CK18	  and	  CK19	  are	  expressed	  in	  ductal	  cells.	  124	  However,	  most	  adenocarcinomas	  (epithelial	  cancer	  that	  develops	  in	  glandular	  tissues)	  express	  the	  following	  keratins:	  CK8,	  CK18	  and	  CK19	  while	  expression	  of	  CK7	  and	  CK20	  is	  variable.	  	  A	  large	  number	  of	  breast	  adenocarcinomas	  including	  ductal	  and	  lobular	  express	  CK7,	  CK8,	  CK18	  and	  CK19.	  	  Ductal	  adenocarcinomas	  typically	  have	  positive	  peripheral	  CK8	  staining	  while	  lobular	  adenocarcinomas	  have	  perinuclear	  CK8	  staining.	  121	  However,	  primary	  breast	  cancers	  can	  undergo	  changes	  in	  keratin	  expression	  during	  metastasis.	  122	  	  	  	   As	  reviewed	  by	  Gusterson	  and	  colleagues,	  heterogeneity	  is	  observed	  in	  all	  aspects	  of	  breast	  cancer	  including	  morphology,	  response	  to	  therapy	  and	  clinical	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outcome.	  	  In	  the	  anatomy	  of	  normal	  breast	  tissue,	  there	  are	  inner	  luminal	  cells,	  a	  distinct	  outer	  cell	  layer	  next	  to	  the	  basement	  membrane	  (myoepithelium)	  and	  a	  basement	  membrane	  or	  basal	  cell	  layer	  (Figure	  1.1).	  	  Myoepithelial	  cells	  are	  cells	  that	  possess	  both	  epithelial	  and	  basal	  or	  contractile	  properties.	  	  Throughout	  the	  basal	  cell	  layer	  there	  is	  morphological	  heterogeneity	  where	  some	  cells	  are	  spindle-­‐like	  and	  some	  are	  cuboidal.	  	  Cell	  morphology	  is	  dependent	  on	  their	  location	  within	  the	  branched	  ductal	  network	  of	  the	  breast	  and	  on	  the	  hormone	  or	  menopause	  status	  of	  the	  tissue.	  	  This	  basal	  layer	  in	  the	  breast	  differs	  from	  basal	  cells	  of	  stratified	  squamous	  epithelium	  by	  expression	  of	  smooth	  muscle	  actin	  (SMA),	  myosin	  and	  neutral	  endopeptidase	  (CD10).	  125	  Basal	  cells	  were	  initially	  characterized	  as	  cells	  that	  express	  high	  molecular	  weight	  cytokeratins	  such	  as	  CK5	  and	  CK14.	  123,125	  In	  normal	  glandular	  epithelia,	  CK5	  and	  CK14	  are	  expressed	  in	  cells	  that	  are	  adjacent	  to	  the	  basement	  membrane	  and	  in	  a	  basal	  position	  from	  the	  ducts	  to	  the	  acini.	  	  Therefore,	  in	  most	  tissues,	  “basal	  position”	  and	  cells	  that	  express	  “basal	  keratins”	  refers	  to	  the	  same	  population	  of	  cells.	  	  However,	  in	  the	  breast,	  cell	  types	  other	  than	  myoepithelial	  cells	  can	  express	  CK5,	  CK14	  and	  CK17,	  such	  as	  luminal	  cells	  located	  in	  the	  terminal	  duct	  lobular	  unit.	  	  Expression	  of	  CK8	  and	  CK18	  is	  only	  found	  in	  luminal	  cells.	  	  However,	  luminal	  cells	  have	  also	  been	  found	  to	  express	  basal	  cytokeratins,	  CK5,	  CK14	  and	  CK17.	  	  Therefore	  the	  term	  “basal”	  can	  be	  defined	  as	  either	  myoepithelium	  or	  the	  subpopulation	  of	  cells	  expressing	  basal	  cytokeratins,	  which	  can	  be	  located	  in	  either	  a	  luminal	  or	  basal	  location	  in	  normal	  glands.	  	  Expression	  of	  CK5,	  CK14	  and	  CK17	  in	  myoepithelial	  cells	  of	  in	  situ	  breast	  lesions	  is	  associated	  with	  a	  poor	  prognosis.	  	  High-­‐grade	  tumors	  expressing	  keratins	  of	  stratified	  epithelium	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(CK4,	  CK14	  and/or	  CK17)	  have	  a	  poor	  prognosis	  and	  generally	  lack	  expression	  of	  ER.	  	  While	  tumors	  of	  grade	  1	  and	  2	  generally	  express	  simple	  epithelial	  (or	  luminal)	  keratins.	  	  Most	  breast	  tumors	  express	  simple	  epithelial	  cytokeratins	  (CK7,	  CK8,	  CK18	  or	  CK19).	  	  Expression	  of	  CK5/6	  is	  associated	  with	  ER-­‐negative	  and	  PR-­‐negative	  tumors,	  which	  have	  high	  expression	  of	  p53,	  EGFR	  and	  a	  high	  proliferative	  index.	  	  Identifying	  differences	  between	  luminal	  and	  basal	  breast	  cancers	  helps	  determine	  the	  best	  therapeutic	  option	  and	  may	  affect	  response	  to	  chemotherapy.125	  	   Another	  protein	  which	  may	  help	  to	  distinguish	  basal	  and	  luminal	  cells	  is	  p63,	  a	  transcription	  factor	  in	  the	  p53	  gene	  family.	  126,127	  The	  p63	  protein	  is	  important	  for	  development	  and	  homeostasis	  of	  ectodermal	  and	  epidermal	  tissues.	  126	  It	  is	  critical	  for	  the	  maturation	  of	  stratified	  epithelia	  such	  as	  limb	  buds,	  skin	  and	  mammary	  glands	  and	  is	  highly	  expressed	  in	  adult	  skin	  basal	  stem	  cells.	  	  P63	  can	  regulate	  proliferation,	  differentiation	  and	  maintenance	  of	  stem	  cell	  populations	  and	  is	  required	  for	  development	  of	  the	  fetal	  mammary	  gland.	  127	  There	  are	  two	  major	  isoforms	  of	  p63.	  	  Tap63	  contains	  the	  N-­‐terminal	  transactivation	  (TA)	  domain,	  while	  ΔNp63	  is	  missing	  the	  N-­‐terminal	  TA	  domain	  but	  has	  a	  second	  internal	  TA	  domain.127	  In	  human	  and	  murine	  breast	  cancer	  samples,	  there	  is	  high	  expression	  of	  ΔNp63	  in	  basal	  myoepithelial	  cells	  and	  TAp63	  is	  expressed	  in	  some	  luminal	  cells.	  	  The	  ΔNp63	  isoform	  promotes	  cell	  survival	  by	  suppressing	  transcription	  of	  pro-­‐apoptotic	  genes	  and	  activating	  transcription	  of	  anti-­‐apoptotic	  genes.	  127	  Sonic	  Hedgehog	  signaling,	  which	  promotes	  self-­‐renewal	  of	  mammary	  stem	  cells,	  is	  also	  promoted	  by	  ΔNp63.	  128	  TAp63	  regulates	  responses	  to	  DNA	  damage	  by	  inducing	  cell	  cycle	  arrest	  or	  apoptosis	  and	  can	  also	  suppress	  TGFβ	  signaling,	  which	  is	  important	  for	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metastasis.126	  Therefore,	  it	  is	  important	  to	  determine	  expression	  levels	  of	  p63	  in	  our	  tissue	  culture	  model.	  	  The	  objective	  of	  this	  study	  was	  to	  better	  characterize	  our	  cell	  line	  models	  of	  tamoxifen	  resistance	  by	  examining	  expression	  of	  several	  basal	  and	  luminal	  keratins.	  	  Keratin	  expression	  will	  be	  determined	  by	  immunohistochemistry	  (IHC)	  for	  the	  parental	  cell	  line,	  MCF-­‐7,	  and	  the	  tamoxifen	  resistant	  cell	  lines,	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28.	  	  Expression	  of	  basal	  cytokeratins	  (CK5,	  CK5/6,	  CK14	  and	  the	  cocktail	  34βE12)	  and	  luminal	  cytokeratins	  (CK8,	  CK17,	  CK18	  and	  CK20)	  as	  well	  as	  the	  transcription	  factor	  p63	  and	  its	  isoform,	  ΔNp63	  (p40),	  will	  be	  determined	  by	  IHC.	  	  The	  CK34βE12	  antibody	  recognizes	  the	  basal	  cytokeratins	  CK1,	  CK5,	  CK10	  and	  CK14.	  	  Additionally,	  methylation	  of	  the	  cytokeratins	  and	  transcription	  factors	  will	  be	  examined	  in	  the	  control	  DMSO-­‐treated	  cell	  lines	  (see	  Chapter	  2).	  	  Determining	  methylation	  levels	  from	  the	  450K	  BeadChip	  array	  will	  indicate	  whether	  expression	  of	  these	  genes	  might	  be	  regulated	  by	  promoter	  methylation.	  	  Characterizing	  the	  keratin	  expression	  profile	  in	  our	  cell	  line	  model	  of	  tamoxifen	  resistance	  will	  provide	  a	  better	  understanding	  of	  the	  changes	  that	  may	  occur	  during	  the	  development	  of	  tamoxifen	  resistant	  disease.	  	  
Materials	  and	  Methods	  	   Cell	  Culture:	  As	  previously	  described,	  MCF-­‐7	  cells	  were	  purchased	  from	  the	  American	  Type	  Culture	  Collection	  (ATCC).	  	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28	  cells	  were	  provided	  by	  John	  Gierthy	  (Wadsworth	  Center	  Albany,	  NY).	  	  Cells	  were	  grown	  in	  Dulbecco’s	  modified	  eagle	  medium	  (without	  phenol	  red).	  	  Medium	  was	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supplemented	  with	  5%	  cosmic	  calf	  serum	  (Hyclone	  Cat.	  No.	  SH30087.03),	  2.0	  mM	  of	  L-­‐glutamine,	  0.1	  mM	  of	  nonessential	  amino	  acids	  and	  250	  ng/mL	  of	  insulin.	  	  Cells	  were	  maintained	  at	  37°C,	  5%	  CO2	  in	  a	  humidified	  incubator	  and	  passaged	  at	  subconfluence	  or	  media	  exchanged	  every	  2	  days.	  	   Immunohistochemistry	  (IHC):	  Cells	  were	  seeded	  on	  poly-­‐L-­‐lysine	  (PLL)-­‐coated	  slides	  (Polysciences,	  Cat.	  No.	  22247,	  Warrington,	  PA)	  at	  a	  density	  of	  approximately	  2	  x	  105	  cells/mL/slide.	  	  Cells	  were	  maintained	  at	  37°C,	  5%	  CO2	  in	  a	  humidified	  incubator	  overnight	  and	  fixed	  approximately	  24	  hours	  later.	  	  First,	  the	  slides	  were	  rinsed	  with	  cold	  phosphate-­‐buffered	  saline	  solution	  (PBS)	  twice	  and	  then	  fixed	  in	  ice	  cold	  100%	  methanol	  for	  10	  min.	  	  The	  slides	  were	  then	  allowed	  to	  dry	  and	  stored	  at	  -­‐20°C	  until	  stained.	  	  Immunohistochemical	  staining	  was	  performed	  at	  Baystate	  using	  the	  ADVANCE	  HRP	  System	  (Dako	  Cat.	  No.	  K4067,	  Carpinteria,	  CA)	  with	  the	  following	  primary	  antibodies:	  TP63	  (Dako	  Cat.	  No.	  M7247,	  Carpinteria,	  CA),	  CK	  34βE12	  (Enzo,	  Cat.	  No.	  ENZ-­‐C34903,	  Farmingdale,	  NY),	  CK	  5	  (Vector,	  Cat.	  No.	  VP-­‐C400,	  Burlingame,	  CA),	  CK	  8	  (Vector,	  Cat.	  No.	  VP-­‐C404,	  Burlingame,	  CA),	  CK	  17	  (Vector,	  Cat.	  No.	  VP-­‐C413,	  Burlingame,	  CA),	  CK	  18	  (Vector,	  Cat.	  No.	  VP-­‐C414,	  Burlingame,	  CA)	  and	  CK	  20	  (Dako,	  Cat.	  No.	  M7019,	  Carpinteria,	  CA).	  	  The	  UltraView	  Universal	  DAB	  Detection	  kit	  (Ventana	  Medical	  Systems,	  Inc.,	  Cat.	  No.	  760-­‐500)	  was	  used	  with	  the	  following	  primary	  antibodies:	  CK	  5/6	  (Ventana	  Medical	  Systems,	  Inc.,	  Cat.	  No.	  790-­‐4554,	  Tucson,	  AZ),	  CK	  14	  (Ventana	  Medical	  Systems,	  Inc.,	  Cat.	  No.	  760-­‐4251,	  Tucson,	  AZ),	  and	  TP40	  (Biocare,	  Cat.	  No.	  ACI3066,	  Concord,	  CA).	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   Appropriate	  negative	  (no	  primary	  antibody)	  and	  positive	  controls	  were	  used	  to	  optimize	  antibody	  performance	  in	  addition	  to	  testing	  a	  dilution	  series	  including	  the	  dilutions	  recommended	  by	  the	  manufacturer.	  	   Review	  of	  Pathology:	  Scoring	  of	  slides	  was	  conducted	  by	  one	  anatomic	  pathologist	  (Rahul	  Jawale).	  	  Slides	  were	  scored	  for	  immunoreactivity	  of	  10	  antigens;	  approximate	  number	  of	  positive	  cells	  was	  recorded	  (%)	  and	  intensity	  of	  immunoreactivity	  was	  reported	  on	  a	  scale	  of	  0	  (negative),	  1+	  (weak),	  2+	  (moderate),	  3+	  (strong).	  	  Scoring	  was	  completed	  in	  one	  session	  with	  a	  single	  observer	  documenting	  records	  (SZ).	  	   Illumina	  Human	  Methylation	  450	  BeadChip:	  Methylation	  of	  the	  genes	  encoding	  the	  cytokeratins	  was	  investigated	  in	  the	  DMSO-­‐control	  and	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treated	  cell	  lines	  as	  previously	  described	  (Chapter	  2)	  using	  the	  450K	  array.	  	   Data	  Analysis:	  The	  methylation	  data	  obtained	  from	  the	  HM450	  BeadChip	  was	  analyzed	  using	  Genome	  Studio	  Methylation	  Module	  (v.1.9.0).	  	  Detection	  p-­‐values	  of	  <	  0.01	  were	  used	  to	  select	  statistically	  significant	  CpG	  site	  data.	  	  Methylation	  data	  was	  exported	  from	  Genome	  Studio	  and	  averages	  were	  calculated	  in	  Excel.	  	  
Results	  
TMX2-­‐28	  Cells	  Have	  a	  Mixed	  Cytokeratin	  Expression	  Profile	  	   None	  of	  the	  cell	  lines	  expressed	  the	  transcription	  factors	  or	  CK	  20	  (Table	  5.1).	  	  There	  was	  also	  no	  protein	  expression	  detected	  with	  the	  CK	  34βE12	  or	  CK	  5/6	  antibodies.	  	  All	  cell	  lines	  express	  high	  levels	  of	  the	  low	  molecular	  weight,	  luminal	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markers,	  CK	  8	  and	  18.	  	  However,	  TMX2-­‐28	  had	  increased	  expression	  of	  the	  high	  molecular	  weight,	  basal	  cytokeratins,	  CK5	  and	  CK14,	  compared	  to	  the	  parental	  cell	  line,	  MCF-­‐7.	  	  Interestingly,	  TMX2-­‐28	  also	  expressed	  higher	  levels	  of	  the	  luminal	  marker,	  CK17,	  compared	  to	  the	  parental	  cell	  line.	  	  The	  cytokeratin	  protein	  expression	  determined	  by	  IHC	  for	  TMX2-­‐28	  and	  MCF-­‐7	  agree	  with	  previously	  published	  mRNA	  data	  from	  our	  lab.	  	  In	  the	  2007	  paper,	  the	  trends	  in	  mRNA	  expression	  of	  CK	  5,	  CK	  14,	  CK	  8,	  CK	  17	  and	  CK18	  are	  in	  alignment	  with	  the	  protein	  expression	  results	  presented	  here.	  	  However,	  Gozgit	  and	  colleagues	  found	  MCF-­‐7	  cells	  express	  high	  levels	  of	  CK	  20	  mRNA.	  75	  While	  the	  IHC	  results	  indicate	  that	  MCF-­‐7	  do	  not	  express	  CK20	  protein.	  	  	   
Expression	  of	  Several	  Cytokeratins	  and	  p40	  May	  Be	  Regulated	  by	  Promoter	  
Methylation	  
Expression	  of	  p40	  May	  Be	  Regulated	  by	  Promoter	  Methylation	  
	   To	  determine	  whether	  DNA	  methylation	  may	  be	  regulating	  expression	  of	  the	  cytokeratins	  or	  transcription	  factors,	  I	  utilized	  the	  450K	  BeadChip	  array	  data	  from	  the	  DMSO	  control-­‐treated	  cell	  lines.	  	  I	  generated	  heatmaps	  to	  visualize	  the	  differences	  in	  methylation	  between	  the	  cells.	  	  The	  p40	  antibody	  recognizes	  the	  ΔNp63	  isoform	  of	  the	  TP63	  gene.	  	  Filtering	  the	  methylation	  array	  data	  for	  CpG	  sites	  corresponding	  to	  the	  ΔNp63	  isoform	  (accession	  numbers	  NM_001114980,	  NM_001114982	  and	  NM_001114983),	  methylation	  of	  these	  CpG	  sites	  is	  high.	  	  The	  mean	  average	  beta	  values	  for	  all	  CpGs	  in	  the	  ΔNp63	  isoform	  for	  each	  cell	  line	  range	  from	  0.71	  –	  0.80	  (Figure	  5.2,	  A).	  	  This	  inverse	  relationship	  between	  promoter	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methylation	  and	  protein	  expression	  indicates	  that	  ΔNp63	  expression	  may	  be	  repressed	  by	  promoter	  methylation.	  	  The	  CpG	  sites	  on	  the	  chip	  included	  loci	  in	  the	  TSS200	  (200	  base	  pairs	  upstream	  from	  transcription	  start	  site),	  TSS1500,	  body	  and	  3’UTR	  (3’	  untranslated	  region)	  of	  the	  three	  p40	  transcripts.	  	  It	  is	  also	  interesting	  that	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  decreased	  methylation	  throughout	  the	  gene	  in	  TMX2-­‐28	  cells	  only,	  indicating	  that	  this	  transcript	  may	  be	  re-­‐expressed	  in	  TMX2-­‐28	  upon	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  The	  mean	  average	  beta	  value	  for	  the	  ΔNp63	  CpGs	  for	  TMX2-­‐28-­‐5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  is	  0.51,	  a	  decrease	  of	  20%	  compared	  to	  TMX2-­‐28-­‐Control	  (Figure	  5.2,	  B).	  
	  
Expression	  of	  Basal	  Cytokeratins,	  CK5	  and	  CK14,	  May	  Be	  Regulated	  by	  
Promoter	  Methylation	  	   Protein	  expression	  of	  CK5	  is	  increased	  in	  TMX2-­‐28	  (Table	  5.1)	  compared	  to	  the	  other	  cell	  lines.	  	  The	  gene	  encoding	  CK5,	  KRT5,	  has	  decreased	  methylation	  in	  three	  CpG	  sites	  (MAPINFO	  no.52914409,	  52914330	  and	  52914229)	  in	  the	  TSS200	  or	  first	  exon/5’UTR	  compared	  to	  the	  three	  other	  cell	  lines	  (Figure	  5.3,	  A).	  	  The	  mean	  average	  beta	  value	  for	  these	  3	  CpGs	  in	  TMX2-­‐28	  is	  0.47	  compared	  to	  0.75	  in	  MCF-­‐7.	  	  Decreased	  methylation	  at	  these	  loci	  along	  with	  an	  increase	  in	  protein	  expression,	  may	  indicate	  that	  methylation	  of	  these	  CpG	  sites	  is	  important	  for	  regulating	  gene	  expression.	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  further	  decreased	  mean	  methylation	  of	  the	  CpGs	  for	  the	  CK5	  gene	  in	  TMX2-­‐28	  from	  0.57	  to	  0.42	  (Figure	  5.3,	  B).	  	  Therefore,	  I	  would	  predict	  increased	  expression	  of	  CK5	  in	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  TMX2-­‐28	  cells.	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   Despite	  the	  mean	  average	  beta	  values	  for	  all	  KRT14	  loci	  being	  similar	  for	  each	  cell	  line,	  the	  mean	  average	  beta	  values	  of	  the	  CpGs	  in	  the	  KRT14	  promoter	  (MAPINFO	  numbers:	  39744055,	  39743427,	  39743273,	  39743241,	  39743164))	  are	  different.	  	  The	  mean	  average	  beta	  value	  for	  these	  sites	  in	  the	  KRT14	  promoter	  for	  TMX2-­‐28	  is	  62%,	  which	  is	  lower	  than	  promoter	  methylation	  for	  MCF-­‐7,	  which	  is	  76%.	  	  This	  decrease	  of	  14%	  may	  be	  responsible	  for	  the	  corresponding	  increase	  in	  CK14	  expression	  in	  TMX2-­‐28.	  	  This	  is	  consistent	  with	  the	  idea	  that	  promoter	  methylation	  may	  be	  regulating	  gene	  expression	  of	  KRT14	  in	  TMX2-­‐28.	  	  There	  is	  also	  a	  decrease	  in	  promoter	  methylation	  between	  TMX2-­‐4	  and	  MCF-­‐7.	  	  However,	  this	  change	  in	  promoter	  methylation	  does	  not	  appear	  to	  be	  regulating	  gene	  expression	  in	  TMX2-­‐4	  because	  there	  is	  no	  increase	  in	  protein	  expression	  (Figure	  5.4,	  A).	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  resulted	  in	  decreased	  KRT14	  promoter	  methylation	  in	  each	  cell	  line	  relative	  to	  the	  control	  (Figure	  5.4,	  B).	  	  Therefore,	  I	  would	  predict	  that	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  would	  result	  in	  increased	  CK14	  expression	  in	  each	  cell	  line.	  	  
Expression	  of	  Luminal	  Cytokeratins,	  CK8,	  CK17,	  CK18	  and	  CK20,	  May	  Be	  
Regulated	  by	  Promoter	  Methylation	  	   The	  parental	  cell	  line,	  MCF-­‐7,	  and	  all	  three	  tamoxifen-­‐resistant	  cell	  lines,	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28,	  have	  high	  expression	  of	  the	  luminal	  cytokeratin,	  CK8.	  	  Each	  cell	  line	  also	  has	  low	  methylation	  for	  each	  KRT8	  loci	  represented	  on	  the	  450	  BeadChip.	  	  The	  mean	  average	  beta	  values	  for	  each	  cell	  line	  for	  all	  KRT8	  loci	  range	  from	  0.11	  –	  0.15	  (Figure	  5.5,	  A).	  	  Low	  methylation	  of	  CpGs	  in	  the	  promoter	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along	  with	  high	  protein	  expression	  may	  indicate	  that	  promoter	  methylation	  is	  involved	  in	  regulating	  gene	  expression	  of	  KRT8.	  	  Treatment	  of	  each	  cell	  line	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  did	  not	  alter	  methylation	  of	  KRT8	  (Figure	  5.5,	  B).	  Expression	  of	  CK17	  determined	  by	  IHC	  is	  higher	  in	  TMX2-­‐28	  compared	  to	  the	  parental	  cell	  line,	  MCF-­‐7.	  	  Interestingly	  methylation	  of	  3	  CpGs	  in	  the	  promoter	  region	  (MAPINFO	  no.	  39781130,	  39781108	  and	  39781055)	  have	  decreased	  methylation	  in	  TMX2-­‐28	  (mean	  average	  beta	  of	  0.35)	  compared	  to	  MCF-­‐7	  (mean	  average	  beta	  of	  0.62)	  (Figure	  5.6,	  A).	  	  There	  was	  also	  a	  decrease	  in	  methylation	  in	  TMX2-­‐4	  and	  TMX2-­‐11.	  	  An	  increase	  in	  CK17	  expression	  was	  observed	  in	  TMX2-­‐11	  but	  not	  TMX2-­‐4	  (Figure	  5.6,	  C).	  	  This	  inverse	  relationship	  between	  DNA	  promoter	  methylation	  and	  protein	  expression	  may	  indicate	  that	  promoter	  methylation	  regulates	  expression	  of	  CK17	  in	  TMX2-­‐11	  and	  TMX2-­‐28.	  	  A	  different	  mechanism	  may	  be	  responsible	  for	  regulating	  expression	  of	  CK17	  in	  TMX2-­‐4.	  	  Additionally,	  the	  mean	  average	  beta	  values	  for	  KRT17	  loci	  for	  each	  cell	  line	  decreased	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  Mean	  Methylation	  of	  KRT17	  loci	  in	  TMX2-­‐28	  had	  the	  largest	  change	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment,	  decreasing	  from	  0.51	  to	  0.39	  (Figure	  5.6,	  B).	  	  Therefore,	  I	  would	  predict	  a	  corresponding	  increase	  in	  CK17	  expression	  in	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  TMX2-­‐28.	  
	   The	  majority	  of	  CpGs	  in	  the	  promoter	  of	  KRT18	  have	  low	  methylation	  (with	  the	  exception	  of	  2	  CpGs	  MAPINFO	  numbers:	  53341686	  and	  53342553)	  for	  MCF-­‐7,	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28.	  	  The	  mean	  average	  beta	  values	  for	  all	  KRT18	  loci	  for	  the	  four	  cell	  lines	  range	  from	  0.18	  –	  0.20	  and	  all	  four	  cell	  lines	  have	  high	  expression	  of	  CK18	  (Figure	  5.7,	  A).	  	  Low	  promoter	  methylation	  along	  with	  high	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protein	  expression	  suggests	  possible	  regulation	  of	  gene	  expression	  by	  promoter	  methylation.	  	  It	  is	  also	  interesting	  to	  note	  that	  for	  CpG	  sites	  MAPINFO	  numbers	  53341319,	  53341686,	  53341805	  and	  53342553,	  the	  methylation	  pattern	  for	  MCF-­‐7	  is	  similar	  to	  that	  of	  TMX2-­‐11	  while	  the	  methylation	  pattern	  for	  TMX2-­‐4	  is	  more	  similar	  to	  TMX2-­‐28	  than	  the	  other	  cell	  lines.	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  had	  little	  effect	  on	  KRT18	  methylation,	  as	  the	  mean	  average	  beta	  values	  ranged	  from	  0.16	  –	  0.20	  (Figure	  5.7,	  B).	  	   The	  IHC	  staining	  shows	  no	  expression	  of	  the	  luminal	  cytokeratin,	  CK20,	  in	  MCF-­‐7,	  TMX2-­‐4,	  TMX2-­‐11	  or	  TMX2-­‐28.	  	  Interestingly,	  the	  majority	  of	  the	  CpG	  sites	  for	  the	  KRT20	  gene	  represented	  on	  the	  450	  BeadChip	  are	  either	  in	  the	  TSS1500	  or	  first	  exon	  and	  have	  high	  methylation	  (mean	  average	  beta	  values	  range	  from	  0.61	  –	  0.74)	  with	  the	  exception	  of	  CpG	  site	  MAPINFO	  number	  39041602	  having	  low	  methylation	  in	  each	  cell	  line	  (Figure	  5.8,	  A).	  	  As	  with	  the	  methylation	  pattern	  observed	  for	  KRT18,	  the	  methylation	  patterns	  for	  MCF-­‐7	  and	  TMX2-­‐11	  are	  more	  similar	  to	  each	  other	  than	  the	  other	  cell	  lines,	  while	  the	  methylation	  patterns	  for	  TMX2-­‐4	  and	  TMX2-­‐28	  are	  more	  similar	  to	  each	  other	  than	  the	  other	  cell	  lines.	  	  Interestingly,	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreased	  the	  mean	  average	  beta	  value	  for	  KRT20	  loci	  in	  MCF-­‐7,	  TMX2-­‐11	  and	  TMX2-­‐28.	  	  TMX2-­‐28	  had	  the	  greatest	  decrease	  in	  mean	  average	  beta	  value	  from	  0.61	  in	  the	  control	  to	  0.46	  in	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  cells	  (Figure	  5.8,	  B).	  	  I	  would	  predict	  CK20	  expression	  to	  increase	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  in	  MCF-­‐7,	  TMX2-­‐11	  and	  TMX2-­‐28	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  TMX2-­‐28	  having	  the	  highest	  expression	  of	  CK20.	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Expression	  of	  the	  Basal	  Cytokeratins,	  CK1,	  CK6	  and	  CK10,	  the	  Luminal	  
Cytokeratin,	  CK17,	  and	  p63	  Does	  Not	  Appear	  to	  Be	  Regulated	  by	  Promoter	  
Methylation	  
KRT1	  and	  KRT10	  Expression	  is	  Not	  Regulated	  by	  Promoter	  Methylation	  
	   There	  is	  no	  protein	  expression	  of	  the	  basal	  cytokeratins	  CK1,	  CK6	  or	  CK10	  (recognized	  by	  the	  34βE12	  antibody)	  in	  MCF-­‐7,	  TMX2-­‐4,	  TMX2-­‐11	  or	  TMX2-­‐28	  (Table	  5.1).	  	  Methylation	  of	  the	  promoter	  CpG	  sites	  represented	  on	  the	  450	  BeadChip	  for	  the	  KRT1	  gene	  are	  approximately	  0.20	  for	  each	  of	  the	  four	  cell	  lines	  (mean	  average	  beta	  values	  for	  all	  KRT1	  cites	  are	  higher	  and	  range	  from	  0.42	  –	  0.55)	  (Figure	  5.9,	  A).	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreased	  KRT1	  methylation	  in	  each	  cell	  line	  except	  TMX2-­‐4.	  	  TMX2-­‐28	  was	  most	  affected	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  with	  a	  decrease	  of	  12%	  in	  methylation	  (Figure	  5.9,	  B).	  	  It	  would	  be	  interesting	  to	  determine	  whether	  this	  change	  in	  methylation	  would	  result	  in	  increased	  expression	  of	  CK1.	  	   There	  are	  three	  transcripts	  of	  the	  CK6	  gene	  represented	  on	  the	  450	  BeadChip,	  KRT6A,	  KRT6B	  and	  KRT6C.	  	  Because	  Ventana	  does	  not	  disclose	  which	  one	  the	  CK5/6	  antibody	  recognizes,	  I	  examined	  DNA	  methylation	  in	  all	  three	  transcripts.	  	  DNA	  methylation	  in	  the	  cell	  lines	  is	  similar	  for	  all	  three	  transcripts	  (Figure	  5.10,	  A,	  B	  and	  C)	  and	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreases	  the	  mean	  average	  beta	  value	  for	  each	  cell	  line,	  except	  TMX2-­‐4	  (Figure	  5.10,	  D,	  E	  and	  F).	  	  The	  CK5/6	  antibody	  should	  detect	  protein	  expression	  of	  CK5	  and	  CK6.	  	  However,	  none	  of	  the	  cell	  lines	  had	  positive	  staining	  with	  the	  CK5/6	  antibody	  yet	  20%	  of	  TMX2-­‐28	  cells	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were	  positive	  for	  CK5	  determined	  by	  IHC	  staining	  with	  the	  individual	  antibody	  against	  CK5	  (Figure	  5.3).	  	  It	  would	  be	  interesting	  to	  examine	  CK6	  expression	  with	  an	  individual	  antibody	  to	  determine	  whether	  CK5/6	  staining	  is	  an	  accurate	  representation	  of	  protein	  expression.	  	  Methylation	  of	  KRT10	  is	  low	  and	  similar	  for	  MCF-­‐7,	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28	  (mean	  average	  beta	  values	  range	  from	  0.40	  –	  0.47).	  	  Methylation	  of	  several	  CpGs	  in	  the	  promoter	  region	  is	  decreased	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7.	  	  However,	  there	  is	  no	  protein	  expression	  of	  CK10	  determined	  by	  34βE12	  antibody	  staining	  for	  any	  of	  the	  cell	  lines	  (Figure	  5.11,	  A).	  	  As	  observed	  previously,	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  has	  the	  greatest	  effect	  on	  methylation	  of	  KRT10	  in	  TMX2-­‐28,	  resulting	  in	  a	  decrease	  of	  8%	  (Figure	  5.11,	  B).	  	  However,	  it	  is	  not	  known	  whether	  this	  small	  decrease	  in	  methylation	  would	  result	  in	  an	  increase	  in	  protein	  expression.	  
	  
IHC	  Results	  from	  the	  34βE12	  Antibody	  are	  Inconclusive	  The	  other	  basal	  cytokeratins	  recognized	  by	  the	  34βE12	  antibody	  are	  CK5	  and	  CK14.	  	  Although	  protein	  expression	  of	  CK5	  and	  CK14	  was	  detected	  in	  TMX2-­‐28	  with	  the	  individual	  antibody	  against	  each,	  there	  was	  no	  expression	  detected	  in	  any	  of	  the	  cell	  lines	  with	  the	  34βE12	  antibody	  (Table	  5.1).	  	  Expression	  of	  CK5	  and	  CK14	  both	  seem	  to	  be	  regulated	  by	  promoter	  methylation	  in	  TMX2-­‐28	  (Figures	  5.3	  and	  5.4).	  	  However	  the	  IHC	  results	  obtained	  with	  the	  individual	  antibodies	  do	  not	  agree	  with	  those	  from	  the	  34βE12	  antibody	  (Figure	  5.12),	  therefore	  it	  would	  be	  best	  to	  examine	  the	  expression	  of	  CK1,	  CK6	  and	  CK10	  with	  individual	  antibodies	  as	  well.	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Expression	  of	  p63	  is	  Not	  Regulated	  by	  Promoter	  Methylation	  According	  to	  the	  IHC	  results	  (Table	  5.1),	  there	  is	  no	  expression	  of	  p63	  in	  MCF-­‐7,	  TMX2-­‐4,	  TMX2-­‐11	  or	  TMX2-­‐28.	  	  Looking	  at	  the	  CpG	  sites	  on	  the	  450	  BeadChip	  which	  correspond	  to	  the	  TP63	  gene	  (filtering	  CpG	  sites	  by	  Refgene	  name	  has	  NM_001114978,	  NM_001114979,	  or	  NM_003722,	  which	  also	  contains	  some	  of	  the	  CpG	  sites	  for	  the	  ΔNp63	  isoform	  of	  TP63	  (p40,	  see	  Figure	  5.2),	  most	  of	  the	  CpGs	  located	  in	  the	  promoter	  of	  TP63	  are	  highly	  methylated	  in	  MCF-­‐7,	  TMX2-­‐4	  and	  TMX2-­‐11	  (Figure	  5.13,	  A).	  	  While	  several	  of	  these	  sites	  have	  decreased	  methylation	  in	  TMX2-­‐28,	  there	  is	  not	  a	  corresponding	  increase	  in	  protein	  expression	  in	  TMX2-­‐28.	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreased	  methylation	  in	  each	  cell	  line	  except	  TMX2-­‐4,	  as	  observed	  with	  several	  of	  the	  cytokeratin	  genes.	  	  TMX2-­‐28	  had	  the	  largest	  decrease	  in	  methylation	  with	  a	  mean	  average	  beta	  value	  of	  0.65	  in	  TMX2-­‐28-­‐Control	  and	  0.49	  in	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  TMX2-­‐28	  (Figure	  5.13,	  B).	  	  It	  would	  be	  interesting	  to	  determine	  whether	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  increased	  p63	  expression	  in	  the	  cell	  lines.	  	  
Discussion	  According	  to	  the	  methylation	  status	  determined	  by	  the	  450	  BeadChip	  and	  protein	  expression	  determined	  by	  IHC	  for	  the	  parental	  cell	  line	  and	  the	  three	  tamoxifen-­‐resistant	  cell	  lines,	  promoter	  methylation	  seems	  to	  play	  a	  role	  in	  regulating	  expression	  of	  p40,	  the	  basal	  cytokeratins	  CK5	  and	  CK14,	  and	  the	  luminal	  cytokeratins	  CK8,	  CK17,	  CK18	  and	  CK20.	  	  This	  is	  because	  the	  patterns	  in	  methylation	  observed	  among	  the	  four	  cell	  lines	  along	  with	  the	  IHC	  results	  are	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consistent	  with	  the	  idea	  that	  promoter	  methylation	  decreases	  gene	  expression.	  	  However,	  promoter	  methylation	  does	  not	  appear	  to	  regulate	  expression	  of	  p63,	  or	  the	  basal	  cytokeratins,	  CK1,	  CK6,	  CK10.	  	  In	  the	  literature	  little	  is	  known	  about	  the	  role	  of	  promoter	  methylation	  and	  regulation	  of	  gene	  expression	  of	  p40,	  p63	  and	  cytokeratins	  in	  breast	  cancer.	  	  Interestingly	  methylation	  has	  been	  shown	  to	  play	  a	  role	  in	  regulating	  expression	  of	  p40,	  p63,	  CK8,	  CK17,	  CK18	  in	  other	  types	  of	  cancers.	  	  Hypermethylation	  of	  a	  5’-­‐flanking	  CpG	  region	  of	  p51	  or	  p63	  was	  observed	  in	  hematological	  cancer	  cell	  lines	  lacking	  expression	  of	  p63.	  129	  TP63	  is	  also	  methylated	  in	  b-­‐cell	  lymphoma	  lines.	  130	  There	  is	  also	  evidence	  that	  p63	  and	  ΔNp63	  (p40)	  expression	  is	  regulated	  by	  methylation	  in	  bladder	  cancer	  cell	  lines.	  	  Treatment	  of	  some	  bladder	  cell	  lines	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  increased	  expression	  of	  p63	  and	  ΔNp63.	  131	  This	  finding	  is	  consistent	  with	  the	  results	  presented	  here,	  that	  p40	  methylation	  is	  high	  in	  all	  four	  cell	  lines	  with	  no	  protein	  expression	  (Figure	  5.2).	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreases	  methylation	  in	  TMX2-­‐28	  and	  I	  would	  predict	  this	  results	  in	  increased	  protein	  expression	  of	  p40.	  	  However	  p40	  protein	  expression	  after	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  was	  not	  quantified.	  	  In	  the	  present	  study,	  p63	  expression	  does	  not	  seem	  to	  be	  regulated	  by	  promoter	  methylation	  as	  methylation	  is	  generally	  high	  in	  MCF-­‐7,	  TMX2-­‐4	  and	  TMX2-­‐11,	  but	  lower	  in	  TMX2-­‐28	  yet	  none	  of	  the	  cell	  lines	  have	  protein	  expression	  (Figure	  5.12).	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreases	  p63	  methylation	  in	  TMX2-­‐28	  and	  I	  would	  predict	  this	  results	  in	  increased	  protein	  expression.	  	  However,	  Park	  and	  colleagues	  also	  found	  that	  certain	  bladder	  cancer	  cell	  lines	  had	  decreased	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expression	  of	  p63	  and	  p40	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  131	  To	  date	  it	  is	  not	  known	  whether	  p40	  or	  p63	  protein	  expression	  increases	  in	  breast	  cancer	  cells	  after	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  	  There	  is	  some	  evidence	  in	  the	  literature	  indicating	  that	  methylation	  may	  play	  a	  role	  in	  regulating	  expression	  of	  CK8.	  	  Certain	  squamous	  cell	  carcinoma	  lines	  have	  increased	  methylation	  and	  corresponding	  decreased	  expression	  of	  CK8.	  132	  The	  gene	  encoding	  CK8,	  KRT8,	  was	  found	  to	  by	  hypomethylated	  with	  increased	  expression	  in	  samples	  of	  breast	  cancer	  brain	  metastases.	  133	  Similarly,	  treatment	  of	  mouse	  utricle	  epithelia-­‐derived	  progenitor	  cells	  (MUCs),	  which	  are	  stem-­‐cell	  like	  cells	  similar	  to	  prosensory	  cells	  which	  become	  inner	  ear	  epithelial	  hair	  cells	  and	  supporting	  cells	  during	  development,	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  resulted	  in	  increased	  expression	  of	  CK8	  amongst	  other	  genes	  as	  well	  as	  decreased	  global	  methylation.	  134	  Another	  study	  found	  13	  of	  20	  interrogated	  CpG	  sites	  in	  KRT8	  to	  be	  hypermethylated,	  which	  was	  correlated	  with	  decreased	  expression	  in	  mouse	  colon	  cells.	  135	  These	  findings	  agree	  with	  the	  results	  presented	  here,	  as	  promoter	  methylation	  of	  KRT8	  is	  low	  and	  expression	  of	  CK8	  is	  high	  in	  all	  cell	  lines	  (Figure	  5.5).	  Methylation	  is	  also	  thought	  to	  regulate	  expression	  of	  CK18.	  	  In	  rat	  small	  intestine	  cells,	  KRT18	  is	  hypermethylated	  and	  gene	  expression	  is	  downregulated.	  135	  Similarly,	  treatment	  of	  MUCs	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreases	  global	  methylation	  and	  increases	  expression	  of	  KRT18.	  134	  With	  all	  four	  of	  the	  cell	  lines	  utilized	  in	  this	  project,	  the	  majority	  of	  CpG	  sites	  on	  the	  450	  BeadChip	  for	  KRT18	  have	  low	  methylation	  and	  each	  cell	  line	  has	  high	  expression	  of	  CK18	  (Figure	  5.7).	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Therefore,	  the	  results	  presented	  here	  are	  congruent	  with	  previously	  published	  findings.	  The	  luminal	  cytokeratin	  CK17	  has	  very	  low	  expression	  in	  MCF-­‐7	  and	  TMX2-­‐4.	  	  However,	  10-­‐15%	  of	  TMX2-­‐11	  cells	  stained	  positive	  for	  CK17	  and	  20-­‐25%	  of	  TMX2-­‐28	  cells	  were	  positive	  for	  CK17	  (Figure	  5.6).	  	  High	  CK17	  expression	  is	  associated	  with	  a	  poor	  prognosis	  for	  cervical	  cancer	  patients.	  	  In	  human	  cervix,	  breast	  and	  pancreatic	  cancer	  cells,	  CK17	  can	  be	  released	  from	  intermediate	  filaments	  and	  translocate	  to	  the	  nucleus.	  	  CK17	  then	  binds	  the	  cyclin	  dependent	  kinase	  inhibitor,	  p27,	  and	  facilitates	  nuclear	  export	  of	  p27	  and	  subsequent	  degradation.	  	  This	  contributes	  to	  sustaining	  proliferation	  and	  tumorigenesis.	  	  Expression	  of	  CK17	  and	  p27	  are	  inversely	  correlated	  in	  clinical	  cervical	  cancer	  samples.	  136	  Interestingly,	  previous	  work	  in	  our	  lab	  has	  shown	  that	  TMX2-­‐28	  cells	  express	  high	  levels	  of	  S-­‐phase	  kinase-­‐associated	  protein	  2(SKP2),	  which	  also	  targets	  p27	  for	  degradation	  by	  phosphorylating	  p27	  at	  Thr187.	  	  SKP2	  therefore	  promotes	  entry	  into	  S-­‐phase	  of	  the	  cell	  cycle.	  	  Although	  TMX2-­‐28	  cells	  overexpress	  SKP2,	  they	  do	  not	  have	  reduced	  levels	  of	  p27.	  	  However,	  knockdown	  of	  SKP2	  in	  TMX2-­‐28	  prevents	  phosphorylation	  of	  p27	  at	  Ser10	  and	  inhibits	  proliferation.	  39	  Therefore,	  because	  TMX2-­‐28	  do	  not	  have	  reduced	  p27	  expression	  and	  CK17	  contributes	  to	  p27	  degradation,	  I	  would	  predict	  low	  expression	  of	  CK17	  in	  TMX2-­‐28.	  	  According	  to	  the	  IHC	  results	  (Table	  5.1),	  20-­‐25%	  of	  TMX2-­‐28	  cells	  express	  a	  high	  level	  of	  CK17.	  	  This	  percentage	  of	  CK17-­‐positive	  cells	  is	  greater	  for	  TMX2-­‐28	  than	  for	  MCF-­‐7,	  TMX2-­‐4	  or	  TMX2-­‐11.	  	  I	  would	  predict	  this	  subpopulation	  of	  TMX2-­‐28	  cells,	  which	  express	  CK17,	  to	  have	  low	  expression	  of	  p27	  and	  therefore	  increased	  proliferation.	  	  Perhaps	  the	  high	  level	  of	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CK17	  in	  this	  subpopulation	  of	  TMX2-­‐28	  contributes	  to	  degradation	  of	  p27	  and	  promotes	  proliferation.	  	   Despite	  a	  small	  portion	  (20%)	  of	  TMX2-­‐28	  cells	  staining	  positive	  for	  CK5,	  there	  was	  no	  positive	  staining	  with	  the	  CK5/6	  antibody	  (Table	  5.1).	  	  The	  CK5/6	  antibody	  can	  distinguish	  between	  cancerous	  and	  non-­‐cancerous	  ductal	  proliferation.	  137	  However,	  the	  sensitivity	  and	  intensity	  of	  individual	  CK5	  antibody	  staining	  is	  higher	  than	  that	  of	  CK5/6	  antibody	  cocktails.	  138	  The	  cell	  line	  slides	  for	  IHC	  were	  fixed	  in	  methanol,	  a	  non-­‐cross-­‐linking	  fixative.	  	  Fixation	  with	  methanol	  removes	  water	  and	  disrupts	  hydrophobic	  bonds	  and	  hydrogen	  bonds,	  which	  causes	  protein	  unfolding.	  	  This	  denaturation	  may	  affect	  immunoreactivity	  depending	  on	  the	  nature	  of	  the	  antigen	  or	  antibody	  in	  this	  case.	  139	  The	  sensitivity	  of	  the	  detection	  kit	  also	  may	  have	  contributed	  to	  the	  discrepancy	  as	  different	  detection	  kits	  were	  used	  for	  the	  CK5	  and	  CK5/6	  antibody.	  	  This	  same	  reasoning	  may	  also	  explain	  the	  inconsistency	  between	  staining	  with	  the	  34βE12	  antibody	  and	  the	  individual	  CK5	  and	  CK14	  antibodies.	  	  The	  34βE12	  antibody	  should	  recognize	  the	  basal	  cytokeratins,	  CK1,	  CK5,	  CK10	  and	  CK14.	   Neither	  MCF-­‐7,	  TMX2-­‐4,	  TMX2-­‐11	  nor	  TMX2-­‐28	  cells	  had	  positive	  staining	  with	  the	  34βE12	  antibody	  (Table	  5.1).	  	  However,	  a	  small	  population	  of	  TMX2-­‐28	  cells	  stained	  positive	  for	  the	  individual	  antibodies	  against	  CK5	  and	  CK14.	  	  This	  could	  be	  attributed	  to	  variations	  in	  the	  antibody	  recognition	  site	  between	  antibodies,	  denaturation	  of	  antigen	  or	  differences	  in	  sensitivity	  of	  the	  antibodies	  or	  detection	  kits.	  	   The	  results	  presented	  here	  with	  regard	  to	  cytokeratin	  expression	  indicate	  that	  MCF-­‐7,	  TMX2-­‐4	  and	  TMX2-­‐11	  express	  luminal	  (low	  molecular	  weight)	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cytokeratins	  while	  TMX2-­‐28	  express	  a	  combination	  of	  luminal	  and	  basal	  cytokeratins.	  	  These	  new	  IHC	  data	  are	  consistent	  with	  previously	  published	  work	  from	  our	  lab75	  and	  demonstrate	  that	  TMX2-­‐28	  have	  a	  mixed	  basal-­‐luminal	  phenotype.	  	  The	  data	  from	  the	  450	  BeadChip	  indicate	  that	  DNA	  promoter	  methylation	  may	  be	  involved	  in	  regulating	  expression	  of	  p40,	  CK5,	  CK14,	  CK8,	  CK17,	  CK18	  and	  CK20	  in	  breast	  cancer	  cells.	  	  The	  role	  of	  methylation	  in	  regulation	  of	  gene	  expression	  could	  be	  verified	  by	  examining	  protein	  expression	  in	  cells	  treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  or	  a	  demethylating	  agent	  and	  confirming	  the	  degree	  of	  DNA	  methylation	  by	  pyrosequencing.	  	  DNA	  methylation	  of	  cytokeratin	  genes	  may	  be	  useful	  as	  an	  alternative	  indication	  of	  tumor	  subtype.	  	  Furthermore,	  analysis	  of	  methylation	  patterns	  in	  patient	  samples	  would	  further	  validate	  the	  use	  of	  these	  cell	  lines	  to	  study	  drug	  resistant	  breast	  cancer.	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Table	  5.1	  Cytokeratin,	  p40	  and	  p63	  Expression	  Determined	  by	  IHC	  for	  Cell	  
Lines	  




Figure	  5.1:	  Components	  of	  the	  Cytoskeleton.	  Three-­‐dimensional	  cross	  section	  view	  of	  a	  cell	  showing	  the	  three	  components	  of	  the	  cytoskeleton;	  intermediate	  filaments,	  microtubules	  and	  microfilaments/	  actin	  filaments.	  Intermediate	  filaments	  are	  composed	  of	  specific	  fibrous	  proteins	  such	  as	  keratins	  and	  desmins.	  	  Microtubules	  are	  hollow	  tubes	  made	  up	  of	  alpha-­‐	  and	  beta-­‐	  tubulin	  assembled	  into	  protofilaments.	  	  Microfilaments	  or	  actin	  filaments	  are	  made	  of	  interlaced	  actin	  chains.	  Image	  modified	  from	  140.	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(A)	  




Figure	  5.2:	  p40	  is	  Highly	  Methylated	  in	  All	  Cell	  Lines.	  Heat	  map	  indicating	  average	  beta	  values	  of	  CpG	  sites	  on	  the	  450K	  BeadChip	  for	  the	  ΔNp63	  isoform	  of	  the	  TP63	  gene	  (recognized	  by	  the	  p40	  antibody)	  for	  each	  cell	  line	  (A)	  and	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  cell	  lines	  (B).	  	  Average	  beta	  value	  is	  represented	  by	  the	  scale,	  highest	  methylation	  value	  (1)	  in	  red	  and	  lowest	  methylation	  value	  (0)	  in	  green	  (see	  scale	  at	  right).	  	  Refgene	  group	  and	  MAPINFO	  number	  for	  each	  CpG	  site	  are	  listed	  to	  the	  left	  of	  each	  heat	  map.	  	  Mean	  average	  beta	  values	  of	  all	  CpG	  sites	  for	  each	  cell	  line	  are	  listed	  under	  the	  corresponding	  columns.	  	  IHC	  results	  are	  also	  listed	  for	  each	  cell	  line	  under	  the	  corresponding	  columns	  as	  percentage	  of	  positive	  cells	  and	  intensity	  (-­‐:	  no	  staining).	  










Figure	  5.3:	  CK5	  Expression	  May	  Be	  Regulated	  by	  Promoter	  Methylation	  in	  
TMX2-­‐28.	  Heatmap	  indicating	  average	  beta	  values	  of	  CpG	  sites	  in	  the	  KRT5	  gene	  for	  each	  cell	  line	  (A)	  and	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  cell	  lines	  (B).	  	  Average	  beta	  value	  is	  represented	  by	  the	  scale,	  highest	  methylation	  value	  (1)	  in	  red	  and	  lowest	  methylation	  value	  (0)	  in	  green	  (see	  scale	  at	  right).	  	  Refgene	  group	  and	  MAPINFO	  number	  for	  each	  CpG	  site	  are	  listed	  to	  the	  left	  of	  each	  heat	  map.	  	  Mean	  average	  beta	  values	  of	  all	  CpG	  sites	  for	  each	  cell	  line	  are	  listed	  under	  the	  corresponding	  columns.	  	  IHC	  results	  are	  also	  listed	  for	  each	  cell	  line	  under	  the	  corresponding	  columns	  as	  percentage	  of	  positive	  cells	  and	  intensity	  (-­‐:	  no	  staining).	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Figure	  5.6:	  CK17	  Expression	  May	  Be	  Regulated	  by	  Promoter	  Methylation.	  Heatmap	  indicating	  methylation	  of	  CpG	  sites	  in	  KRT17	  gene,	  represented	  by	  average	  beta	  values	  (scale	  at	  right),	  and	  corresponding	  protein	  expression	  determined	  by	  IHC	  for	  each	  cell	  line	  (A)	  and	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  cell	  lines	  (B).	  	  Orange	  box	  indicates	  three	  CpGs	  in	  the	  promoter	  with	  decreased	  methylation	  in	  TMX2-­‐28	  compared	  to	  MCF-­‐7.	  	  Left:	  Refgene	  Group	  location	  and	  MAPINFO	  number	  for	  each	  CpG	  site.	  	  Bottom:	  Mean	  average	  beta	  values	  for	  all	  CpGs	  and	  percent	  positive	  cells	  and	  intensity	  determined	  from	  IHC	  scoring.	  	  Representative	  images	  of	  IHC	  slides	  stained	  for	  CK17	  in	  the	  positive	  control	  and	  MCF-­‐7,	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28	  (C).	  	  Magnification	  =	  200X.	  
	  
























Figure	  5.9:	  Expression	  of	  CK1	  Does	  Not	  Appear	  to	  be	  Regulated	  by	  Promoter	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Figure	  5.10.	  CK6	  Expression	  Does	  Not	  Appear	  to	  be	  Regulated	  by	  Promoter	  
Methylation.	  Heatmap	  indicating	  methylation	  of	  CpG	  sites	  in	  KRT6A	  (A),	  KRT6B	  (B)	  and	  KRT6C	  (C)	  gene,	  represented	  by	  average	  beta	  values	  (scale	  at	  right),	  and	  corresponding	  protein	  expression	  determined	  by	  IHC	  for	  each	  cell	  line	  and	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  cell	  lines	  for	  KRT6A	  (D),	  KRT6B	  (E)	  and	  KRT6C	  (F).	  	  Left:	  Refgene	  Group	  location	  and	  MAPINFO	  number	  for	  each	  CpG	  site.	  	  Bottom:	  Mean	  average	  beta	  values	  for	  all	  CpGs	  and	  percent	  positive	  cells	  and	  intensity	  determined	  from	  IHC	  scoring	  (recognized	  by	  the	  34βE12	  antibody,	  (-­‐:	  no	  staining).	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Figure	  5.11:	  Expression	  of	  CK10	  Does	  Not	  Appear	  to	  be	  Regulated	  by	  Promoter	  




Figure	  5.12:	  IHC	  Staining	  with	  Pan	  Cytokeratin	  Antibodies	  and	  Individual	  CK	  Antibodies.	  Representative	  images	  for	  staining	  of	  positive	  controls	  and	  TMX2-­‐28	  with	  the	  34βE12	  antibody	  and	  the	  antibodies	  recognizing	  CK5/6,	  CK5	  and	  CK14.	  	  Magnification	  =	  200X.	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(A)	  
	  (Figure	  5.13)	  
	  




Figure	  5.13:	  Expression	  of	  p63	  is	  Not	  Regulated	  by	  Promoter	  Methylation.	  Heatmap	  indicating	  methylation	  of	  CpG	  sites	  for	  TP63	  (filtering	  in	  Genome	  Studio	  for	  CpG	  sites	  that	  have	  Refgene	  name	  equal	  to	  NM_001114978,	  NM_001114979,	  or	  NM_003722,	  this	  overlaps	  with	  some	  of	  the	  CpG	  sites	  contained	  in	  the	  ΔNp63	  isoform)	  represented	  by	  average	  beta	  values	  (scale	  at	  right)	  for	  each	  cell	  line	  (A)	  and	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  cell	  lines	  (B).	  	  Left:	  Refgene	  Group	  location	  and	  MAPINFO	  number	  for	  each	  CpG	  site.	  	  Bottom:	  Mean	  average	  beta	  values	  for	  all	  CpGs	  and	  percent	  positive	  cells	  and	  intensity	  determined	  from	  IHC	  scoring	  (recognized	  by	  the	  34βE12	  antibody,	  (-­‐:	  no	  staining).	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CHAPTER	  6	  
DISCUSSION	  AND	  FUTURE	  DIRECTIONS	  
	  
Introduction	  	   Breast	  cancer	  is	  a	  heterogeneous	  disease	  and	  affects	  women	  of	  all	  ages.	  	  Approximately	  one	  of	  eight	  women	  will	  develop	  breast	  cancer	  throughout	  their	  lifetime.	  2	  During	  carcinogenesis	  breast	  cancer	  cells	  acquire	  certain	  characteristics	  that	  allow	  for	  escape	  of	  normal	  cell	  regulatory	  processes.	  	  These	  traits,	  also	  known	  as	  hallmarks	  of	  cancer,	  apply	  to	  every	  type	  of	  cancer	  and	  allow	  cancer	  cells	  to,	  for	  example,	  sustain	  growth	  signaling,	  evade	  the	  immune	  system	  and	  disseminate	  to	  other	  parts	  of	  the	  body.	  7,8	  	  Expression	  of	  hormone	  receptors	  is	  one	  of	  the	  most	  important	  aspects	  in	  terms	  of	  identifying	  breast	  cancer	  subtypes,	  determining	  prognosis	  and	  predicting	  response	  to	  therapy.	  	  About	  70%	  of	  breast	  cancers	  express	  estrogen	  receptor	  alpha	  (ER)	  and	  can	  be	  treated	  with	  the	  antiestrogen	  tamoxifen.	  23	  However,	  about	  one-­‐third	  of	  women	  treated	  with	  tamoxifen	  for	  5	  years	  will	  have	  a	  recurrence.	  26	  This	  presents	  a	  huge	  clinical	  obstacle	  because	  these	  patients	  have	  limited	  treatment	  options.	  	  Changes	  in	  DNA	  methylation	  and	  epigenetics	  are	  implicated	  in	  cancer	  development	  and	  specifically	  tamoxifen	  resistance.	  	  Aberrant	  DNA	  methylation	  is	  an	  early	  event	  in	  carcinogenesis13	  and	  is	  known	  to	  occur	  in	  breast	  cancer.	  16	  Alterations	  in	  DNA	  methylation	  occur	  in	  ER-­‐positive,	  tamoxifen-­‐resistant	  cell	  lines.	  25,27,31	  However,	  the	  role	  of	  DNA	  methylation	  in	  ER-­‐negative,	  tamoxifen-­‐resistant	  disease	  is	  not	  well	  understood.	  	  The	  goal	  of	  this	  project	  was	  to	  evaluate	  the	  role	  of	  DNA	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methylation	  in	  ER-­‐negative,	  tamoxifen-­‐resistant	  disease	  and	  the	  use	  of	  the	  DNMT1-­‐inhibitor,	  5-­‐Aza-­‐2’-­‐deoxycytidine,	  as	  a	  potential	  epigenetic	  therapy	  for	  ER-­‐negative	  recurrent	  disease.	  	   In	  this	  study,	  I	  use	  three	  tamoxifen-­‐resistant	  cell	  lines,	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28,	  selected	  from	  the	  parental	  cell	  line,	  MCF-­‐7,	  after	  exposure	  to	  tamoxifen	  for	  6	  months.	  	  TMX2-­‐4	  and	  TMX2-­‐11	  cells	  express	  ER,	  but	  are	  resistant	  to	  tamoxifen,	  while	  TMX2-­‐28	  cells	  lost	  expression	  of	  ER.	  37	  Using	  the	  Illumina	  Human	  Methylation	  450	  BeadChip,	  I	  confirmed	  results	  of	  a	  previous	  study31	  indicating	  that	  TMX2-­‐11	  and	  TMX2-­‐28	  are	  differentially	  methylated	  with	  respect	  to	  the	  parental	  cell	  line,	  MCF-­‐7.	  	  TMX2-­‐4	  cells	  also	  exhibit	  differential	  methylation	  compared	  to	  MCF-­‐7.	  	  Additionally,	  I	  found	  MCF-­‐7	  cells	  and	  the	  three	  tamoxifen-­‐resistant	  cell	  lines	  each	  respond	  differently	  to	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  Also	  in	  agreement	  with	  previous	  work,	  75	  expression	  of	  a	  mixed	  basal	  and	  luminal	  cytokeratin	  profile	  was	  confirmed	  in	  TMX2-­‐28	  by	  immunohistochemistry	  (IHC).	  	  
DNA	  Methylation	  Patterns	  Differ	  Between	  the	  Parental	  and	  	  
Tamoxifen-­‐resistant	  Cell	  Lines	  	   DNA	  methylation	  is	  an	  epigenetic	  modification	  that	  can	  be	  altered	  in	  cancer	  cells.	  	  CpG	  sites	  are	  found	  throughout	  the	  genome	  and	  are	  typically	  methylated.	  	  Normally	  CpG	  islands	  located	  in	  gene	  promoters	  are	  unmethylated.	  	  However,	  CpG	  islands	  are	  frequently	  methylated	  in	  cancer	  and	  prevent	  transcription.	  20,30	  Methylation	  patterns	  in	  non-­‐promoter	  regions	  and	  gene	  body	  regions	  may	  also	  play	  a	  role	  in	  regulating	  transcription	  along	  with	  histone	  modifications.	  14,20,30	  Global	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hypomethylation	  is	  more	  common	  in	  breast	  cancer	  than	  other	  types	  of	  cancer.	  30	  Methylation	  of	  gene	  panels	  and	  CpG	  signature	  loci	  have	  been	  associated	  with	  breast	  cancer	  development	  and	  disease	  progression.	  141-­‐143	  Although	  ER-­‐positive	  breast	  cancers	  have	  been	  shown	  to	  have	  higher	  frequencies	  of	  methylation	  than	  ER-­‐negative	  cancers,	  hypermethylated	  CpG	  sites	  in	  ER-­‐negative	  cancers	  are	  usually	  closer	  to	  gene	  promoters.	  119	  Changes	  in	  DNA	  methylation	  have	  been	  found	  in	  ER-­‐positive,	  tamoxifen-­‐resistant	  cell	  lines.	  25,27,31	  However,	  little	  is	  known	  about	  the	  role	  of	  methylation	  in	  ER-­‐negative,	  tamoxifen-­‐resistant	  breast	  cancer.	  	  	  	   I	  first	  confirmed	  results	  from	  a	  previous	  study	  in	  our	  lab31indicating	  that	  TMX2-­‐28	  are	  hypermethylated	  compared	  to	  MCF-­‐7.	  	  The	  results	  from	  the	  Illumina	  Human	  Methylation	  450	  BeadChip	  confirmed	  that	  TMX2-­‐4,	  TMX2-­‐11	  and	  TMX2-­‐28	  have	  different	  methylation	  profiles	  than	  the	  parental	  line,	  MCF-­‐7	  (Figure	  2.3).	  	  This	  indicates	  that	  DNA	  methylation	  could	  be	  involved	  in	  resistance	  to	  tamoxifen	  in	  these	  cell	  lines.	  	  Next,	  I	  investigated	  changes	  in	  DNA	  methylation	  induced	  by	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine.	  	  Treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  caused	  cell	  line-­‐specific	  changes	  in	  DNA	  methylation,	  with	  TMX2-­‐28	  being	  the	  most	  sensitive	  cell	  line	  to	  the	  DNMT1-­‐inhibitor	  (Figure	  2.4).	  	  I	  also	  found	  global	  differences	  in	  mRNA	  expression	  between	  MCF-­‐7	  and	  TMX2-­‐28	  (Figure	  2.5).	  	  I	  hypothesized	  that	  differences	  in	  mRNA	  expression	  between	  TMX2-­‐28	  and	  MCF-­‐7	  were	  caused	  by	  differences	  in	  promoter	  methylation,	  which	  alter	  gene	  transcription.	  	  	  	   To	  identify	  genes	  with	  altered	  expression	  after	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  in	  TMX2-­‐28,	  I	  utilized	  DNA	  methylation	  data	  from	  the	  450	  BeadChip.	  	  I	  identified	  a	  set	  of	  27	  genes	  with	  increased	  methylation	  in	  TMX2-­‐28	  compared	  to	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MCF-­‐7	  that	  also	  had	  decreased	  methylation	  in	  the	  promoter	  after	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  (Table	  2.8).	  	  I	  predicted	  that	  the	  behavior	  of	  TMX2-­‐28	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  was	  the	  result	  of	  changes	  in	  gene	  expression	  due	  to	  changes	  in	  promoter	  methylation.	  
	  
5-­‐Aza-­‐2’-­‐deoxycytidine	  Alters	  DNA	  Methylation,	  Proliferation,	  Migration	  and	  
Adhesion	  in	  TMX2-­‐28	  
	   Preliminary	  studies	  in	  our	  lab	  indicated	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  inhibited	  proliferation	  in	  the	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  line,	  TMX2-­‐28	  (Figures	  3.1).	  	  I	  predicted	  that	  the	  behavior	  of	  TMX2-­‐28	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  was	  the	  result	  of	  changes	  in	  gene	  expression	  due	  to	  changes	  in	  promoter	  methylation.	  	  I	  also	  investigated	  whether	  5-­‐Aza-­‐2’-­‐deoxycytidine	  affected	  other	  aspects	  of	  cell	  behavior	  related	  to	  the	  hallmarks	  of	  cancer.	  	  First	  I	  verified	  previous	  results	  from	  our	  lab	  indicating	  that	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreased	  proliferation	  in	  TMX2-­‐28,	  but	  not	  the	  parental	  cell	  line,	  MCF-­‐7	  (Figure	  3.2).	  	  Then	  I	  wanted	  to	  determine	  whether	  5-­‐Aza-­‐2’-­‐deoxycytidine	  affects	  migration	  of	  TMX2-­‐28,	  which	  have	  been	  shown	  to	  be	  more	  migratory	  and	  invasive	  than	  MCF-­‐7	  cells.	  38,74	  The	  2-­‐dimensional	  scratch-­‐wound	  assay	  showed	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  inhibits	  the	  migratory	  ability	  of	  TMX2-­‐28	  while	  promoting	  migration	  in	  MCF-­‐7	  (Figure	  3.5).	  	  This	  experiment	  also	  indicating	  that	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  promotes	  TMX2-­‐28	  detachment	  from	  the	  monolayer	  (Figure	  3.4)	  and	  decrease	  TMX2-­‐28	  cell	  viability	  (Figure	  3.5).	  	  Further	  experiments	  confirmed	  that	  treatment	  of	  TMX2-­‐28	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  inhibits	  cell	  adhesion	  to	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fibronectin.	  	  However,	  5-­‐Aza-­‐2’-­‐deoxycytidine	  does	  not	  affect	  adhesion	  of	  MCF-­‐7	  cells	  to	  fibronectin	  (Figures	  3.7	  and	  3.8).	  	   Based	  on	  these	  results	  and	  the	  genes	  identified	  from	  the	  methylation	  analysis,	  TROP2	  was	  identified	  as	  a	  candidate	  for	  regulating	  the	  behavior	  of	  TMX2-­‐28	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  TROP2,	  the	  protein	  encoded	  by	  the	  TACSTD2	  gene,	  is	  silenced	  by	  DNA	  methylation	  in	  lung	  adenocarcinoma.	  	  Furthermore,	  treatment	  of	  lung	  cancer	  cell	  lines	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreased	  promoter	  methylation	  and	  increased	  TROP2	  expression.	  	  Forced	  expression	  of	  TROP2	  in	  lung	  cancer	  cell	  lines	  inhibits	  proliferation	  and	  colony	  formation	  by	  decreasing	  AKT	  and	  ERK	  activation.	  	  The	  authors	  found	  that	  TROP2	  inhibits	  IGF-­‐1R	  signaling	  and	  loss	  of	  TROP2	  in	  lung	  cancer	  via	  hypermethylation	  or	  loss	  of	  heterozygosity	  increases	  IGF-­‐1R	  signaling	  and	  promotes	  cancer	  cell	  proliferation	  via	  AKT	  and	  MAPK	  signaling.	  61	  Interestingly,	  TROP2	  is	  also	  known	  to	  inhibit	  adhesion	  of	  prostate	  cancer	  cells	  to	  fibronectin	  by	  promoting	  focal	  adhesion	  turnover.	  106	  However,	  TROP2	  seems	  to	  have	  a	  tissue-­‐specific	  function	  as	  TROP2	  expression	  promotes	  growth	  in	  other	  cell	  types.	  59,64,117	  Therefore,	  I	  wanted	  to	  investigate	  the	  role	  of	  Trop	  in	  the	  ER-­‐negative,	  tamoxifen-­‐resistant	  cell	  line,	  TMX2-­‐28.	  	  I	  confirmed	  the	  data	  from	  the	  450	  BeadChip	  by	  pyrosequencing.	  	  Indeed	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreases	  TACSTD2	  promoter	  methylation	  in	  TMX2-­‐28	  but	  does	  not	  affect	  methylation	  in	  MCF-­‐7	  (Figure	  3.9).	  	  I	  then	  tested	  the	  hypothesis	  that	  increased	  TROP2	  expression	  in	  TMX2-­‐28	  due	  to	  decreased	  promoter	  methylation	  was	  involved	  in	  regulating	  the	  decrease	  in	  proliferation,	  migration	  and	  adhesion	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	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Role	  of	  TROP2	  in	  Regulation	  of	  Proliferation,	  Migration	  and	  Adhesion	  	  
in	  Cell	  Line	  Model	  
	   To	  determine	  the	  role	  of	  TROP2	  in	  regulating	  proliferation,	  migration	  and	  adhesion,	  I	  generated	  a	  stable	  MCF-­‐7	  cell	  line	  with	  decreased	  expression	  of	  TROP2	  (MCF-­‐7-­‐Trop2-­‐Kd)	  and	  a	  stable	  TMX2-­‐28	  cell	  line	  with	  increased	  expression	  of	  TROP2	  (TMX2-­‐28-­‐Trop2)	  (Figure	  4.1).	  	  MCF-­‐7	  has	  low	  TACSTD2	  promoter	  methylation	  and	  high	  TROP2	  expression	  while	  TMX2-­‐28	  has	  high	  TACSTD2	  promoter	  methylation	  and	  low	  expression.	  	  This	  is	  consistent	  with	  the	  hypothesis	  that	  promoter	  methylation	  is	  regulating	  gene	  expression.	  	  Treatment	  of	  TMX2-­‐28	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreases	  TACSTD2	  promoter	  methylation	  and	  increases	  mRNA	  expression.	  	  Treating	  TMX2-­‐28	  cells	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  decreases	  proliferation	  and	  2-­‐dimensional	  migration	  and	  inhibits	  cell	  adhesion	  to	  fibronectin.	  	  Based	  on	  the	  changes	  in	  cell	  behavior	  of	  TMX2-­‐28	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  and	  results	  in	  the	  literature	  regarding	  TROP2,	  61,106	  I	  predicted	  that	  forced	  expression	  of	  TROP2	  in	  TMX2-­‐28	  would	  result	  in	  decreased	  proliferation,	  migration	  and	  cell	  adhesion.	  	  	  	   Contrary	  to	  my	  prediction,	  TMX2-­‐28-­‐Trop2	  cells	  had	  no	  change	  in	  proliferation	  and	  had	  increased	  adhesion	  to	  fibronectin	  and	  increased	  migration	  compared	  to	  the	  TMX2-­‐28-­‐Control	  cell	  line	  (Figures	  4.2,	  4.3	  and	  4.4).	  	  This	  indicates	  that	  the	  decrease	  in	  proliferation,	  adhesion	  and	  migration	  of	  TMX2-­‐28	  in	  response	  to	  treatment	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  is	  not	  due	  to	  TROP2	  expression.	  	  Although	  increased	  TROP2	  expression	  has	  been	  shown	  to	  promote	  cell	  growth	  and	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proliferation,	  which	  is	  in	  some	  instances	  due	  to	  increased	  phosphorylation	  of	  ERK1/2,	  59,64,110,111	  this	  is	  not	  the	  case	  in	  TMX2-­‐28.	  	  This	  suggests	  that	  TMX2-­‐28	  utilize	  a	  mechanism	  that	  is	  independent	  of	  TROP2	  to	  promote	  growth	  signaling.	  	  TMX2-­‐28	  cells	  are	  known	  to	  overexpress	  S-­‐phase	  kinase-­‐associated	  protein	  2	  (SKP2),	  a	  component	  of	  the	  SCFSKP2	  complex,	  which	  targets	  CDK	  inhibitors,	  such	  as	  p27,	  for	  degradation.	  	  However,	  TMX2-­‐28	  cells	  have	  high	  expression	  of	  p27.	  39	  Therefore,	  if	  SKP2	  overexpression	  is	  the	  predominant	  mechanism	  by	  which	  TMX2-­‐28	  cells	  sustain	  proliferative	  signaling	  I	  predict	  the	  expression	  of	  other	  CDK	  inhibitors,	  such	  as	  p16	  or	  p21,	  to	  be	  low	  in	  TMX2-­‐28.	  	  Cancer	  cells	  are	  thought	  to	  rely	  on	  more	  than	  one	  growth	  signaling	  pathway	  or	  combination	  of	  pathways	  to	  promote	  tumor	  growth.	  7,8	  This	  is	  likely	  the	  case	  in	  TMX2-­‐28.	  However,	  it	  is	  not	  known	  which	  pathway	  is	  affected	  by	  5-­‐Aza-­‐2’-­‐deoxycytidine	  in	  TMX2-­‐28.	  	  	  This	  could	  be	  determined,	  for	  example,	  by	  examining	  the	  phosphorylation	  patterns	  of	  cell	  cycle	  regulatory	  proteins	  in	  both	  control	  and	  5-­‐Aza-­‐2’-­‐deoxycytidine-­‐treated	  TMX2-­‐28	  cells.	  	   Knockdown	  of	  TROP2	  in	  MCF-­‐7	  increased	  proliferation	  (Figure	  4.5).	  	  This	  indicates	  that	  TROP2	  acts	  to	  suppress	  proliferation	  in	  MCF-­‐7.	  	  This	  could	  be	  related	  to	  the	  ability	  of	  TROP2	  to	  bind	  IGF-­‐1	  and	  inhibit	  IGF-­‐1R	  signaling.61	  Expression	  of	  IGF-­‐1R	  was	  not	  examined	  in	  the	  present	  study,	  however	  it	  is	  known	  that	  MCF-­‐7	  cells	  express	  IGF-­‐1R	  and	  respond	  to	  stimulation	  with	  IGF-­‐1.	  144	  TROP2	  may	  act	  to	  suppress	  some	  IGF-­‐1R	  signaling	  in	  MCF-­‐7	  by	  binding	  IGF-­‐1.	  	  Therefore,	  I	  predict	  MCF-­‐7-­‐Trop2-­‐Kd	  cells	  would	  have	  increased	  IGF-­‐1R	  signaling	  and	  AKT	  activation.	  	  In	  the	  future,	  this	  hypothesis	  could	  be	  examined	  by	  immunoblotting	  with	  phosphor-­‐
	  215	  
specific	  antibodies	  for	  downstream	  signaling	  proteins	  in	  the	  IGF-­‐1R	  pathway,	  such	  as	  AKT.	  	   I	  also	  quantified	  adhesion	  to	  fibronectin	  in	  the	  stable	  cell	  lines.	  	  Fibronectin	  is	  a	  component	  of	  the	  extracellular	  matrix	  (ECM),	  which	  is	  produced	  during	  involution	  and	  breast	  cancer	  development;	  it	  is	  important	  for	  remodeling	  the	  ECM	  and	  forming	  the	  pre-­‐metastatic	  niche.	  145,146	  TMX2-­‐28-­‐Trop2	  cells	  had	  increased	  adhesion	  to	  fibronectin,	  which	  was	  opposite	  of	  my	  prediction	  (Figure	  4.3).	  	  The	  results	  from	  the	  adhesion	  experiments	  in	  the	  MCF-­‐7-­‐Trop2-­‐Kd	  cells	  were	  inconclusive	  (Figure	  4.6).	  	  There	  is	  also	  evidence	  in	  the	  literature	  suggesting	  that	  increased	  TROP2	  expression	  inhibits	  adhesion.	  	  Fetal	  mouse	  kidney	  cells	  with	  high	  TROP2	  expression	  have	  decreased	  adhesion	  to	  collagen.	  105	  Forced	  expression	  of	  TROP2	  in	  prostate	  cancer	  cells	  inhibits	  adhesion	  to	  fibronectin.	  	  This	  is	  probably	  due	  to	  relocalization	  of	  RACK1	  to	  the	  membrane,	  increased	  phosphorylation	  of	  Src	  and	  FAK,	  which	  results	  in	  increased	  turnover	  of	  focal	  adhesions.	  106	  However,	  TROP2	  can	  also	  promote	  migration	  of	  prostate	  cancer	  cells	  on	  fibronectin.	  	  Authors	  found	  this	  to	  be	  dependent	  on	  β1	  integrins.	  	  Interaction	  of	  TROP2	  with	  α5β1	  integrin	  and	  talin	  causes	  α5β1	  relocalization	  to	  the	  leading	  edge	  of	  the	  cell	  and	  increases	  Rac1	  GTPase	  acivity.	  	  TROP2	  can	  also	  activate	  PAK4,	  which	  results	  in	  increased	  focal	  adhesion	  turnover.	  57	  The	  TMX2-­‐28-­‐Trop2	  cell	  line	  had	  increased	  adhesion	  to	  fibronectin	  and	  therefore	  stable	  focal	  adhesions.	  	  However	  the	  localization	  and	  activation	  of	  focal	  adhesion	  signaling	  proteins	  was	  not	  examined	  in	  this	  study.	  	  I	  predict	  decreased	  phosphorylation	  of	  signaling	  proteins	  and	  absence	  of	  RACK1	  at	  the	  cell	  membrane.	  	  This	  could	  be	  examined	  by	  western	  blotting	  with	  phosphor-­‐specific	  antibodies	  and	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immunofluorescence	  microscopy.	  	  It	  would	  also	  be	  important	  to	  determine	  expression	  levels	  of	  β1	  integrins	  in	  TMX2-­‐28-­‐Trop2.	  	  I	  predict	  TMX2-­‐28-­‐Trop2	  would	  have	  low	  expression	  of	  α5β1	  integrin.	  	   It	  is	  also	  important	  to	  consider	  that	  the	  adhesion	  experiments	  in	  the	  present	  study	  examined	  how	  well	  cells	  adhere	  to	  fibronectin-­‐coated	  tissue	  culture	  plates	  in	  a	  short	  time	  frame.	  	  The	  strength	  of	  cell	  adhesion	  could	  also	  be	  quantified	  by	  examining	  the	  time	  frame	  for	  detachment	  or	  the	  force	  required	  to	  detach	  cells.	  	  Fibronectin	  is	  just	  one	  component	  of	  the	  ECM,	  other	  components	  such	  as	  collagen	  or	  combinations	  of	  components	  could	  be	  examined	  in	  a	  2-­‐	  or	  3-­‐dimensional	  tissue	  culture	  setting.	  	  This	  may	  provide	  a	  more	  physiologically	  accurate	  setting	  to	  quantify	  adhesion.	  	   If	  TMX2-­‐28-­‐Trop2	  cells	  have	  stable	  focal	  adhesions,	  it	  is	  surprising	  that	  they	  had	  increased	  migration	  in	  the	  transwell	  assay	  (Figure	  4.4)	  because	  migration	  requires	  focal	  adhesion	  turnover.	  	  Meanwhile,	  there	  was	  no	  change	  in	  migration	  of	  the	  MCF-­‐7-­‐Trop2-­‐Kd	  cells.	  	  Perhaps	  TROP2	  altered	  subcellular	  localization	  of	  a	  portion	  of	  molecules	  involved	  in	  focal	  adhesion	  signaling,	  allowing	  them	  to	  be	  poised	  for	  activation	  when	  needed.	  	  This	  hypothesis	  could	  be	  examined	  by	  immunoblotting	  or	  immunofluorescence	  microscopy	  using	  phosphor-­‐specific	  antibodies.	  	  Increased	  TROP2	  expression	  is	  known	  to	  promote	  invasion	  in	  other	  cell	  line	  models.	  59,111,117	  This	  agrees	  with	  results	  presented	  here	  that	  TMX2-­‐28-­‐Trop2	  cells	  have	  increased	  migration.	  	  Correspondingly	  in	  the	  literature,	  knockdown	  of	  TROP2	  has	  been	  shown	  to	  inhibit	  invasion	  and	  migration	  in	  tissue	  culture	  models.108,117,147	  Perhaps	  there	  was	  no	  effect	  on	  migration	  when	  knocking	  down	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TROP2	  expression	  in	  MCF-­‐7	  cells	  because	  of	  the	  inherent	  non-­‐invasive	  characteristics	  of	  this	  cell	  line.	  	  Therefore,	  it	  would	  be	  important	  in	  the	  future	  to	  investigate	  the	  effect	  of	  TROP2	  overexpression	  and	  knockdown	  in	  other	  breast	  cancer	  cell	  lines.	  
	   	  
TACSTD2	  Methylation	  and	  TROP2	  Expression	  in	  Clinical	  Samples	  	   TACSTD2	  methylation	  was	  examined	  in	  clinical	  breast	  cancer	  samples	  using	  the	  Illumina	  Human	  Methylation	  450	  BeadChip	  and	  TROP2	  protein	  expression	  was	  examined	  by	  IHC.	  	  Despite	  my	  predictions	  from	  the	  TMX2-­‐28	  cell	  line	  model,	  there	  was	  no	  inverse	  correlation	  between	  methylation	  and	  TROP2	  expression	  in	  the	  breast	  cancer	  samples.	  	  There	  was,	  however,	  a	  change	  in	  methylation	  of	  the	  3	  
TACSTD2	  CpG	  cites	  identified	  in	  TMX2-­‐28	  (Chapter	  2)	  in	  the	  predicted	  direction	  for	  the	  group	  of	  ER-­‐positive	  primary	  tumors	  that	  recur	  as	  ER-­‐negative.	  	  In	  this	  group,	  methylation	  for	  each	  of	  the	  3	  CpGs	  was	  higher	  in	  the	  ER-­‐negative	  recurrent	  tumor	  than	  the	  ER-­‐positive	  primary	  tumor	  (Figure	  4.9,	  A).	  	  The	  difference	  in	  methylation	  was	  only	  significant	  for	  CpG	  1	  however,	  the	  sample	  size	  was	  small	  with	  only	  6	  ER-­‐positive	  primary	  tumors	  and	  7	  ER-­‐negative	  recurrent	  tumors	  for	  this	  group.	  	  Regardless	  of	  this	  increase	  in	  methylation,	  there	  was	  no	  difference	  in	  expression	  of	  membrane	  TROP2	  between	  the	  ER-­‐positive	  primary	  tumors	  that	  recur	  as	  ER-­‐negative	  tumors.	  	  However,	  the	  sample	  size	  is	  so	  small	  that	  if	  methylation	  and	  protein	  expression	  were	  examined	  in	  a	  larger	  sample	  size,	  there	  may	  be	  a	  corresponding	  decrease	  in	  protein	  expression	  with	  increased	  methylation.	  	  It	  would	  also	  be	  interesting	  to	  examine	  DNA	  methylation	  for	  breast	  cancer	  samples	  in	  the	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literature	  for	  which	  there	  is	  TROP2	  expression	  data	  available.	  60,65,109,114	  In	  agreement	  with	  previous	  findings	  in	  the	  literature,	  109	  the	  ER-­‐negative/HER-­‐positive	  tumors	  in	  the	  current	  study	  had	  higher	  expression	  of	  membrane	  TROP2	  than	  the	  other	  tumors	  grouped	  by	  ER/HER2	  status	  (Figure	  4.13,	  A).	  	  However,	  the	  increase	  was	  not	  statistically	  significant	  and	  there	  was	  no	  difference	  in	  cytoplasmic	  TROP2	  expression	  according	  to	  ER/HER2	  status	  (Figure	  4.13,	  B).	  	  Contrary	  to	  a	  previous	  report	  that	  found	  membrane-­‐localized	  TROP2	  was	  associated	  with	  poor	  survival,	  65	  expression	  of	  membrane-­‐localized	  TROP2	  in	  the	  present	  study	  was	  high	  in	  non-­‐recurrent	  tumors	  (Figure	  4.14,	  A).	  	  This	  could	  simply	  be	  a	  reflection	  of	  the	  small	  sample	  size	  here	  (n	  =	  66)	  compared	  to	  their	  study	  (n	  =	  702).	  	  Also	  contradictory	  to	  predictions	  based	  on	  results	  from	  the	  literature,	  I	  found	  no	  difference	  in	  membrane	  TROP2	  expression	  according	  to	  tumor	  grade	  or	  Ki67	  score	  (Figure	  4.15,	  A	  and	  B).	  	  In	  the	  future,	  it	  would	  be	  important	  to	  examine	  TROP2	  expression	  in	  clinical	  samples	  with	  a	  larger	  sample	  size.	  	  It	  may	  also	  be	  beneficial	  to	  use	  a	  specific	  antibody,	  which	  recognizes	  either	  cytoplasmic	  or	  membrane-­‐bound	  TROP2	  exclusively,	  to	  avoid	  ambiguity	  of	  pathological	  scoring.	  	   Given	  the	  high	  percentage	  of	  clinical	  samples	  with	  expression	  of	  cytoplasmic	  (98%)	  or	  membrane-­‐localized	  TROP2	  (89%),	  TROP2	  may	  be	  useful	  marker	  for	  targeted	  delivery	  of	  therapeutics	  in	  breast	  cancer.	  	  Antibodies	  against	  TROP2	  have	  been	  used	  in	  cell	  lines	  to	  target	  epithelial	  cells	  and	  deliver	  drug	  conjugates.148-­‐152	  A	  clinical	  trial	  using	  a	  TROP2	  antibody-­‐topoisomerase-­‐I	  inhibitor	  conjugate	  was	  conducted	  and	  included	  4	  patients	  with	  triple	  negative	  breast	  cancer	  with	  promising	  results.	  	  Treatment	  increased	  the	  time-­‐to-­‐progression,	  determined	  by	  measuring	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response	  evaluation	  criteria	  in	  solid	  tumors	  (RECIST),	  in	  3	  of	  the	  4	  patients.	  153	  The	  data	  presented	  here	  indicate	  that	  a	  large	  number	  of	  breast	  tumors	  express	  membrane-­‐localized	  TROP2	  and	  support	  the	  idea	  of	  its	  use	  for	  targeted	  drug	  delivery.	  	   The	  data	  presented	  here	  provide	  insight	  into	  the	  role	  of	  DNA	  methylation	  and	  regulation	  of	  gene	  expression	  in	  ER-­‐negative,	  tamoxifen-­‐resistant	  breast	  cancer.	  	  Cell	  behavior	  and	  changes	  in	  DNA	  methylation	  in	  response	  to	  5-­‐Aza-­‐2’-­‐deoxycytidine	  were	  also	  evaluated.	  	  This	  study	  indicates	  that	  DNA	  methylation	  in	  cell	  line	  models	  may	  be	  applicable	  to	  clinical	  samples.	  	  However,	  further	  studies	  are	  needed	  to	  determine	  whether	  DNA	  methylation	  is	  correlated	  to	  gene	  expression	  and	  to	  determine	  the	  role	  of	  TROP2	  signaling	  in	  ER-­‐negative,	  tamoxifen-­‐resistant	  breast	  cancer.	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COMPARISON	  OF	  CELL	  LINE	  REPLICATES	  ON	  450	  BEADCHIP	  	  	   In	  order	  to	  examine	  the	  reproducibility	  and	  reliability	  of	  methylation	  data	  from	  the	  450	  BeadChip,	  I	  compared	  global	  methylation	  (all	  CpG	  sites	  on	  the	  array)	  for	  cell	  line	  replicates.	  	  First,	  I	  compared	  methylation	  from	  the	  initial	  450	  BeadChip	  experiments	  in	  our	  lab31	  to	  the	  DMSO-­‐control-­‐treated	  cells	  in	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  experiments	  (see	  Chapter	  2)	  for	  MCF-­‐7,	  TMX2-­‐11	  and	  TMX2-­‐28	  (TMX2-­‐4	  was	  not	  included	  in	  the	  initial	  450	  BeadChip	  study).	  	  As	  expected,	  R2	  is	  close	  to	  one	  for	  each	  cell	  line	  (Figure	  A.1).	  	  Some	  variability	  was	  expected,	  as	  the	  cells	  in	  the	  initial	  experiment	  were	  not	  exposed	  to	  DMSO.	  	   Next,	  I	  wanted	  to	  compare	  methylation	  between	  the	  two	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treated	  cell	  line	  replicates	  that	  were	  analyzed	  using	  the	  Human	  450	  BeadChip.	  	  For	  these	  biological	  replicates,	  r2	  ranged	  from	  0.95	  to	  0.99	  (Figure	  A.2).	  	  This	  data	  along	  with	  the	  data	  from	  Figure	  A.1	  confirm	  that	  the	  data	  from	  the	  Human	  450	  Methylation	  BeadChip	  is	  reproducible	  and	  reliable.	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(A)	   	   	   	   	   	   	   	   	   	   (B)	  
	   	   	   	   	   	  
(C)	  
	   	   	   (Figure	  A.1)	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Figure	  A.1:	  Scatter	  Plots	  Comparing	  DNA	  Methylation	  in	  Cell	  Line	  Replicates.	  Scatter	  plots	  indicating	  genome-­‐wide	  methylation	  differences	  between	  cell	  lines	  from	  the	  initial	  experiment	  in	  our	  lab31	  (“…_1”)	  and	  the	  DMSO-­‐control-­‐treated	  cells	  from	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine	  experiment	  (“…_2”)	  for	  (A)	  MCF-­‐7,	  (B)	  TMX2-­‐11	  and	  (C)	  TMX2-­‐28.	  	  Each	  black	  dot	  on	  the	  plot	  represents	  a	  CpG	  site	  analyzed	  on	  the	  Human	  Methylation	  450	  BeadChip.	  	  Center	  red	  line	  represents	  equal	  average	  beta	  values	  in	  the	  two	  samples	  and	  outer	  red	  lines	  indicate	  a	  1.8-­‐fold	  change	  in	  average	  beta	  values.	  Value	  of	  r2	  from	  Genome	  Studio	  represents	  goodness-­‐of-­‐fit	  of	  linear	  regression.	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(A)	   	   	   	   	   	   	   	   	   	   (B)	  
	   	   	   	   	   	  
(C)	   	   	   	   	   	   	   	   	   	   (D)	  
	   	   	   	   	   	  (Figure	  A.2)	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Figure	  A.2:	  Scatter	  Plots	  Comparing	  DNA	  Methylation	  in	  Cell	  Line	  Replicates	  from	  the	  5-­‐Aza-­‐2’-­‐deoxycytidine	  





OPTIMIZATION	  OF	  SEEDING	  DENSITIES	  FOR	  ADHESION	  ASSAY	  	   In	  order	  to	  determine	  the	  appropriate	  seeding	  density	  for	  the	  adhesion	  assay,	  MCF-­‐7	  and	  TMX2-­‐28	  cells	  were	  seeded	  in	  a	  96-­‐well	  plate	  coated	  with	  fibronectin	  one	  day	  before	  in	  various	  densities	  (n	  =	  6),	  the	  top	  two	  rows	  of	  the	  plate	  were	  left	  uncoated	  as	  a	  negative	  control.	  	  To	  determine	  the	  limit	  of	  detection,	  a	  two-­‐tailed	  Student’s	  t-­‐test	  was	  used	  to	  determine	  if	  the	  absorbance	  readings	  for	  20,000	  cells/well	  were	  different	  than	  the	  absorbance	  readings	  for	  each	  of	  the	  other	  cell	  densities.	  	  There	  was	  no	  difference	  between	  the	  absorbance	  readings	  for	  20,000	  and	  10,000	  cells/well.	  	  Therefore,	  the	  assay	  cannot	  distinguish	  absorbance	  values	  for	  10,000	  or	  fewer	  cells/well.	  	  There	  was	  a	  difference	  between	  readings	  between	  20,000	  cells/well	  and	  the	  3	  other	  densities	  tested.	  	  However,	  the	  background	  staining	  was	  very	  high	  in	  the	  wells	  without	  cells	  (Figure	  A.1).	  	  Therefore,	  I	  need	  to	  minimize	  the	  background	  staining	  in	  order	  to	  have	  a	  more	  sensitive	  assay.	  	   To	  minimize	  background	  staining,	  the	  crystal	  violet	  staining	  solution	  was	  filtered	  through	  Whatman	  filter	  paper	  by	  gravity.	  	  After	  staining,	  the	  plate	  was	  rinsed	  by	  submerging	  it	  in	  water	  instead	  of	  pipetting	  water	  into	  the	  wells	  as	  the	  initial	  protocol	  indicated.	  	  The	  adhesion	  assay	  was	  repeated	  with	  MCF-­‐7	  cells	  and	  a	  higher	  initial	  cell	  density	  of	  56,000	  cells/well	  (n	  =	  12).	  	  The	  differences	  in	  absorbance	  readings	  were	  analyzed	  using	  a	  Student’s	  t-­‐test.	  	  This	  time,	  the	  background	  staining	  (absorbance	  values	  for	  wells	  coated	  with	  fibronectin,	  but	  not	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INNITIAL	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  EXPERIMENTS	  
	  













ADHESION	  OF	  ADHERENT	  AND	  FLOATING	  CELL	  POPULATIONS	  TREATED	  WITH	  
5-­‐AZA-­‐2’-­‐DEOXYCYTIDINE	  
	  	   Because	  previous	  experiments	  showed	  that	  TMX2-­‐28	  cells	  treated	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  detach	  from	  the	  monolayer,	  I	  wanted	  to	  determine	  if	  there	  was	  a	  difference	  in	  adhesion	  between	  the	  adherent	  cells	  and	  the	  adherent	  cells	  combined	  with	  those	  cells	  that	  were	  in	  suspension.	  	  For	  the	  first	  experiment,	  two	  replicate	  flasks	  were	  seeded	  for	  each	  treatment.	  	  On	  the	  day	  of	  the	  adhesion	  assay,	  the	  adherent	  cells	  were	  trypsinzed,	  counted	  and	  seeded	  for	  the	  assay.	  	  For	  the	  second	  set,	  cells	  that	  were	  floating	  in	  the	  spent	  media	  were	  combined	  with	  adherent	  cells,	  counted	  and	  seeded	  for	  the	  assay.	  	  Cells	  were	  seeded	  on	  the	  pre-­‐coated	  fibronectin	  plate	  at	  15,400	  cells/well	  (due	  to	  limited	  number	  of	  cells	  in	  one	  of	  the	  samples)	  (Figure	  D.1).	  	  Remaining	  cell	  pellets	  from	  each	  treatment	  flask	  were	  divided	  into	  two	  and	  stored	  at	  -­‐80°C	  for	  DNA	  and	  RNA	  isolation	  at	  a	  later	  date.	  	  	   Differences	  among	  cell	  lines	  and	  treatment	  were	  analyzed	  by	  two-­‐way	  ANOVA	  and	  post-­‐hoc	  t-­‐tests.	  	  The	  two-­‐way	  ANOVA	  examined	  the	  effect	  of	  cell	  line	  and	  treatment	  on	  adhesion.	  	  The	  interaction	  between	  cell	  line	  and	  treatment	  approached	  significance	  (F	  =	  2.21,	  p	  =	  0.05).	  	  There	  was	  a	  significant	  effect	  of	  cell	  line	  on	  adhesion	  (F	  =	  8.23,	  p	  <	  0.0001)	  and	  treatment	  on	  adhesion	  (F	  =	  23.11,	  p<	  0.0001)	  (Figure	  D.1,	  A).	  	  There	  was	  a	  time-­‐dependent	  decrease	  in	  adhesion	  with	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment.	  	  Additionally,	  differences	  in	  adhesion	  between	  treatment	  for	  MCF-­‐7	  and	  TMX2-­‐28	  cell	  lines	  were	  analyzed	  by	  student’s	  t-­‐test.	  	  For	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Figure	  D.1:	  Adhesion	  of	  Adherent	  Cell	  Populations	  and	  Combined	  Cell	  
Populations.	  Cells	  were	  seeded	  in	  duplicate	  flasks	  and	  treated	  with	  DMSO	  control	  or	  5-­‐Aza-­‐2’-­‐deoxycytidne	  for	  48	  or	  72	  hours	  prior	  to	  seeding	  on	  a	  pre-­‐coated	  fibronectin	  plate	  for	  adhesion	  assay.	  	  For	  one	  set	  of	  flasks,	  the	  spent	  media	  was	  removed	  and	  only	  the	  cells	  adhered	  to	  the	  flask	  were	  used	  in	  the	  adhesion	  assay.	  	  For	  the	  second	  set,	  cells	  floating	  in	  the	  spent	  media	  were	  combined	  with	  cells	  adhered	  to	  the	  flask	  (combined)	  and	  seeded	  for	  the	  adhesion	  assay.	  	  Adhesion	  to	  fibronectin-­‐coated	  plate	  represented	  as	  percentage	  of	  control	  for	  MCF-­‐7	  and	  TMX2-­‐28	  for	  adherent	  cells	  only	  and	  adherent	  cells	  combined	  with	  cells	  in	  suspension	  (combined)	  (n	  =	  8).	  	  Percent	  adhesion	  of	  all	  cell	  populations,	  normalized	  to	  the	  control	  for	  each	  cell	  line	  (A).	  	  Percent	  adhesion	  of	  only	  the	  adherent	  populations	  (B).	  	  Percent	  adhesion	  of	  only	  the	  combined	  populations	  (C).	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